Protocol I9H- MC-FFAA(b)  
 
 
A Phase 1 Randomized, Placebo -Controlled Study of LY3316531 in Healthy Subjects and  
an Open -Label, Single -Dose Study in Patients with Psoriasis  
 
 
[STUDY_ID_REMOVED] 
 
 
Approval Date: 17-Aug-2018 
 
 
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  1
LY3316531P ro toco l  I9H - MC- FFAA(b )
A  Phase  1  Random i zed,  P lacebo - Con t ro l ledS tudyo f  
LY3316531in  Hea l thy  Sub jec ts  and  an  Open- Labe l ,
S ing le- Dose  S tudy in  Pa t ien ts  w i th  Pso r ias is
Con f iden t ia l  In fo rma t ion
The  in fo rma t ion  con ta ined  in  th is  p ro toco l  is  con f iden t ia l  and  is  in tended  fo r  the  use  o f  
c l in ica l  inves t iga to rs .   I t  is  the  p rope r ty  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies  and  
shou ld  no t  be  cop ied  by  o r  d is t r ibu ted  to  pe rsons  no t  invo lve d  in  the  c l in ica l  inves t iga t ion  o f  
LY3316531,  un less  such  pe rsons  a re  bound  by  a  con f iden t ia l i ty  ag reemen t  w i th  E l i  L i l ly  
and  Company  o r  i ts  subs id ia r ies .
No te  to  Regu la to ry  Au tho r i t ies :  Th is  documen t  may  con ta in  p ro tec ted  pe rsona l  da ta  
and /o r  comme rc ia l ly  con f iden t ia l  in fo rma t ion  exemp t  f rom  pub l ic  d isc losu re .   E l i  L i l ly  and  
Company  reques ts  consu l ta t ion  rega rd ing  re lease / redac t ion  p r io r  to  any  pub l ic  re lease .   In  
the  Un i ted  S ta tes ,  th is  documen t  is  sub jec t  to  F reedom  o f  In fo rma t ion  Ac t  (FO IA )  
Exemp t ion  4and  may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  w r i t ten  
app rova l  o f  E l i  L i l ly  and  Company  o r  i ts  subs id ia r ies .
App ro va l  Da te :  17 -Aug -2018  GMTLY3316531
E l i  L i l l y  and  Compan y
Ind ianapo l i s ,  Ind iana  USA  46285
C l in i ca l  Pha rma co log y  P ro to co l  E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l ly:
02Novembe r  2017
Amendmen t  (a )  E lec t ron ica l ly  S igned  and  App roved  by  L i l ly:  
18Janua r y2018
Amendmen t  (b )  E le c t ron i ca l l y  S igned  and  App ro ved  b y  L i l l y  on  da te  p ro v ided  be low .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 2
LY3316531Table of Contents
A Phase 1 Randomized, Placebo -Controlled Study  of 
LY3316531 in Healthy  Subjects and an Open -Label,
Single -Dose Study  in Patients with Psoriasis
Section Page
Protocol  I9H-MC-FFAA(b) A Phase 1 Rando mized, Placebo -Controlled 
Study  of LY3316531 in Healt hy Subjects and an Open -Label , 
Single-Dose Study  in Pat ients with Psori asis....................................................................... 1
Table of Contents ........................................................................................................................ 2
1. Protocol  Synopsi s................................................................................................................ 9
2. Schedule of Act ivities....................................................................................................... 12
2.1. Part A (SAD in Healthy Subjects) ................................................................................ 13
2.2. Part B (Mult iple-Dose Study  in Heal thy Subjects) ........................................................ 16
2.3. Part C (Single -Dose Study  in Pat ients with Psori asis) ................................................... 20
3. Introduction ...................................................................................................................... 24
3.1. Study  Rati onale ............................................................................................................ 24
3.2. Background .................................................................................................................. 24
3.3. Benefit /Risk Assessment .............................................................................................. 25
4. Object ives and Endpo ints.................................................................................................. 27
5. Study  Design ..................................................................................................................... 29
5.1. Overall Design ............................................................................................................. 29
5.1.1. Part A (SAD in Healthy Subjects) ........................................................................ 31
5.1.2. Part B (Mult iple-Dose Desi gn in Heal thy Subjects) .............................................. 31
5.1.3. Part C (Single -Dose Design in Patients with Psorias is)......................................... 32
5.2. Number of Participants .................................................................................................32
5.2.1. Part A (SAD Design in Healt hy Subjects) ............................................................ 32
5.2.2. Part B (Mult iple-Dose Desi gn in Heal thy Subjects) .............................................. 33
5.2.3. Part C (Single -Dose Design in Patients with Psori asis) ......................................... 33
5.3. End of Study  Definit ion............................................................................................... 33
5.4. Scientific Rationale for Study  Design ........................................................................... 33
5.5. Justification for Dose ................................................................................................... 34
6. Study  Popul ation............................................................................................................... 36
6.1. Inclusio n Cri teria.......................................................................................................... 36
6.1.1. For Healthy Subjects ............................................................................................ 36
6.1.2. For Pati ents wi th Psori asis.................................................................................... 37
6.2. Exclusio n Cri teria........................................................................................................ 38
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 3
LY33165316.2.1. For Healthy Subjects and Patients with Psoriasis .................................................. 38
6.2.2. For Healthy Subjects Only ................................................................................... 41
6.2.3. For Pati ents wi th Psori asis Only ........................................................................... 41
6.3. Lifest yle and/or Dietary Requirements ......................................................................... 43
6.3.1. Meals and Dietary  Restri ctions............................................................................. 43
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 43
6.3.2.1. Caffeine .......................................................................................................... 43
6.3.2.2. Alcoho l........................................................................................................... 43
6.3.2.3. Smoking ......................................................................................................... 44
6.3.3. Activity................................................................................................................ 44
6.3.4. Contraception ....................................................................................................... 44
6.4. Screen Failures ............................................................................................................. 45
7. Treatment .......................................................................................................................... 47
7.1. Treatment Administered ............................................................................................... 47
7.1.1. Packaging and Labeling ....................................................................................... 47
7.2. Method of Treatment Assignment ................................................................................ 48
7.2.1. Selection and Timing o f Doses ............................................................................. 48
7.3. Blinding ....................................................................................................................... 48
7.4. Dose Modificat ion........................................................................................................ 49
7.4.1. Dose Deci sion (Part C) ......................................................................................... 49
7.4.2. Dose Escal ation (Parts A and B) ........................................................................... 49
7.4.3. Speci al Treatm ent Consi derat ions........................................................................ 51
7.4.3.1. Management of Infusio n Reactions .................................................................51
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 52
7.6. Treatment Compliance .................................................................................................52
7.7. Concomitant Therapy ................................................................................................... 53
7.8. Treatment after the End of the Study ............................................................................ 53
8. Discontinuati on Cri teria .................................................................................................... 54
8.1. Discontinuati on from Study  Treatm ent......................................................................... 54
8.1.1. Discontinuati on of  Inadvertent ly Enrolled Patients/Subjects .................................54
8.2. Discontinuati on from the Study .................................................................................... 54
8.3. Patients/Subjects Lost to Follow -up.............................................................................. 56
9. Study  Assessments and Procedures ................................................................................... 57
9.1. Efficacy Assessments ................................
................................................................... 57
9.2. Adverse Events ............................................................................................................ 57
9.2.1. Serious Adverse Events ........................................................................................ 58
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 59
9.2.2. Com plaint Handling ............................................................................................. 59
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  4
LY3316531CC I9 .3 . T r e a tm e n t  o f  O v e r d o s e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 9
9 .4 . S a fe t y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
9 . 4 . 1 . L abo r a to ry T e s t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
9 .4 .2 . V it a l  S i gn s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9
9 . 4 . 3 . E l e c t r o c a r d i o g r am s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0
9 . 4 . 4 . S a fe t y  Mon ito r ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 1
9 .4 .4 . 1 . H ep a t ic  S a f e t y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 1
9 .4 .4 .3 . C -SSRS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2
9 .5 . P h a rm a co k i n e ti c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2
9 . 5 . 1 . B io an a ly s i s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3
9 .6 . P h a rm a c o d y n am i c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3
9 . 6 . 1 . P h a rm a c o d y n am i c  A s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3
9 .6 .1 .1 . Exp lo r a to ry  P h a rm a c o d y n am i c  S am p l e s  f o r  P a t i e n t s  w i t h  
P so r ia s i s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3
9 .6 .1 .2 . D is e a s e  A c t i v i t y  M e a s u r e s  f o r  P a t i e n t s  w i t h  P s o r i a s i s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3
9 . 6 . 2 . Im m un o g e n i c i ty  A s s e s sm e n t s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4
9 .7 . G e n e ti c s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5
9 .8 . B iom a rk e r s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5
9 .9 . H e a l th  E conom i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 6
1 0 .S t a t is t i c a l  C o n s i d e r a t i o n s  a n d  D a t a  A n a l y s i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
10 .1 .S amp l e  S i z e  D e t e rm i n a t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
10 .2 .Popu la t i o n s  f o r  A n a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
1 0 . 2 . 1 . S tudy P a r t i c i p a n t  D i s p o s i t i o n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
1 0 . 2 . 2 . S tudy P a r t i c i p a n t  C h a r a c t e r i s t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
10 .3 .S t a t is t i c a l  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7
1 0 . 3 . 1 . S a fe t y  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
10 .3 .1 .1 . C l i n i c a l  E v a l u a t i o n  o f  S a f e ty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
10 .3 .1 .2 . S t a t is t i c a l  E v a l u a t i o n  o f  S a f e ty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
1 0 . 3 . 2 . P h a rm a c o k i n e ti c  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
10 .3 .2 .1 . P h a rm a c o k i n e ti c  A n a l y s e s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8
10 .3 .2 .2 . P h a rm a c o k i n e ti c  S t a t i s t i c a l  I n f e r e n c e. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9
1 0 . 3 . 3 . P h a rm a c o d y n am i c  A n a l y s e s  a n d  C l i n i c a l  A c ti v i t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9
10 .3 .3 .1 . P h a rm a c o k i n e ti c /P h a rm a c o d y n am i c  A n a l y s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9
10 .3 .3 .2 . H e a lth  Ou t com e  M e a s u r e s  f o r  S u b j e c t s  w i t h  P s o r i a s i s. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9
1 0 . 3 . 4 . E v a l u a ti o n  o f  Imm u n o g e n i c i ty. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 5
LY331653110.3.5. Data Review During the Study ............................................................................. 70
10.3.6. Interim Analyses .................................................................................................. 70
11. References ........................................................................................................................ 71
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 6
LY3316531List of Tables
Table Page
Table FFAA.4.1. Object ives and Endpo ints....................................................................... 27
Table FFAA.5.1. Summary  of Maximum Number of Patients/Subjects per Cohort ............ 30
Table FFAA.5.2. Margin of Safet y for Administration of LY3316531 Based on 
Administered Dose and Predicted Exposure ............................................ 35
Table FFAA.7.1. Permi tted Medicat ions for Treatm ent of Psori asis................................... 53
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 7
LY3316531List of Figures
Figure Page
Figure FFAA.5.1. Illustrati on of  study  design for Protocol I9H -MC-FFAA. ........................ 31
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 8
LY3316531List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 74
Appendix 2. Clinical Laboratory  Tests ........................................................................ 79
Appendix 3. Study  Governance, Regulatory , and Ethi cal Considerati ons.................... 81
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y............ 84
Appendix 5. Blood Sam pling Summary ...................................................................... 85
Appendix 6. Protocol  FFAA PK, Immunogenicit y, and ECG Sampling 
Schedule .................................................................................................88
Appendix 7. Protocol  Amendment I9H -MC-FFAA (b) Summary 
A Phase 1 Rando mized, Placebo -Controlled Study  of LY3316531 
in Healt hy Subjects and an Open -Label, Single -Dose Study  in 
Patients wi th Psori asis............................................................................ 96
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 10
LY3316531Part A (Single -Ascending Dose [ SAD ]in Healthy Subjects):   After a screening period up to 28 days, eligible 
subjects wi llbe randomiz edto receive a subcutaneous (SC) or intravenous (IV) dose of LY3316531 (3 mg IV, 15 
mg IV, 75 mg IV, 300 mg IV , 300 mg SC, 900 mg IV, or 2000 mg IV [planned dose] )or placebo (IV) on the  
morning of Day 1.  Subjects will remain in the CRU for 24 hours after study drug administration and attend 
scheduled visits at the CRU for 12 weeks to assess the measurements for safety , tolerability , and PK .  Sentinel 
dosing for the first 2 subject s of Cohort s1 and 2 will be performed with 1 subject receiving LY3316531 and the 
other receiving placebo in a blinded manner .
Part B (Multiple -
Dose in Healthy Subjects) :  After a screening period up to 28 days , eligible subjects will be
randomiz ed to receive a planned IV dose of LY3316531 (2000 mg [planned dose ])or placebo on the morning of 
Days 1, 29, and 57 .  The planned dose of 2000 mg LY3316531 may be adjusted based on safety, PK, and target -
engagement data obtained in Part A of the study.  An optional SC or IV second multiple -dose cohort will be 
determined after reviewing the data from the first cohort.   
Subjects will be remain in the CRU for 24hours after receiving each dose of study drug and attend scheduled visits 
at the CRU for 12 weeks following the final ( third )dose of LY3316531 to assess the measurements for safety , 
tolerability, and PK .
Part C (Single -Dose in Patients with Ps oriasis) :  After a screening period up to 35 days , eligible p atient swith 
psoriasis will be enroll ed to receive a single dose of LY3316531 on the morning of Day 1.  Patients will receive 300 
mg IV in Cohort 1 or, in the 2 optional cohorts, receive either a SCor IVdose (to be determined) not to exceed the 
maximum tolerated dose in Part A or the highest dose previously evaluated in healthy  subjects.  Patien ts will remain 
in the CRU for 24 hours after study drug administration and attend scheduled visits at the CRU for 1 6weeks 
following administration of the study drug to assess the measurements for safety , tolerability, PK, and PD .  Patients 
who respond to LY3316531 therapy will enter an extended follow -up period, which requires monthly visits up to 
Week 52 .  Patients who enter the extended follow -up period should be discontinued from the study when additional 
therapy  become s necessary ( as determined by the investigator and patient). 
Number of Patients/Subjects :
Part A: It is planned that up to 52subjects may be enrolled in Part A of this study to obtain evaluable data from 46 
subjects .  The healthy  subject SAD is planned to include 7 cohorts. Cohort s 1and 2 are each planned to have 4 
subjects (3 LY3316531:1 placebo) , whereas Cohorts 3, 4, 6, and 7are each plan ned tohave 8 subjects (6 
LY3316531:2 placebo).   Coh ort 5 is planned to have 6 subjects ,all receiving LY3316531.
Part B:   It is planned that up to 20subjects may be enrolled in Part B of this study to obtain evaluable data from 16 
subjects (total number of subjects for planned and optional cohorts ).  The healthy subject multi ple-dose part of the 
study is planned to include up to 2cohort s (2000 mg IV cohort with the option for 1 additional cohort )with 8 
subjects per cohort (6 LY331 6531:2 placebo).
Part C:   It is planned that up to 30patients may be enrolled in Part C of this study to obtain evaluable data from up 
to 24 patien ts(total number of patients forplanned and optional cohorts) .  The patients with psoriasis single -dose 
part of the study is planned to include up to 3 cohorts (300 mg IV cohort with the option for 2 additional cohorts )
with a minimum of 7 patients planned but up to 8 patients allowed percohort ( 8LY3316531).   The decision to 
initiate enrollment in the opti onal cohorts will be based on the clinical activity ,safety, and tolerability of 
LY3316531 as observed in C
ohort 1.  For example, a lower dose of LY3316531 may be investigat ed if the dose 
used in Cohort 1 is highly efficacious ,based on the clinical activity measurement ( Psoriasis Area and Severity Index
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 11
LY3316531[PASI ]scores) , orif safety concerns arise.  Conversely, a higher dose may be explored in an optional cohort if it is 
determined that LY3316531 had minimal effect on PASI score s.
Statistical Analysis:
Safety:   All investigational product s(IPs) and protocol procedure adverse events will be listed, and if the frequency 
of events allows, safety data will be summarized using descriptive methodology.  The incidence of 
treatment -emer gent adverse events andserious adverse events will be presented by severity and by association with 
treatment as perceived by the investigator. Symptoms reported to occur prior to treatment with study drug will be 
distinguished from those reported as new or increased in severity during the trial. Safety parameters that will be 
assessed include laboratory tests, vital signs, electrocardiogram, body weight, immunogenicity, and injection -site 
reactions.
Pharmacokinetics: PK parameter estimate s for LY3 316531 will be calculated using standard noncompartmental 
methods of analysis.   Parameters for estimation will include absolute bioavailability following SC administration, 
maximum observed drug concentration (C max), time to reach C max, area under the conc entration versus time curve 
(AUC )from time 0 to time of last measurable concentration (t last), AUC from time zero to infinity (AUC 0-∞), 
percentage extrapolated AUC from t lastto infinity, half -
life, apparent clearance, and apparent volume of 
distribution.   The dose proportionality of selected LY3 316531 PK parameters will be examined across the dose 
range using a power model approach.  Population PK analysis methods may be utilized if necessary.
Pharmacodynamic s:  Relationships between LY3316531 exposure an d CGRP target engagement may be explored 
using graphical -and model -based approaches for all parts of the study (Parts A, B, and C).  In patien ts with psoriasis
(Part C) , PD data obtained will be documented in the study report by dose, plasma drug concentrations, and time 
from dose.  Figures showing values of potential PD markers versus time will be created for each dose, with a line for 
each patient.  Absolute percentage change from baseline for all will be summarized by providing the mean, standar d 
deviation, median, minimum, and maximum for each cohort and overall for each sample day/time combination and 
maximum over the entire study.  Data may be log -transformed prior to summarizing if necessary.  The interpatient 
and intrapatient variability in human PD responses may also be assessed if appropriate.
Exposure– response relationship sfor clinical activity measures in psoriasis (such as PASI score, static Physician 
Global Assessment , and body surface area ) and safety endpoints will be investigated in itially using graphical 
methods.  Modeling approaches that relate exposure to the response at various time points or longitudinal models 
that relate the time course of exposure to the time course of response may be explored.
Statistical:   PK/ PDanalyses wi ll be conducted on data from all patients/subjects who receive at least 1dose of the 
IPand have evaluable PK. Placebo data from all cohorts will be pooled across all dose -escalation cohorts for the 
purpose of analysis.   Clinical activity and PD analyses will be conducted for all patients with psoriasis who receive 
the study  drug (Part C only) .  Pharmacodynamic parameters, and their change from baseline ,will be summarized at 
each applicable visit using descriptive statistics (number of subjects, mean, st andard deviation, median, minimum, 
and maximum for continuous variables and number of subjects, frequency, and percent for categorical variables ).  
No statistical inferences will be made and no control for multiplicity is planned.  Additional analyses may be 
performed .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 12
LY33165312.Schedule of A ctivities
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 13
LY33165312.1. Part A (SAD in Healthy Subjects)
Study Schedule for Protocol I9H -MC-FFAA (Part A )
Screening Baseline Postdose
Visit No. V1 V2 V3 V4 V5aV6 V7 V8 V9 V10 V11 V12 ED
Study Day -26d from 
Day -2-1 1 2 4 ± 
1 d8 ± 
1 d11 ± 
1 d15 ± 
2 d22 ± 
2 d29 ± 
2 d43 ± 
3 d57 ±
3 d71 ± 
3 d85 
±3d
Admission to CRU X
Discharge from CRU X
Informed consent X
Review/confirm I/E 
criteriaX X
Complete medical 
history  X
Complete physical 
examinationX X X
Weight X X X
Height X
Symptom -directed 
physical examinationWhen needed
Concomitant 
medicationsX XbX X X X X X X X X X X X
Vital signs (pulse rate, 
blood pressure, and 
temperature)c,dX X Predose, 
end of 
infusion, 
and2, 6, 12
hafter SC 
injection or 
start of 
infusion24 h after
SC 
injection 
or start of 
infusionX X X X X X X X X X X
Review preexisting 
conditio ns/AEsX XbX X X X X X X X X X X X
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  14
LY3316531S c r e en in g B a s e l in e P o s td o s e
V i s i t  N o . V 1  V 2 V 3  V 4  V 5aV 6  V 7  V 8  V 9 V 1 0  V 1 1  V 1 2 ED
S tud y  D a y - 2 6  d  f r om  
D a y  -2- 1  1  2 4  ±  
1d8  ±  
1d1 1  ±  
1d1 5  ±  
2d2 2  ±  
2d2 9  ±  
2d4 3  ±  
3d5 7  ±
3d7 1  ±  
3d8 5  
± 3d
I n j e c t i o n - s i t e  
a s s e s sm e n t( i n c l u d i n g  
)a , eX  X XX
ECG sd , fX S e e  ECG  s am p l i n g  s c h e d u l e( A p p e n d i x  6)
LY 33 1 6 5 3 1  o r 
p l a c e b oa dm i n i s t r a t i o n  
( IV  o r  SC )X
Q u a n t iFERON®- TB
G o l d  t e s to r  TSTX
R e a d  TST  ( i f  
a p p l i c a b l e )Xg
H IV /HBV /HCV X
FSHhX
Pr e g n a n c y  t e s thX  X XXX  X
S e r um  c h em i s t r y  a n d  
h em a t o l o g yX  X X  X  X X  X  X  X  X  X  X  X
U ri n a l y s i s X  X X XX  X X  X
U ri n e  d r u g  s c r e e n  a n d  
e t h a n o l  t e s tX X
P h a rm a c o g e n e t i c s
( e x p l o r a t o r y  s to r ag e  
s am p l e s  f o r  DNA )X
Imm u n o g e n i c i t yiS e e  imm u n o g e n i c i t y  s am p l i n g  s c h e d u l e  (A p p e n d i x  6)
LY 33 1 6 5 3 1  
c o n c e n t r a t i o n(PK )i S e e  PK  s am p l i n g  s c h e d u l e  (A p p e n d i x  6)
T a r g e t  e n g a g em e n t  
a s s a y  ( t o t a l  CGRP )Xj2 4  h  
a f t e r  SC  
i n j e c t i o n  
o r s t a r t  o f  
i n f u s i o nXXXXX  XCC I
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  15
LY3316531S c r e en in g B a s e l in e P o s td o s e
V i s i t  N o . V 1  V 2 V 3  V 4  V 5aV 6  V 7  V 8  V 9 V 1 0  V 1 1  V 1 2 ED
S tud y  D a y - 2 6  d  f r om  
D a y  -2- 1  1  2 4  ±  
1d8  ±  
1d1 1  ±  
1d1 5  ±  
2d2 2  ±  
2d2 9  ±  
2d4 3  ±  
3d5 7  ±
3d7 1  ±  
3d8 5  
± 3d
S k i n  B i o p s ykXl
A b b r e v i a t i o n s :   AE  =  a d v e r s e  e v e n t ;  CGRP  =  ca l c i t o n i n  g e n e - r e l a t e d  p e p t i d e ;CRU  =  c l i n i c a l  r e s e a r c h  u n i t ;  d  =  s t u d y  d a y ;  DNA  =  d e o x y r i b o n u c l e i c  a c i d ;  ECG  =  
e l e c t r o c a r d i o g r am ;  ED  =  e a r l y  d i s c o n t i n u a t i o n ;  FSH=f o l l i c l e - s t im u l a t i n g  h o rm o n e ;  h  =  h o u r ( s ) ;  HBV  =  h e p a t i t i s  B  v i r u s ;  HCV  =  h e p a t i t i s  C  v i r u s;  H IV  =  
h um a n  imm u n o d e f i c i e n c y  v i r u s ;  I /E  =  i n c l u s i o n / e x c l u s i o n ;  IV  =  i n t r a v e n o u s ;  N o .=n um b e r ;  PK=p h a rm a c o k i n e t i c ;  SC=s u b c u t a n e o u s ;  
;  TB=t u b e r c u l o s i s ;  TST  =  t u b e r c u l i n  s k i n  t e s t ;  V  =  v i s i t ;  .
aRe q u i r e d  f o r  s u b j e c t s  r e c e i v i n g  SCd o s i n g  o n l y .
bA t  t h e  d i s c r e t i o n  o f  t h e  CRU ,  t h e  b a s e l i n e  m e a s u r em e n t  f o r  t h i s  a s s e s sm e n t  c a n  b e  c o l le c t e d  a t  a n y  t im e  a f t e r  t h e  s u b j e c t ’ sa dm i s s i o n  t o  t h e  CRU  u p  u n t i l  
LY 3 3 1 6 5 3 1  o r  p l a c e b o  a dm i n i s t r a t i o n  o n  D a y  1 .
cA d d i t i o n a l  v i t a ls i g n  m e a s u r em e n t s  m a y  b e  ob t a in edw he nc l i n i c a l l y  i n d i c a t e d .   V i t a l  s i g n s  s h o u l d  b e  t a k e n  f o l l ow i n g  a n  a p p r o x im a t e  5- m i n u t e  r e s t  i n  s u p i n e  
p o s i t i o n .   T em p e r a t u re  m e a s u r em e n t  i s  r e q u i r e d  o n l y  a ts c r e e n i n g  a n db a s e l i n e .
dECG ,  v i t a l  s i g n ,  a n d  PK  s am p l i n g  s h o u l d  o c c u r  a t  a p p r o x im a t e l y  t h e  s am e  t im e .   ECG  r e c o r d i n g  a n d  v i t a l  s i g n  m e a s u r em e n tss h o u l d  o c c u r  p r i o r  t o  t h e  b l o o d  
d r aw .
eT im e s  a r e  r e f e r e n c e d  t o  s t a r t  o f  d o s i n g .  0 - h o u r  a s s e s sm e n t s  s h o u l d  b e  p e r f o rm e dw i t h i n  1m i n u t e  a f t e r  g i v i n g  a l l  SCi n j e c t i o n s .  A s s e s sm e n t s  s h o u l d  o c c u r  o n  
D a y 1  ( 0  m i n ,  1 0  m i n ,  0 . 5  h ,  1  h ,  3  h ,  a n d  6  h ) ,  D a y  2  ( 2 4  h ) ,  D a y  8  ( 1 6 8  h ) ,  a n d  D a y  1 5  ( 3 3 6  h )  a f t e r  SC  i n j e c t i o n  o f  LY 3 3 1 6 5 3 1 .   Ad d i t i o n a l  a s s e s sm e n t s  
m ay b e p e r f o rm e d  i f  d e em e d  n e c e s s a ry  b y  t h ei n v e s t i g a t o r .
fEl e c t r o c a r d i o g r am s  s h o u l d  b e  t a k e n  f o l l ow i n g  a n  a p p r o x im a t e  5 - m i n u t e  r e s t  i n  s u p i n e  p o s i t i o n .   E l e c t r o c a r d i o g r ams  a r er e q u e s t e d  t o  b e  t a k e n  a t  t h e  s p e c i f i e d  
t im e ;  h ow e v e r ,  a b e r r a t i o n s  t o  s p e c i f i e d  r e c o r d i n g  t im e s  w i l l  n o t  b e  c o n s i d e r e d  p r o t o c o l  d e v i a t i o n s  a s  l o n g  a s  t h e  ECGsa r e  t a k e n  a n d  t h e  a c t u a l  r e c o r d i n g  t im e  
i s  d o c um e n te d .   El e c t r o c a r d i o g r am s  w i l l  b e  c o l l e c t e d  i n  t r i p l i c a t ee x c e p t  a t  s c r e e n i n g  w h e r ea  s i n g l eECG  w i l l  b e  c o l l e c t e d(S e c t i o n  9 . 4 . 3) .
gTh ef o l l ow - up  TSTr e a d i n g  s h o u l d  o c c u r  2  t o  3  d a y s  a f t e r  V 1 .
hA  s e r um  p r e g n a n c y  t e s t  w i l l  b e  c o n d u c t e d  at  s c r e e n i n g  o n l y .   U r i n e  p r e g n a n c y  t e s t  w i l l  b e  u s e d  a t  a l l  o t h e r  t im e  p o i n t s .   F o r w om e n  w h o  a r e  c o n s i d e r e d  t o  b e  
p o s tm e n o p a u s a l ,  FSH  s h o u l db e  d r aw n  t o  c o n f i rm  p o s tm e n o p a u s a l  s t a t u s  a s  d e f i n e d  i n  i n c lu s io n  c r i t e r i o n  [ 1 b ]  a n d  t o  b e  c o n s i d e r e d  e x em p t  f o r  f u r t h e r  
p r e g n a n c y  t e s t s  d u r i n g  t h e  s t u d y .
iR e f e r  t o  A p p e n d i x  6f o r  s p e c i f i c  PKa n d  imm u n o g e n i c i t ys am p l i n g  s c h e d u l e .  S am p l e s  a r e  r e q u e s t e d  t o  b e  t a k e n  a t  t h e  s p e c i f i e d  t im e ;  h ow e v e r ,  a b e r r a t i o n s  t o  
s p e c i f i e d  s am p l i n gt im e s  w i l l  n o t  b e  c o n s i d e r e d  p r o t o c o l  d e v i a t i o n s  a s  l o n g  a s  t h e  s am p l e s  a r e  t a k e n  a n d  t h e  a c t u a l  s am p l i n g  t im e  i s  r e c o r d e d .  I t  i s  e s s e n t i a l  
t h a t  t h e  a c t u a l  t im e so f  d o s e s  a n d  s am p l e s  a r e  r e c o r d e d  a c c u r a t e l y  o n  t h e  a p p r o p r i a t e  f o rm s .
jT h i s  a c t i v i t y  s h o u l d  b e  c om p l e t e d  b e f o r e  LY 3 3 1 6 5 3 1  o r  p la c e b o  a dm i n i s t r a t i o n  ( p r e d o s e ) .
kS k i n  b i o p s i e s  w i l l  b e  p e r f o rm e d  i n  t h e  f i r s t  2 0  h e a l thy  s u b j e c t s  t o  v o l u n te e rf o r  t h i s  p ro c e d u r ei n  P a r t s  A  a n d  B ,  c o l l e c t i v e l y .
lCC I
A f t e r  s u b j e c t  e l i g i b i l i t y  i s  c o n f i rm e d ,  sk i n  b i o p s i e s  c a n  b e  c o l l e c t e d  a t  a n y  t im e  p r i o r  t od o s i n g .CC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 16
LY33165312.2. Part B ( Multiple -Dose Study in Healthy Subjects)
Study Schedule for Protocol I9H -MC-FFAA (Part B )
Screening Baseline Postdose
Visit No. V1Dose Periods 1, 2, and 3
V20 V21 V22 ED
V2,8,14 V3,9,15 V4,10,16 V5,11,17aV6,12,18 V7,13,19
Study Day (s) -26 d from 
Day -2-1 1 2 4 ± 1 d 8 ± 1 d 11 ± 1 d 15 ± 2 d22 ± 2 d 85 
±3d113
±4 d141 
±4 d 28 29 30 32 ± 1 d 36 ± 1 d 39 ± 1 d 43 ± 2 d 50 ± 2 d
56 57 58 60 ± 1 d 64 ± 1 d 67 ± 1 d 71 ± 2 d 78 ± 2 d
Week(s) 0,4,8 1,5,9 2,6,10 3,7,11 12 16 20
Admi ssion to CRU Xb
Discharge from CRU Xc
Informed consent X
Review/confirm I/E 
criteriaX Xd
Complete medical 
history  X
Complete physical 
examinationX X X
Weight X X X
Height X
Symptom -directed 
physical examinationWhen needed
Concomitant 
medicationsX XeX X X X X X X X X X
Vital signs (heart rate, 
blood pressure, and 
temperature)f,gX X Predose, 
end of 
infusion, 
and 2, 6, 12 
h after SC 
injectionhor 
start of 
infusion24 h after 
SC 
injectionh
or start of  
infusionX X X X X X X X X
Review preexisting 
conditio ns/AEsX XeX X X X X X X X X X
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 18
LY3316531Screening Baseline Postdose
Visit No. V1Dose Periods 1, 2, and 3
V20 V21 V22 ED
V2,8,14 V3,9,15 V4,10,16 V5,11,17aV6,12,18 V7,13,19
Study Day (s) -26 d from 
Day -2-1 1 2 4 ± 1 d 8 ± 1 d 11 ± 1 d 15 ± 2 d22 ± 2 d 85 
±3d113
±4 d141 
±4 d 28 29 30 32 ± 1 d 36 ± 1 d 39 ± 1 d 43 ± 2 d 50 ± 2 d
56 57 58 60 ± 1 d 64 ± 1 d 67 ± 1 d 71 ± 2 d 78 ± 2 d
Week(s) 0,4,8 1,5,9 2,6,10 3,7,11 12 16 20
assay  (total CGRP) SC 
injectionh
or start of  
infusion
Skin biopsyrXs
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  19
LY3316531Ab b r e v i a t i o n s :   AE  =  a d v e r s e  e v e n t ;  CGRP  =  c a l c i t o n i n  g e n e- r e l a t e d  p e p t i d e ;  CRU  =  c l i n i c a l  r e s e a r c h  u n i t ;  C -SSRS  =  C o l um b i a- S u i c i d e  S e v e r i t y  R a t i n g  S c a l e ;  
d  =  s tudy  d ay ;  DNA  =  d e o x y r i b o n u c l e i c  a c i d ;  ECG  =  e l e c t r o c a r d i o g r am ;  ED  =  e a r l y  d i s c o n t i n u a t i o n ;  FSH=f o l l i c l e - s t im u l a t i n g  h o rm o n e ;  FU  =  f o l l ow- up ;  h  
=  h o u r ( s ) ;  HBV  =  h e p a t i t i s  B  v i r u s ;  HCV  =  h e p a t i t i s  C  v i r u s ;  H IV  =  h um a n  imm u n o d e f i c i e n c y  v i r u s ;  I /E  =  i nc l u s i o n / e x c l u s i o n ;IV  =i n t r a v e n o u s ;
N o .=n um b e r ;  PK=p h a rm a c o k i n e t i c ;  SC=s u b c u t a n e o u s ;  ;  TB=t u b e r c u l o s i s ;  TST  =  t u b e r c u l i n  s k i n  t e s t ;  
V  =  v i s i t;  
aV i s i t s  5 ,  1 1 ,  a n d  1 7  (D a y s  11 ,3 9 ,  a n d  6 7 )  a r e  re q u i r e d  f o r  s u b j e c t s  r e c e i v i n g  SC  i n j e c t i o n so nly .
bA dm i s s i o n  t o  t h e  CRU  o c c u r s  o n  D a y s  - 1 ,  2 8 ,  a n d  5 6 .
cD i s c h a r g e  f r om  t h e  CRU  o c c u r s  o n  D a y s  2 ,  3 0 ,  a n d  5 8 .
dT h i s  a c t i v i t ys h o u l d  o c c u r  o n  D a y  - 1  on ly .
eA t  t h e  d i s c r e t i o n  o f  t h e  CRU ,  t h e  b a s e l i n e  m e a s u r em e n t  f o r  t h i s  a s s e s sm e n t  c a n  b e  c o l l e c t e d  a t  any  t im e  a f t e r  t h e  s u b j e c t ’ sa dm i s s i o n  t o  t h e  CRU  u p  u n t i l  
LY 3 3 1 6 5 3 1  o r  p l a c e b o  a dm i n i s t r a t i o n  o n  D a y  1 .
fA d d i t i o n a l  v i t a l  s i g n  m e a s u r em e n t s  m a y  b e  o b t a i n e d  w h e n  c l i n i c a l l y  i n d i c a t e d .   V i t a l  s i g n s  s h o u l d  b e  t a k e n  f o l l ow i n g  a n  a p p r o x im a t e  5- m i n u t e  r e s t  i n  s u p i n e  
p o s i t i o n .   T em p e r a t u r e  m e a s u r em e n t  i s  r e q u i r e d  o n l y  a ts c r e e n i n g  a n db a s e l i n e .
gECG ,  v i t a l  s i g n ,  a n d  PK  s am p l i n g  s h o u l d  o c c u r  a t  a p p r o x im a t e l y  t h e  s am e  t im e .   ECG  r e c o r d i n g  a n d  v i t a l  s i g n  m e a s u r em e n t ss h o u l d  o c c u r  p r i o r  t o  t h e  b l o o d  
d r aw .
hSC  i n j e c t i o n  i s  o n l y  i f  an  op t io n a lSCc o h o r t  i s  a d d e d .
iT im e s  a r e  r e f e r e n c e d  t o  s t a r t  o f  d o s i n g .  0- h o u r  a s s e s sm e n t s  s h o u l d  b e  p e r f o rm e d  w i t h i n  1m i n u t e  a f t e r  g i v i n g  a l l  SC  i n j e c t i o n s .   A s s e s sm e n t s  s h o u l d  o c c u r  o n  
D a y 1  ( 0  m i n ,  1 0  m i n ,  0 . 5  h ,  1  h ,  3  h ,  a n d  6  h) ,D a y  2  ( 2 4  h ) ,  D a y  8  ( 1 6 8  h ) ,  a n d  D a y  1 5  ( 3 3 6  h ) a f t e r  SC  i n j e c t i o n  o f  LY 3 3 1 6 5 3 1 .   A d d i t i o n a l  a s s e s sm e n t s  
m ay b e  p e r f o rm e d  i f  d e em e d  n e c e s s a r y  b y  t h e  i n v e s t i g a to r .
jR e q u i r e d  f o r  s u b j e c t s  w h o  w i l l  r e c e i v e  SC  i n j e c t i o n s  o n l y .
kI f  t h e  o p t i o n a l  c o h o r t  u s e s  SC  d o s i n g ,  t h e n  i n j e c t i o n - s i t e  a s s e s sm e n t s  w i l l  b e  p e r f o rm e d .
lECG s  s h o u l d  b e  t a k e n  f o l l ow i n g  a n  a p p r o x im a t e  5- m i n u t e  r e s t  i n  s u p i n e  p o s i t i o n .  ECGs  a r er e q u e s t e d  t o  b e  t a k e n  a t  t h e  s p e c i f i e d  t im e ;  h ow e v e r ,  a b e r r a t i o n s  
t o  s p e c i f i e d  r e c o r d i n g  t im e s  w i l l  n o t  b e  c o n s i d e r e d  p r o t o c o l  d e v i a t i o n s  a s  l o n g  a s  t h e  ECG sa r e  t a k e n  a n d  t h e  a c t u a l  r e c o r d i n g  t im e  i s  d o c um e n te d .   Si n g l e  
s a f e t y  ECG s  w i l l  bec o l l e c t ed  un l e s s  t h e  ECG  v a l u e s  f o r  s u b j e c t s  i n  P a r t  A  s h ow  c l i n i c a l l y  s i g n i f i c a n t  c h a n g e s( f o r  e x am p l e , i n c r e a s e  i n  PR  o r  QT  i n t e r v a l ) .  
S e e  S e c t i o n  9 . 4 . 3f o r  m o r e  d e t a i l s  o n  ECG s .  
mT h e  f o l l ow - u p  TST  r e a d i n g  s h o u l d  o c c u r  2  t o  3  d a y s  a f t e r  V 1 .
nA  s e r um  p r e g n a n c y  t e s t  w i l l  b e  c o n d u c t e d  a t  s c r e e n i n g  o n l y .   U r i n e  p r e g n a n c y  t e s t  w i l l  b e  u s e d  a t  a l l  o t h e r  t im e  p o i n t s .   F o r w om e n  w h o  a r e  c o n s i d e r e d  t o  b e  
p o s tm e n o p a u s a l ,  FSH  s h o u l db e  d r aw n  t o  c o n f i rm  p o s tm e n o p a u s a l  s t a t u s  a s  d e f i n e d  i n  I n c l u s i o n  C r i t e r i o n  [ 1b ]  a n d  t o  b e  c o n s i d e r e d  e x em p t  f o r  f u r t h e r  
p r e g n a n c y  t e s t s  d u r i n g  t h e  s t u d y .
oR e f e r  t o  A p p e n d i x  6f o r  s p e c i f i c  PKa n d  imm u n o g e n i c i t ys am p l i n g  s c h e d u l e .  S am p l e s  a r e  r e q u e s t e d  t o  b e  t a k e n  a t  t h e  s p e c i f i e d  t im e ;  h ow e v e r ,  a b e r r a t i o n s  t o  
s p e c i f i e d  s am p l i n gt im e s  w i l l  n o t  b e  c o n s i d e r e d  p r o t o c o l  d e v i a t i o n s  a s  l o n g  a s  t h e  s am p l e s  a r e  t a k e n  a n d  t h e  a c t u a l  s am p l i n g  t im e  i s  r e c o r d e d .  I t  i s  e s s e n t i a l  
t h a t  t h e  a c t u a l  t im e so f  d o s e s  a n d  s am p l e s  a r e  r e c o r d e d  a c c u r a t e l y  o n  t h e  a p p r o p r i a t e  f o rm s .
pC -SSRS  s h o u l d  b e  a dmi n i s t e r e d  b e f o r e  s u b j e c t s  a r e  d i s c h a r g e d  f r om  t h e  CRU  o n  D a y  2 .
qT h i s  a c t i v i t y  s h o u l d  b e  c om p l e t e d  b e f o r e  LY 3 3 1 6 5 3 1  o r  p l a c e b o  a dm i n i s t r a t i o n  ( p r e d o s e ) .
rS k i n  b i o p s i e s  w i l l  b e  p e r f o rm e d  i n  t h e  f i r s t  2 0  h e a l t h y  s u b j e c t s  t o  v o l u n t e e r  f o r  t h i s  p r o c e d u r e  i n  P a r t s  A  a n d  B ,  c o l l e c t i v e l y .
sCC I
A f t e r  s u b j e c t  e l i g i b i l i t y  i s  c o n f i rm e d ,  s k i n  b i o p s i e s  c a n  b e  c o l l e c t e d  a t  a n y  t im e  p r i o r  t o  d o s i n g .CC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 20
LY33165312.3. Part C (S ingle -Dose Study in Patients with Psoriasis)
Study Schedule for Protocol I9H -MC-FFAA (Part C)
Screening Baseline Postdose Extended FU
Visit No. V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 ED FUaED
Study Day(s) -33d from 
Day -2-1 1 2 4 ± 
1 d8 ± 
1 d15 ± 
2 d22 ± 
2 d29 ± 
2 d43 ± 
3 d57 ±
3 d71 ± 
3 d85 
±3d113
±4 dUp to  
365 ± 5 d
Week(s) 0 1 2 3 4 6 8 10 12 16 Up to 52
Admi ssion to CRU X
Discharge from CRU X
Informed consent X
Review/confirm I/E 
criteriaX X
Complete medical 
history  X
Complete physical 
examinationX X
Weight X X X X X X
Height X
Symptom -directed 
physical examinationWhen needed
Chest x- ray X
Concomitant 
medicationsX XbX X X X X X X X X X X X X X
Vital signs (heart 
rate, blood pressure, 
and temperature)c,dX X Predose, end of 
infusion, and 2, 
6, 12 h after SC 
injectioneor start 
of infusion24 h after 
SC 
injectione
or start of  
infusionX X X X X X X X X X X X X
Review preexisting 
conditio ns/AEsX XbX X X X X X X X X X X X X X
ECGsd,fX See ECG sampling schedule (Appendix 6 )
LY3316531 
administration (IV or 
SC)X
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  21
LY3316531S c r e en in g B a s e l in e P o s td o s e E x t end ed  FU
V i s i t  N o . V 1  V 2 V 3  V 4  V 5  V 6  V 7  V 8  V 9 V 1 0 V 1 1 V 1 2 ED FUaED
S tud y  D a y ( s ) - 3 3d  f r om  
D a y  -2- 1  1 2 4  ±  
1d8  ±  
1d1 5  ±  
2d2 2  ±  
2d2 9  ±  
2d4 3  ±  
3d5 7  ±
3d7 1  ±  
3d8 5  
± 3d1 1 3
± 4dUp  t o   
3 6 5  ±  5d
W e ek ( s ) 0 1  2  3  4  6  8  1 0  1 2  1 6 Up  t o  5 2
Q u a n t iFERON®- TB  
G o l d  t e s t  o r  TSTX
R e a d  TST  ( i f  
a p p l i c a b l e )Xg
H IV /HBV /HCV X
FSHhX
Pr e g n a n c y  t e s thX  X X  X  X  X  X  X  X
S e r um  c h em i s t r y  a n d  
h em a t o l o g yX  X X  X  X  X  X  X  X  X  X  X  X  X  X  X
U ri n a l y s i s X  X X X  X X
U ri n e  d r u g  s c r e e n  
a n d  e t h a n o l  t e s tX  X
P h a rm a c o g e n e t i c s  
( e x p l o r a t o r y  s to r ag e  
s am p l e s  f o r  DNA )X
Imm u n o g e n i c i t yd ,iS e e  imm u n o g e n i c i t y  s am p l i n g  s c h e d u l e  (A p p e n d i x  6)
LY 33 1 6 5 3 1
c o n c e n t r a t i o n(PK )d ,i S e e  PK  s am p l i n g  s c h e d u l e  (A p p e n d i x  6)
C -SSRS /S e l f- H a rm  
S u p p l em e n t  a n d  FUX  X XjX  X  X  X  X  X  X  X  X  X  X  X  X
T a r g e t  e n g a g em e n t  
a s s a y  ( t o t a l  CGRP )Xk2 4  h  a f t e r  
SC  
i n j e c t i o ne
o r s t a r t  o f   
i n f u s i o nX  X  X  X  X  X  X  X  X
P a t i e n t ’ s  G l o b a l  
A s s e s sm e n ta n d  PSSlXkX  X  X  X  X  X  X  X  X
PAS I ,  sPGA ,  a n d  
BSAX XkX  X  X  X  X  X  X  X  X  X
HS- CRP X XkX  X  X  X  X
 C o n c e n t r a t i o n XkX  X  X  X  X CC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 22
LY3316531Screening Baseline Postdose Extended FU
Visit No. V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 ED FUaED
Study Day(s) -33d from 
Day -2-1 1 2 4 ± 
1 d8 ± 
1 d15 ± 
2 d22 ± 
2 d29 ± 
2 d43 ± 
3 d57 ±
3 d71 ± 
3 d85 
±3d113
±4 dUp to  
365 ± 5 d
Week(s) 0 1 2 3 4 6 8 10 12 16 Up to 52
Explo ratory  storage 
samples (serum, 
plasma, RNA)XkX X X X
Skin biopsy XmXn
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 23
LY3316531Abbreviations:  AE = adverse event; BSA = body surface area; CGRP = calcitonin gene -related peptide ;CRU = clinical research unit; C-SSRS = Columbia -
Suicide Severity Rating Scale ;d = study day; DNA = deoxyribonucleic acid; ECG =electrocardiogram; ED = early discontinuation; FSH = follicle -
stimulating hormone; FU = follow -up; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV =human immunodeficiency virus; HS-CRP = high sensiti vity-
C reactive protein; I/E = inclusion/exclusion; IL = interleukin; IV = intravenous; No.=number; PASI =Psoriasis Area and Severity Index; PK = 
pharmacokinetic; PSS = psoriasis symptom scale; RNA = ribonucleic acid; SC=subcutaneous ; sPGA= static Physician Global Assessment; TB =
tuberculosis ; TST = tuberculin skin test ; V = visit .
aMonthly  follow -up vis its will occur during this time period for patients who respond to treatment with LY3316531 after the initial 16 -week follow -up perio d
(see Section 5.1.3 for more details) .
bAt the discretion of the CRU, the baseline measurement for this assessment can be collected at any time after thepatient ’sadmission to the CRU up until 
LY3316531 or placebo administration on Day 1.
cAdditional vital sign measurements may be obtained when clinically indicated.  Vital signs should be taken following an approximate 5 -minute rest in supine
position.   Temperature measurement is required only at screening and baseline.
dECG, vital sign, and PK sampling should occur at approximately the same time.  ECG recording and vital sign measurement shoul d occur prior to the blood 
draw .
eSC injection is o nly if an optio nal subcutaneous -injection cohort is added .
fECGs should be taken following an approximate 5 -minute rest in supine position. ECG s are requested to be taken at the specified time; however, aberrations 
to specified record ing times will not be considered protocol deviations as long as the ECG sare taken and the actual record ing time is document ed.  Single 
safety ECGs will be collected unless the ECG values for subjects in Part A show clinically significant changes (for exam ple,increase in PR or QT interval) .  
See Section 9.4.3 for more details on ECGs .
gThe follow -up TST reading should occur 2 to 3 days after V1.
hAll female subjects of childbearing potential will have serum pregnancy test at screening only. Urine pregnancy test will be used at all other time points.  For 
women who are considered to be postmenopausal, FSH should be drawn to confirm postmenopausal s tatus as defined in inclusio n criterion [8b ] and to be 
considered exempt for further pregnancy tests during the study.
iRefer to Appendix 6 for specific PK and immunogenicity sampling schedule. Samples are requested to be taken at the specified time; however, aberrations to 
specified sampling times will not be considered protoco l deviations as long as the samples are taken and the actual sampling time is recorded. It is essential 
that the actual times of doses and samples are recorded accurately on the appropriate forms.
jC-SSRS should be administered before subjects are discharged from the CRU on Day 2.
kThis activity should be completed on Day -1or Day 1 before LY3316531 or placebo administration (predose).
lAll patient -reported outcomes are to be collected from the subject prior to clinical assessment by the investig ator.
mAfter patient eligibility is confirmed, b aseline skin biopsies can be collected at any  time starting on Day -7up until dosing.
nPostdose skin biopsies should be collected on Day 15± 2days. 
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  24
LY33165313 .In t roduc t ion
3 .1 .S tudy  Ra t iona le
LY 3 3 1 6 5 3 1  i s  a  h um a n i z e d  b i s p e c i f i c  a n tibody  th a t  s e l e c t i v e l y  b i n d s  t o  i n t e r l e u k i n - 23  ( IL - 23 )  
a n d  c a l c i t o n i n  g e n e - r e l a t ed  p ep t i d e  (CGRP ) .   T h i s  d u a l  i n h i b i t o ri s  a n  i n n o v a ti v e  a t t em p t  t o  
t a rg e t  p a t hw a y s  t h a t  a f f e c tth e  p a tho l ogya s s o c i a t e d  w i t h  au to - i n f l amm a t o r y  c o n d i t i o n s .
S tudy I9H - MC- FFAA  (FFAA )  i s  a  P h a s e  1 ,  f i r s t - i n - hum an  s tudy  toe x p l o r e  t h e  s a f e t y , 
to l e r a b i l i t y ,  a n d  p h a rm a c o k i n e ti c s  ( PK)o f  s i n g l e  a n d  m u l t i p l e  d o s e s  o f  LY 3 3 1 6 5 3 1  i n  h e a l t h y  
s u b j e c t s  a n dth e  s a f e t y , to l e r ab i l i ty ,  PK ,  and  p h a rm a c o d y n am i c s  (PD)o fas i n g l e  d o s eo f  
LY 3 3 1 6 5 3 1i n  p a t i e n t s  w i t h  p s o r i a s i s .   Thee v a l u a t i o n  o f  LY 33 1 6 5 3 1i n  p a ti e n t s  w i th  p s o r i a s i s  
w i l l  a i d  i n  th ed e t e rm in a t i on  o f  a  s a f e  d o s e  l e v e lo r  r a n g e ,  ch a r a c t e r i z e  PK  a n d  PD ,  a n d  e x p l o r e  
c l i n i c a l  a c t i v i t y  d a t a  fo r  fu tu r e  s tud i e s .
Sk inb i o p s i e s  w i l l  a l s o  b e  t a k e n  t o  o b s e r v e  t h e  e f f e c t s  o f  LY 3 3 1 6 5 3 1  o n  p s o r i a ti c  s k i n  l e s i o n s .   
 
 
W h i l e  Study  F FAA  w i l l  e v a l u a t e  LY 3 3 1 6 5 3 1  i n  p a t i e n t s  w i t h  p s o r i a s i s ,  a t o p i c  d e rm a ti t i s  a n d  
C r o h n ’ s  d i s e a s e  a r e  a l s o  p o t e n t i a l  f u t u r e  i n d i c a ti o n s .
3 .2 .Backg round
CC IA  typ i c a l  o rg an - s p e c i f i c ,T - c e l l - d r iv en  in f l amm a to ry  d i s e a s e ,  p so r i a s i s  h a d  b e e n  c o n s i d e r e d  a  
Th e l p e r  (T h )  1 - ty p e  s k i n  d i s e a s e  f o r  d e c a d e s  u n ti l  a  n ew  T h  p o p u l a t i o n ,  T h 1 7 ,  w a s  i d e n t i f i e d  
(L ew  e t  a l .  2 0 0 4 ;  S t e i nm a n  2 0 0 7 ;  W e a v e r  e t  a l .  2 0 0 7 ) .   H ow e v e r ,  s u b s t a n t i a l  c l i n i c a l  a n d  b a s i c  
r e s e a r c h  o b s e r v a t i o n s  now  sugg e s t  th a t  th e  IL - 2 3 /T h 1 7  a x i s  i s  e s s e n ti a l  i n  t h e  p a t h o g e n e s i s  o f  
p so r i a s i s  (D i  C e s a r e  e t  a l .  2009 ) .   IL - 2 3 ,  a  m em b e r  o f  t h e  IL - 1 2  f am i l y  o f  c y tok in e s ,  i s  a  
h e t e r o d im e r i c  p r o t e i n  c om p r i s e d  of  2  s u b u n i t s ;  t h e  p 4 0  s u b u n i t ,  w h i ch  i t  sh a r e s  w i th  IL - 1 2 ,  a n d  
th e  p 1 9  s u b u n i t ,  b e l i e v e d  t o  b e  s p e c i f i c  t o  IL - 2 3 .   IL - 23  i s  p rodu c ed  by  an t i g en - p r e s e n ti n g  c e l l s ,  
s u c h  a s  d e n d r i t i c  c e l l sand  m a c r o p h a g e s ,  a n d  p l a y s  a n  im p o r t a n t  r o l e  i n  m a i n t e n a n c e  a n d  
am p l i f i c a ti o n  o f  T h 1 7  c e l l s  (L e e  e t  a l .  2 0 0 4 ;  P i s k i n  e t  a l .  2 0 0 4 ) .   I n  a d d i ti o n ,  T h 1 7  c e l l s  a n d  t h e i r  
d ow n s t r e am  e f f e c t o r  m ol e c u l e s ,  i n c l u d i n g  IL - 17A ,  IL - 17F ,  IL - 21 ,  IL - 2 2 ,  a n d  t um o r  n e c r o s i s  
f a c t o r  a l p h a  (TNF - α ) ,  a r e  f o u n d  a t  i n c r e a s e d  l e v e l s  i n  h um a n  p s o r i a t i c  s k i n  l e s i on s  a n d  
c i r c u l a t i o n  (Bon i f a c e  e t  a l .  2 0 0 7 ;  L ow e s  e t  a l .  2 0 0 8 ;  C a r u s o  e t  a l .  2 0 0 9 ;  K a g am i  e t  a l .  2 0 1 0 ) .
T r e a tm e n t  o f  p s o r i a s i s  w i t h  b i ol o g i c  th e r apy ,  p a r t i cu l a r ly  w i th  tho s e  ag en t s  t a rg e t ing  th e  
IL -2 3 /T h 1 7  a x i s ,  h a s  d em o n s t r a t e d  c l i n i c a l  a c t i v i t y  i n  p a ti e n ts  w i th  p so r i a s i s  (C row  2012 ) .   
A g e n t s  s p e c i f i c a l l y t a rg e t ing  th e  IL - 2 3  p 1 9  s u b u n i t h a v e  d em o n s t r a t e d  c l i n i c a l  a c t i v i t y  i n  
p so r i a s i s  (K r u e g e r  e t  a l .  2 0 1 5 ;  P a p p  e t  a l .  
2 0 1 5 ;  G o r d o n  e t  a l .  2 0 1 5 ;  K op pe t  a l .  2015 ;  So f en  e t  a l .  2014 )  a n d  C r o h n ’ s  di s e a s e  (S a n d s  e t  a l .  
2 0 1 5 ) .CC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 25
LY3316531Calcitonin gene-related peptide is a 37 -amin o acid neuropepti de member of a family  of 
pepti des that i ncludes amylin, adrenomedullin ,and cal citonin .The predominant form of CGRP 
is known as -CGRP, wi th a second isoform , -CGRP, being produced from a separate gene but 
having high sequence ho molo gy (Steenbergh et al . 1985).  Both isoforms have similar bio logical  
activit ies, but differ in their expressio n patterns; -CGRP i s expressed mainly in the peripheral 
and central  nervous system while -CGRP i s expressed m ostly  in the enteri c nervous system 
(Mul derry  et al . 1988) . Calcitonin gene -related pepti deis a potent vasodilator (Brain et al. 
1985) . While CGRP antagonists seem to restore normal tonus in CGRP -induced dilation of 
isolated arteri al rings , the evidence to date suggests that CGRP antagonists do not al
ter basal  
vascular tone (Chait man et al. 2012; Verheggen et al. 2002) .  Calcitonin gene -related pepti dehas
a well-established rol e in neurogenic inflammat ion and nociception (Hirsch et al. 2013). It is 
able to facilitate the production and secretio n of numerous pro- inflammatory mediators that lead 
to hy peremia, edema ,and pain in inflamed tissues (Cady et al. 2011).  The CGRP pathway  may
play a specific role in inflammatory  skin disorders having direct effects onimmune cells, 
cytokine producti on, a nd itch and pain pathol ogies in various dermatoses (Lott iet al. 2014 ; 
Kashem et al. 2015 ). Interestingly , CGRP regulate s sensory  neurons through the IL -23/IL -17 
axis as well (Ri ol-Blanco et al . 2014; Ding et al. 2016) .  In addit ion to i ts involvement in 
inflammat ion and noci ception, it is believed that CGRP canincrease IL-23producti on (Kashem 
et al. 2015 ).
Several nonclinical studies were performed to support the use of LY3316531 in humans.  
Weekly administration of LY3316531 to cyno molgus m onkeys in a general toxicology  study  
resul ted in no adverse drug- related findings at doses of 20 or 60 mg/kg ( subcutaneous [ SC]), or 
200 m g/kg ( intravenous [ IV]) for 3 months.   The exposure mult iple and dose m ultiple to the 
highest human dose, based o n this monkey study , are 5 ×and 28 ×,respectively.  Addit ionally , a 
tissue cross -reactivit y study  was perform ed wi th LY3316531 in human and monkey tissues ,
which produced no toxico logically important difference in t issue binding between the species.
3.3. Benefi t/Risk Assessment
The nonclinical safet y informat ion for LY3316531 supports the transit ion from preclinical status 
to a clinical, first-in-human study .  On the basis o f the nonclinical data, LY3316531 is not 
considered to be a high -risk co mpound.  This protocol reflects the fact that LY3316531 has not 
been administered to humans previously, and to mitigate this risk, the study  has been designed to 
be conducted in accordance with principles outlined in the Guideline on St rategies to Identify 
and Mit igate Ri sksfor First-in-Human Clinical Trials with Investigational Medicinal Products .  
Any identified risks are consi dered to be m onitorable and m anageable at the planned dose range 
with starting dose of 3 mgup to a maximum dose not to exceed 2000 mg for LY3316531 in 
healt hy subjects and pat ientswith psori asis.
There i s no antici pated therapeuti c benefi t for the healt hy subjects. There is a potential for 
patients wi th psoriasis to experience some level of therapeutic benefit during this study , as 
blockade o f IL-23 is known to improve psoriasis .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 26
LY3316531More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated adverse events (AEs) of LY3316531 are to be found in the 
Invest igator’s Brochure (IB) .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 27
LY33165314.Objectives and Endpoints
TableFFAA .4.1shows the object ives and endpo ints of the study .
TableFFAA .4
.1. Objectives and Endpoints
Primary Objectives Primary Endpoints
To explore the s afety  and tolerability  of single and 
multiple doses of LY3316531 in healthy subjects
To explore the safety and tolerability of asingle dose of 
LY3316531 in patients with psoriasisIncidence of a dverse events, TEAEs, and SAEs
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  28
LY3316531Ob j e c t i v e s  and  Endp o in t s
S e c ond a r y  Ob j e c t i v e s S e c ond a r y  Endp o in t s
T o  c h a r a c t e r i z e  t h e  PK  o f  LY 3 3 1 6 5 3 1  f o l l ow i n g  IV  a n d  
SC  a dm i n i s t r a t i o ni n  h e a l t h y  s u b j e c t s
T o  c h a r a c t e r i z e  t h e  PK  o f  LY 3 3 1 6 5 3 1  f o l l ow i n g  IV  
a dm i n i s t r a t i o n  i np a t i e n t s  w i t h  p s o r i a s i sCm axandAUC
E xp l o r a t o r y  Ob j e c t i v e s E xp l o r a t o r y  Endp o in t s
T o  e v a l u a t e  t h e  i n j e c t i o n  t o l e r a n c e  a f t e r  SC  
a dm i n i s t r a t i o n  o f  LY 3 3 1 6 5 3 1P a i n  s c a l e  s c o r e s  a n d  s e v e r i t y  o f  ISR
T o  e v a l u a t e  t h e  f o rm a t i o n  o f  ADA  t o  LY 3 3 1 6 5 3 1  P r e s e n c e  o f  ADA  a g a i n s tLY 3 3 1 6 5 3 1
T o  e v a l u a t e  t h e  PD  r e s p o n s e  ( t a r g e t  e n g a g em e n t )  o f  
LY 3 3 1 6 5 3 1  u s i n g  t o t a l  CGRPS umm a r y  o f  t o t a l  CGRP  c o n c e n t r a t i o n s  f o r  e a c h  c o h o r t  
a n d  s t u d y  t im e  p o i n t
T o  e v a l u a t ep a t i e n t- r e p o r t e d  o u t c om e s ,  i n c l u d i n g  
m e a s u r em e n t  o fd i s e a s e  a c t i v i t y  o f  LY 3 3 1 6 5 3 1i n  
p a t i e n t s  w i t h  p s o r i a s i sS umm a r y  (m e a n ,  s t a n d a r d  d e v i a t i o n ,  m e d i a n ,  m i n im um ,  
a n d  m a x im um )  o f  a b s o l u t e  p e r c e n t a g e  c h a n g e  f r om  
b a s e l i n e  f o r  a l l  o f  e a c h  c o h o r t  a n d  o v e r a l l  f o r  e a c h  
s am p l e  d a y / t im e  c om b i n a t i o n  a n d  m a x im um  o v e r  t h e  
e n t i r e  s t u d yf o r  t h e  p a t i e n t ’ s  g l o b a l  a s s e s sm e n t
T o  e v a l u a t e  r e l a t i o n s h i p s  b e tw e e n  LY 3 3 1 6 5 3 1  ex p o s u r e
andPD  a n d  c l i n i c a l  a c t i v i t y  m e a s u r e sa n d  s a f e t y  
e n d p o i n t sGr a p h i c a l  a n d  m o d e l - b a s e d  s umm a r i e s  o f  r e l a t i o n s h i p s  
b e tw e e n  LY 3 3 1 6 5 3 1  e x p o s u r e  a n d  t o t a l  CGRP ,  ,  
PAS I ,  sPGA ,  ECG s ,  a n d  s a f e t y  e n d p o i n t s  o f  i n t e r e s tCC I
A b b r e v i a t i o n s :   ADA  =  a n t i d r u g  a n t i b o d y ;  AUC  =  a r e a  u n d e r  t h e  c o n c e n t r a t i o n  v e r s u s  t im e  c u r v e ;  CGRP  =  
c a l c i t o n i n  g e n e - r e l a t ed  p e p t i d e ;  C m a x=  m a x im um  o b s e r v e d  d r u g  c o n c e n t r a t i o n;  ECG  =  e l e c t r o c a r d i o g r am ;  IL  =  
i n t e r l e u k i n ;  ISR  =  i n j e c t i o n - s i t e  r e a c t i o n ;  IV  =  i n t r a v e n o u s ;  PAS I=P s o r i a s i s  A r e a  a n d  S e v e r i t y  I n d e x;  PD  =  
p h a rm a c o d y n am i c s ;  PK  =  p h a rm a c o k i n e t i c s ;SAE  =  s e r i o u s  a d v e r s e  e v e n t ;  SC  =  s u b c u t a n e o u s ;  sPGA  =  s t a t i c  
Phys i c i a n  G l o b a l  A s s e s sm e n t ;  TEAE  =  t r e a tm e n t - em e r g e n t  a d v e r s e  e v e n t .CC ICC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 29
LY33165315.Study  Design
5.1. OverallDesign
Study  FFAA is a 3-part Phase 1, mult icenter, randomized, sponsor unblind, subject -and 
investig ator-blind (invest igator will be partially blind edfor Cohorts 1 and 2 and unblind for 
Cohort 5 in Part A) , placebo -controlled, parallel -dose group, single
-ascending dose (SAD)
design (Part A ),and multiple-dose design (Part B) inhealthysubjects .  In addi tion, Part C of this 
study  is an open -label, single -dose design in pat ientswith psoriasis. There are 3 parts to this 
study to expl ore the safet y, tolerabilit y, PK, and PD of LY3316531:
Part A: SAD design in healt hy subjects,
Part B: Multiple-dose design in healt hy subjects,
Part C: Single -dose designin pat ients with psori asis.
Table FFAA. 5.1provides a detailed descript ion of subject/pati ent cohorts and planned doses for 
Parts A, B, and C.  Figure FFAA.5. 1demonstrate s the relationship amongParts A, B, and C.  
Part A will begin first and will trigger the init iation of Parts B and C ,which will run in parallel.
Patients/
subjects will be admitted to the clinical research unit ( CRU )on Day  -1 (Days -1, 28, and 
56 in Part B) and fast overnight. Patients/ subjects will receive a dose of study  drug or pl acebo 
on Day  1 (Day s 1, 29, and 57 in Part B) and will undergo the study  assessments specified in the 
Schedule of Activities (Secti on 2). Patients/ subjects m ay be di scharged 24 hours after dose 
administration on Day  2 (Day s 2, 30, and 58 in Part B) .  In case of safet y concerns,
patients/subjects will be required to stay  in the CRU for a longer period at the discret ion of the 
investigator. Patients/ subjects will return to the CRU for outpatient visit s for procedures 
specified in the Schedule of Activities(Secti on 2).
The decisio n to escal ate to the next higher dose of LY33 16531 will be based on safet ydata 
through Day  15from at least 7subjec ts (5 or 6 subjects will have received LY3316531 
determined by rando mizat ion) fromthe preceding dose cohort.  Exceptions will be for Cohorts 1 
and 2,and Cohort 5 if available at the time of decision in Part A ,where safety data fro m all 
subjects through Day 15 will be required.   
More detailed informat ion about the safet y reviews 
and dosing decisio ns m ay be found in Sect ion7.4.2.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 30
LY3316531Table FFAA .5.1. Summary of Maximum Number of Patient s/Subject s per Cohort
Cohort #Planned D ose/
Administration RouteNumber of
Planned SubjectsTotal Number of 
Planned Subjects
LY PBO
Part A
SAD Cohort 1a3 mg/IV 3 1 4
SAD Cohort 2a15 mg/IV 3 1 4
SAD Cohort 3 75 mg/IV 6 2 8
SAD Cohort 4 300 mg/IV 6 2 8
SAD Cohort 5 300 mg/SC 6 0 6
SAD Cohort 6 900 mg/IV 6 2 8
SAD Cohort 7 2000 mg/IV 6 2 8
Part B
Multiple-Dose Cohort 1 2000 mg/IV 6 2 8
Multiple-Dose Cohort 2bRoute and dose TBD 6 2 8
Part C
Patient Cohort 1c300 mg/IV 8 0 8
Patient Cohort 2b,cRoute and dose TBD 8 0 8
Patient Cohort 3b,cRoute and dose TBD 8 0 8
Abbreviations: IV = intravenous; LY = LY3316531; PBO = placebo; SAD = single -ascending dose; SC = 
subcutaneous ; TBD = to be determined .
aSentinel dosing will be used in this cohort.
bOptional subject or patient cohort.  Actual dose and route of administration will be determined based on 
cumulative data from previous cohorts, but will not e xceed 2000 mg of LY3316531 administered IV.
cA minimum of 7 patient s are planned but up to 8 patients areallowed per cohort .
A follow-up visit will be performed according to the Schedule of Act ivities (Secti on 2).
Study  governance considerations are described in detail in Appendix 3 .
Figure FFAA.5. 1illustrates the study  design.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 31
LY3316531Abbreviations:   IV = intravenous; LY = LY3316531; MD = multiple dose; PBO = 
placebo; PK = pharmacokinetic sampling; SAD = single -ascending dose; SC = 
subcutaneous; SR = safety review meeting ; TBD = to be determined .
Figure FFAA.5. 1. Illustration of study design for Protocol I9H -MC-FFAA .
5.1.1. Part A (SAD in Healthy Subjects)
Seven planned dose -escalat ion cohorts will be enrolled to receive eit her IV or SC administration 
of LY3 316531 (3, 15, 75, 300, 900, or an addit ional dose not to exceed 2000 m g)or placebo .
Sentinel do sing will be used in Cohorts 1 and 2 to minimize the risk to subjects receiving this 
novel ant ibody .  Initially, 2 subjects (1 receiving LY3 316531 and 1 receiving placebo) will be 
dosed in a blinded manner (sent inel subjects) and these subjects will be fo llowed f or at l east 
24hours postdose before the remaining subjects in that cohort aredosed (subject blind only) .  
The rem aining subjects may thenbe dosed on the same day or subsequent days (but not 
necess arily consecutive days), as determined by the invest igator .  Dose escalation to the next 
cohort can begin after a safet y review of data fro m the preceding cohort (see Section 7.4.2 fora 
more detailed descript ion).  All 6 subjects in Cohort 5 will receive 300 m g of LY3316531 SC.
All subjects who meet eligibilit y criteria will  be followed f or 12 weeks post -treatm ent 
administration.   
A subject’s participat ion is considered as complete if he/she received the study 
drug and completes all act ivities up to and including at least Day  57.  Subj ects m ay be replaced if
PK data are not collected up to and including Day 57 .  
5.1.2. Part B (Multiple -Dose Design inHealthy Subjects)
One planned multiple-dose cohort will be enro lled to re ceiveIV administration of LY3316531 
(2000 mg) or placebo.   Thedose and route of administration (IV or SC) for anoptional second 
multiple-dose cohort wouldbe determined after revi ewing the data from the first IV cohort .
It is planned that areview of the safet y data fro m Cohort 7(Part A) andthepreliminary PK data
(maximum observed drug concentration 
[Cmax] and area under the concentration versus t ime 

I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 32
LY3316531curve [AUC ]) from Cohorts 1, 2, and 3 ( through Day  29) in Part A will tri gger enro llment to the 
first cohort in Part B .  Secti on7.4.1 provides detailed informat ion on how the dose level for t he 
optional cohort will be determined and when the cohorts will begin enrollment procedures.
All subjects who meet eligibilit y criteria will receive 3 doses of LY3316531 (1 dose every  
4weeks) and be followed f or 12 weeks afterthe final treatm ent administrati on.A subject’s 
participat ion is considered as complete if he/she received the study drug and completes all 
activit ies up to and including at least Day  85.  Subjects may be replaced if PK data are not 
collected up to and including D ay 85.
5.1.3. Part C (Single -Dose Design in Patients with Psoriasis)
One planned single -dose cohort will be enro lled to receive IVadministration of LY3316531 with 
the opti on of  2 subsequent cohorts where the dose levels and route of administration (SC or IV) 
woul dbe determined after revi ewing the data from the first IV cohort .
The first cohort is planned to receive 300 mg of LY3316531 pending the analysis o f available 
safet y data fro m Part A.  The safet y scenari os for AEs, SAEs, and adverse laboratory  
abnorm alitiesdescribed in Sect ion 7.4.2 that woul d prevent dose escalat ion in Parts A and B are 
the sam e that wouldprevent initiation ofPart C .The actual starting dose and expected exposure 
will not exceed the dose/exposure that is concurrently being evaluated in Part A.  Any available
preliminary PK data from Cohorts 1, 2, and 3 (through Day 29) in Part A will be considered in 
the deci sion to ini tiate Part C as well.   
Similarly, the dose for the optional cohorts will be determined based on cumulat ive data fro m 
previous cohorts, but will not exceed 2000 mg o f LY3316531.  Section 7.4.1 provides detailed 
inform ation on how dose levels for the 2 optional cohorts will be determined and when the 
cohorts will begin enrollment procedures.
All patients who respond to LY3316531 treatment by exhi biting at least50% reduction from 
baseline Psori asis Area and Severit y Index(PASI )score at Week 12 (Visit 11; Day 85) can enter 
an extended fo llow-up peri od for up to 52weeks post-treatm ent administration (see Section 2.3).  
Other subjects who do not meet the above criterion for PASI reduction should be considered for 
discontinuat ion from the study at Week 16 (Vi sit 12;Day 113). Exceptions could be considere d 
after a di scussio n between the sponsor and invest igator.
A pat ient’s participat ion is considered as complete if he/she received the study drug and 
completes all act ivities up to and including at least Day 85.  Patients may be replaced if PK or 
PD data ar e not collected up to and including Day 85.
5.2. Number of Participants
5.2.1. Part A (SAD Design in Healthy Subjects)
Up to 52subjects may be enro lled sothat approximately 46subjects complete Part A .  For 
purposes of this study , a subject completes Part A when he/she co mpletes all scheduled 
procedures up to and including at least Day 57 .  
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 33
LY3316531Refer to the Schedule of Activit ies(Secti on 2.1)for data to be collected at the time of 
discontinuat ion and fo llow-up .
5.2.2. Part B ( Multiple -Dose Design in Healthy Subjects)
Up to 20subjects may be enro lled so that approximately 16subjects complete Part B (total 
number of subjects for planned Cohort 1 and the 1 optional c ohort) .  Subj ects who drop out of 
the Part B prior to receiving the third dose will be replaced.  However, subjects who drop out 
following administrati on of  the thi rd dose, or wi thdraw fro m Part B due to safety reasons will not 
be replaced, unless more than half o f the subjects in a given cohort have dropped out after the 
third dose.   For purposes of Part B , a subject completes the study  when he/she co mpletes all 
scheduled procedures up to and incl uding at l east Day  85.
Refer to the Schedule of Activit ies(Secti on 2.2)for data to be collected at the time of 
discontinuat ion and fo llow-up.
5.2.3. Part C (S ingle -DoseDesign in Patients with Psoriasis)
Up to 30patients may be enrolled so that up to 24patients complete Part C (total number of 
patients pl anned for Cohort 1 and the 2 optional cohorts) .  For purposes of Part C , a patient
completes the study  when he/she co mpletes all schedul ed procedures up to and including at least 
Day 85.
Refer to the Schedule of Activit ies (Secti on 2.3) for data to be collected at the ti me of 
discontinuat ion and fo llow
-up.
5.3. End of Study Definition
End of the study is the date of the last visit or last scheduled procedure shown in the Schedule o f 
Activities(Secti on2) for the last patient/subject .
5.4. Scientific Rationale for Study Design
This study  will be the first assessment of the safety and tolerabilit y of single and multiple 
(monthly) doses of LY3 316531 in humans.   A
parallel- group desi gn was selected based on the 
expected long half -life o f the molecule in humans.  Although a crossover design could provi de 
more robust data, the long washout perio d required for the anticipated 2-to 3-week half-life 
woul d make i t impract ical.  In addit ion, wi th an antibody  such as LY3316531, there is the 
potenti al for devel oping ant idrug antibodies (ADAs) , whi ch coul d confound analyses for 
subsequent doses.
Safety and tol erabilit y assessments will be made over all dose levels.  Subjects (all cohorts) will 
remainin the CRU for at least24 hours aftereach dose ofLY33 16531 or placebo, to provi de 
adequate and close safety  monitoring.   
Sentinel dosing will be u sed in Cohorts 1 and 2 of Part A 
to minimize safet yriskswith this m olecule.
For Part A, s ubjects are blinded and invest igators are partially blinded to treatments to minimize 
bias during data collect ion (see Section 5.1.1 ).  As there is only a single cohort of subjects 
receiving LY33 16531 via the SC route in Part A , itis not planned to include subjects receiving 
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  34
LY3316531SC  p l a c ebo ,  a s  a d e q u a t e  con t ro l d a t a  w i l l  b e  ob t a i n e d  f r o m  th e  IV  c o h o r t .A  s i n g l e- do s e  d e s ign  
i s  a p p r o p r i a t e  t o  a s s e s s  t h e  i n i t i a l  s a f e t y  p r o f i l e  o f  t h e  d r u g  w h i l e  m i n im i z i n gsub j e c t  r i sk ;i t  a l so  
p rov i d e s  a n  o p p o r t u n i ty  to  exp l o r e  s a f e ty  a n d  PK  a c r o s s  a  b r o a d  r a n g e  o f  d o s e s  i n  a n  a d e q u a t e  
n um b e r  o f  s u b j e c t s  t o  d e t e rm i n e  a  r a n g e  o f  d o s e s  a n d  r e g im e n s  t o  b e  e v a l u a t e d  i n  l a t e r  s t u d i e s .
F o r  P a r t  B ,  s u b j e c t s  a n d  i n v e s ti g a t o r s  a r e  b l i n d e d  t o  t r e a tm e n t s  t o  m i n im i z e  b i a s  d u r i n g  d a t a  
c o l l e c t i o n .   In tr a v e n o u sp l a c ebo  con t ro ls u b j e c t s  a r e  i n c l u d e d  t o  a l l ow  f o r  a  m o r e  robu s t  
i n t e rp r e t a t i on  o f  d a t a .   P r e l im i n a r y  s a f e ty  d a t a  f r om  t h e  SADpo r t i o n  i n  P a r t  A  w i l l  s u p p o r t  t h e  
u t i l i z a ti o n  o f  h e a l t h y  s u b j e c t s  i n  t h e  m u l ti p l e - do s epo r t i on  in  P a r t  B .   Th e  m u l ti p l edo s e  i s  th e  
n e x t  l o g i c a l  s t ep  f o r  c l i n i c a l  e v a l u a ti o n  o f  ani n v e s t i g a t i o n a l  p r o d u c t( IP ) .
T h e  s t a r t i n g  d o s e  i n  P a r ts  B  a n dC  o f  t h e  s t u d y w i l l  b e  a dm i n i s t e r e d  v i a  t h e  IVrou t e .I f  
add i t i on a l  coho r t s  a r e  d o s e d ,  d e p e n d i n g  o n  t h e  d o s e  l e v e l  c h o s e n ,  t h e  SC  r o u t e  m a y  b e  u s e d  i f  
f e a s i b l e  (m a x im um  con c en t r a t i on  o fLY3 3 1 6531  i s7 5m g /mL ).   In  add i t i on ,  a  w i d e  do s e  r ang e  
h a s  b e e n  c h o s e ni n  P a r t  A  a s  th i s  s tudy  w i l l  suppo r t  m u l t i p l e  ind i c a t i on s ,  i n c l u d i n gi n f l amm a t o r y  
bow e l  d i s e a s e ,  wh i ch  m ay  r e q u i r e  h i g h e r  d o s e s  o f  LY 3 3 1 6 5 3 1  t o  r e a c h  t h e r a p e u t i c  l e v e l s  a s  
com p a r e d  to  p s o r i a s i s .
A  p o p u l a t i o n  of  h e a l th y  s u b j e c t s  w a ss e l e c t e d  t o  a s s e s s  t h e  PK ,  s a f e t y ,a n d  t o l e r a b i l i t y  o f  
LY 3 31 6 5 3 1b a s e d  u p o n  t h e  l i k e l i h o o d  o f  l e s s  p h y s i ol o g i c  v a r i ab i l i ty  i n  th e  ab s en c e  o f  d i s e a s e  
s t a t e s  t h a t  m a y  a f f e c t  m u l t i p l e  o rg an  sy s t em s .   Mo r eov e r ,  h e a l thy  s u b j e c t s  a r e  u s u a l l y  d e v oi do f  
o t h e r  c o n f o u n d i n g  f a c t o r s  s u c h  a s  c o n c om i t a n t  m e d i c a ti o n s .  T h e  i n c lu s i on  o f p a t i en t s  w i th  
p so r i a s i s  w i l l  a i d  i n  t h ed e t e rm i n a ti o n  o f  s a f e  d o s e  l e v e l s ,a  c h a r a c t e r i z a t i o n  o fPK  a n d  PD ,  a n d  
th e  e x p l o r a t i on  o fc l i n i c a l  a c t i v i t y  d a t a  fo r  fu tu r e  s tud i e s .
5 .5 .Jus t i f ica t ion  fo r  Dose
Th e  w id e  do s e  r ang e  s e l e c t ed  fo r  P a r t  A  o f  t h es tudy  i sb a s e d  o n  PK  a n d  e f f i c a c y  d a t a  a v a i l a b l e  
f r o m  c l in i c a l  s tud i e s  w i th  th e  IL -2 3  m ono c l on a l  an t ibody  ( mA b)(  )a n d  t h e  CGRP  
mA b  (  ) ,  coup l ed  w i th  p r e c l in i c a l  PK  in fo rm a t i o n  f o r  LY 3 3 1 6 5 3 1  i n  c y n o m ol g u s
m on k e y s  a n d  r e l a t i v e  p o t e n c y  i n f o rm a ti o n  c o l l e c t e d  i n  h um a n i z e d  IL -2 3  m ou s e  PD  m o d e l  
exp e r im en t s .   Th e  p la n n e d  s t a r t i n g  d o s e  o f  3m g  IV  i s  e x p e c t e d  t o  h a v e  m i n im a l  b i ol o g i c a l  
a c t i v i t y  and  th e  m ax imum  do s e  o f  2000m g  IV  i s  e x p e c t e d  t o  s u p p o r t  t h e  h i g h e s t  d o s e s  t h a t  m a y  
b e  e v a l u a t e d  i n  t h e  m ul t i p l e - do s ea n d  P h a s e  2  s t u d i e s .   
 T h e  s t a r t i n g  a n d  m a x im um  
d o s e s  a r e  e x p e c t e d  t o  p r o d u c e  AUC s  t h a t  a re  8 5 1a n d  5×l ow e r,  r e sp e c t i v e ly ,th a n  t h e  AUC  
o b s e r v e d  a t  t h e  NOAEL  d o s e  i n  t o x i c o l o gy  s tud i e s  i n  c y n o m ol g u s  m o n k e y s  (T a b l e  FFAA .5 .2CC I
) .
T h e  do s e ( s )f o r  P a r t s  B  a n d  C  w i l l  b e  s e l e c t e d  b a s e d  o n  a v a i l a b l e  PK a n d  s a f e t y  d a t a  f r om  P a r t  A  
o f  th e  s tudy .   Th e  h igh e s t  do s e  th a t  m a y  b e  e v a l u a t e d  i n  P a r t  B  w i l l  n o t  e x c e e d  t h e  m ax im um  
to l e r a t ed  do s e  (MTD )i n  P a r t  A .   I n  t h e  e v e n t  PK  d a t a  f r om  P a r t  A  i n d i c a t e  t h a t  s i g n i f i c a n t  d r u g  
a c c um u l a t i o n  i s  l i k e l y  t o  o c c u r  w i t h  d o s e s  o f  2 0 0 0m g  LY 3 3 1 6 5 3 14  a dm i n i s t e r e d  ev e ry  4w e e k s,  
th e  do s e  a dm i n i s t e r e d  i nP a r t  B  w i l l  b e  r e d u c e d .  CC I
CC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 36
LY33165316.Study  Population
Eligibilit y of patients/subjects for the study  will be based on the results of screening medical 
history , physical  examinat ion, vital signs, clinical laboratory  tests ,and an electrocardiogram 
(ECG) . 
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented .
Screening may occur up to 28 days (35 days for pati ents) prior to enrollment.  Subjects who are 
not enrolled wit hin 28days (35 day s for pati ents) of screening may be subjected to an addit ional 
medical assessment and/or clinical measurements to confirm their eligibilit y.
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, isnot permitted
.
6.1. Inclusion Criteria
Patients/s ubjects are eligible for inclusio n in the study  only if they  meet all of the following 
criteria at screening and/or enrollment :
6.1.1. For Healthy Subjects
[1] a re overtly healt hy males or females, as determined by  medical history  and 
physical examinat ion.
[
1a]male subjects :
agree to eitherremain abstinent (ifthisis their preferred andusual lifest yle)
or usecondoms with spermicide aswell as1 additional highly effect ive
method of contraception or effect ivemethod ofcontraception during the 
study  and f or 5 months following the l ast dose.
[1
b]female subjects:
must test negative for pregnancy at the time of screening andbe of
non-childbearing potenti al, as defined by at least 1 of the fo llowing:
at least 6 weeks have elapsed after bilateral oophorectomy, tubal 
ligation, or hy sterectomy
postm enopausal as defined in Sect ion 6.3.4
female infert ility due to other causes that have been discussed with, 
and accepted, by  the sponsor .
[
2] a re between 18 and 64yearsof age, inclusive, at the time of screening .
[
3]have a body  mass index of 18 to 32.0 kg/m2, incl usive, and a minimum body  
weight of  
50 kg.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 37
LY3316531[4] have clinical laboratory  test resul ts wi thin norm al reference range for the 
popul ation or invest igativesite, or resul tswith acceptabl e deviat ions that are 
judged to be not clinically significant by  the investigator .
[5] have venous access sufficient to allow for blood sampling and administration 
of IPfor IV administration as per the protocol .
[6] are willing and able to undergo punch biopsies according to the Schedule of 
Activities (Section 2.2).
[
7] a re reliable and willing to make themselv es available for the duration of the 
study  and are willing to follow study  procedures .
[8] are able and willing to give signed informed consent .
6.1.2. For Patients with Psoriasis
[9] present with chronic plaque psoriasis based on an investigator- confirmed 
diagno sis of chronic psoriasis vulgaris for at least 6 months prior to baseline 
and meet the following criteria:
plaque psori asis invo lving ≥
5% body  surface area (BSA )in affected skin 
other than the face and scalp at screening (Visit 1) and baseline (Day 1, 
Visit 2)
static Physician Glo bal Assessment (sPGA )score of ≥2 at screening (Visit 
1) and baseline (Day 1, Visit 2)
are willing and able to undergo punch biopsies a ccording to the Schedule 
of Activities(Secti on 2.3).
[
9a]male patients:
agree to eitherremain abstinent (ifthisis their preferred andusual lifest yle)
or usecondoms with spermicide aswell as1additional highly effective
method of contraception or effect ivemethod ofcontraception during the 
study  and f or 5months following the l ast dose of the IP.
[9
b]female patients:
both childbearing and non -childbearing potenti al must test negative for 
pregnancy at the time of screening.
agree to use 2 effective methods of contraception during the study  and f or
5months fo llowing the l ast dose of the IPunless they are not of child -
bearing potential, as defined by at least 1 of the fo llowing:
at least 6 weeks have elapsed after bilateral oophorectomy, tubal ligation , 
or hysterectomy
postm enopausal as defined in Sect ion 6.3.4
female infert ility due to other causes that have been discussed with, and 
accepted, by  the sponsor .
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  38
LY3316531[1 0 ]a r e  ≥ 1 8  y e a r s  o f  a g e.
[1 1 ]h av e  a  m in imum  body  w e igh t  o f  50  kg .
[ 1 2]h a v e  a d e q u a t e  o r g a n  f u n c t i o n ,  i n c l u d i n g :
• h em a to l og i c :   ab so l u t e  n e u t r o p h i l  c o u n t  ≥ 1 . 5× 1 0 9/L  ( ≥ 1 . 5× 1 03/µL  o r  ≥ 1 . 5  
G I /L ) ,  p la t e l e t  coun t  ≥ 1 0 0× 1 0 9/L  ( ≥ 1 0 0× 1 03/µL  o r  ≥ 1 0 0  G I /L ) ,  
h em o g l ob i n  l ev e l  ≥10 .0  g /dL  (≥100  g /L ) ,  lympho cy t e  coun t  >500c e l l s /µL  
(>0 .50 × 1 03/µL  o r  > 0 . 5 0  G I /L ) ,  a n d  t o t a l  w h i t e  b l oo d  c e l l  c o u n t  
≥ 3 . 0× 1 09/L  ( ≥ 3 . 0× 1 03/µL  o r  ≥ 3 . 0  G I /L )
• ch em i s t ry :   
 s e rum  c r e a t i n i n e ,  a l a n i n e  am ino t r an s f e r a s e  (ALT ) ,  and  a sp a r t a t e  
am i n o t r a n s f e r a s e  (AST )  l e v e l s  ≤ 2×  u p p e r  l im i t  o f  n o rm a l  (ULN )
 to t a l  b i l i r u b i n  l e v e l  (TBL )  ( s u b j e c t sw ith  G i lb e r t ’ s  synd rom e  m u s t  h a v e  
s e rum  d i r e c t  b i l i rub in  <1 .5  m g /dL )a n d  a l k a l i n e  p h o s p h a t a s e  (ALP )  < 1 . 5 ×  
ULN.
[1 3 ]h a v e  v e n o u s  a c c e s s  s u f f i c i e n t  t o  a l l ow  f o r  b l o o d  s am p l i n g  a n d  a dm i n i s t r a t i o n  
o f  IPth roughIV  ( i f  a p p l i c a b l e ) ,  a s  p e r  t h e  p r o t o c o l .
[1 4 ]a r e  r e l i a b l e  a n d  w i l l i n g  t o  m a k e  t h em s e l v e s  a v a i l a b l e  f o r  t h e  d u r a t i o n  o f  t h e  
s tudy ,  and  a r e  ab l e  and  w i l l ing  to  fo l low  s tudy  p ro c edu r e s .
[1 5 ]h a v e  g i v e n  w r i t t e n  i n f o rm e d  c o n s e n t  a p p r o v e d  b y  L i l l y  a n d  t h e  e th i c a lr e v i ew  
b o a r d  (ERB )  g o v e r n i n g  t h e  s i t e .
6 .2 .Exc lus ion  C r i te r ia
P a t ien t s / s ub j e c t s  w i l l  b e  e x c l u d e d  f r om  s tudy  e n r o l lm e n ti f  t h e y  m e e t  a n y  o f  th e  f o l l o w i n g  
c r i t e r i a  a t  s c r e e n i n g  a n d / o r  e n r o l lm e n t :
6 .2 .1 .Fo r  Hea l thy  Sub jec ts  and  Pa t ien ts  w i th  Pso r ias is
[1 6 ]a r e  i n v e s t i g a t i v es i t e  p e r sonn e l  d i r e c t l y  a f f i l i a t e d  w i t h  t h i s  s t u d y  and  th e i r  
imm e d i a t e  f am i l i e s .   Imm e d i a t e  f am i l y  i s  d e f i n e d  a s  a  s p o u s e ,  b i o l o g i c a l  o r  
l e g a lgu a rd i an ,  c h i l d , o r  s i b l i n g .
[ 1 7 ]a r e  L i l ly  emp l oy e e s  o r  a r e  em p l oy e e s  o f  a  th i rd - p a r ty  o rg an i z a t i o n  i n v o l v e d  
wi th  th es tud y .
[1 8 ]a r e  c u r r e n t l y  e n r o l l e d  i n  a  c l in i c a l  s tudy  i n v o l v i n g  a n  IP  o r  any  o th e r  ty p e  o f  
m e d i c a l  r e s e a r c h  j u d g e d  n o t  t o  b e  s c i e n ti f i c a l l y  o r  m e d i c a l l y  c o m p a ti b l e  w i t h  
th i s  s tudyo r  h a v e  r e c e i v e d  a n y  n o n - b i ol o g i c  IP  w i th in  30  d ay s  o r  5  h a l f - l i v e s  
(w h i c h e v e r  i s  l o n g e r )  o f  t h e i r  i n i t i a l  s c r e e n i n g  v i s i t .
CC I [ 1 9 ]h a v e  p r e v i o u s l y  c om p l e t e d  a  c l i n i c a l  t r i a l  i n v e s t i g a t i n g   ( IL -2 3  
a n t ibody )  o r  (CGRP  an t ibody )  and  h av e  p r ev iou s ly  r e c e iv ed  
e i th e r  o f  th e s e  IP s .CC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 39
LY3316531[20] amarked baseline prolongat ion of QT/ corrected QT interval (QTc) (for 
example, repeated demonstration of a QTc Binterval  >470 ms);
A history  of addi tional risk factors for T orsades de Pointes (for example, heart failure, 
persistent hypokalemia , family  history  of long QT syndro me); 
The use of conco mitant m edicat ions that prolong the QT/QTc interval .
[
21]have known or ongoing neuropsy chiatri c disorders .
[22] for Parts B and C only , patients who have answered ‘y es’ to ei ther Quest ion 4 
(Active Suicidal Ideat ion with Som e Intent to Act, Wit hout Specific Plan) or 
Quest ion 5 (Active Suicidal Ideat ion with Specific Pl an and Intent) on the 
“Suicidal Ideati on”porti on of  the Columbia -Suicide Severi ty Rating Scale
(C
–SSRS ), or answer “yes”to any  of the sui cide-related behaviors (actual 
attem pt, interrupted attempt, aborted attempt, reparatory  act or behavior) on 
the “Suicidal Behavior” portion of the C–
SSRS; and the ideat ion or behavior 
occurred within the past m onth.
NOTE:  a patient does not necessarily have to be excluded if they  have 
self-injuri ous behavior that would be classified as non -suicidal self -injuri ous 
behavior.  Of course, if this situat ion arises, it is likely the subject should be 
referr ed to a psy chiatri st or appropri ately trained professio nal.
[23]have evidence of clinically significant active infectio n, fever of 100.5° F 
(38°C) or above, at screening or baseline (Day  1).
[24]had any  surgical  procedure (except for minor surgery  requi ring local or no 
anesthesia and without any  com plicat ions or sequelae) within 12 weeks prior 
to screening, or any  planned surgical procedure scheduled to occur during the 
study .
[25] have received live vaccine(s) ( includ ingattenuated live vaccines) within 
28days of screening or intend to receive during the study (non -live or 
inact ivated vaccinat ions are allowed).
[26] have a history  of multiple or severe allergies or has had an anaphylact ic 
reacti on to prescri ption or non -prescri ption drugs or food .
[27]have a history  of allergy  to m Abs or to the drug excipients, or have clinically  
significant m ultiple or severe drug allergies, intolerance to topical 
corticosteroi ds, or a hi story  of severe post -treatm ent hy persensi tivity react ions 
(including, but not limi ted to, ery thema mul tiforme major, linear 
immunogl obulin A [IgA] dermatosis, toxic epidermal necrolysis, or 
exfoliative dermat itis).
[28]
have had serious, opportunist ic, or chronic/recurring infect ion within 6 
months prior to screening.  Examples include but are not limited to infect ions 
requi ring IV ant ibiotics, hospitalizat ion, or prolonged anti-infect ivetreatment .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 40
LY3316531[29]had any  malignancy  within the past 5 years except for basal cell or squamous 
epithelial carcino mas of the skin that have been resected with no subsequent 
evidence of recurrence for at least 3 y ears pri or to screening and cervical 
carcino ma insitu wi th no evidence of recurrence within the 5 years prior to 
baseline.
[30] c urrent smoker >10 cigarettes or other tobacco products per day .  Are 
unable/unwilling to stop smoking tobacco products while in the study unit.
Heavy smokers (as per judgment of the invest igator) should be excluded from 
the study .  
[31]are regular users of known drugs of abuse and/or have posit ive findings on 
urinary  drug tests at screening; OR an average weekly  alcoho l intake that 
exceeds 21 units per week (males) or 14 units per week (females), OR are 
unwilling to stop alcoho l consumption during study visits/t ime in the research 
unit (1 unit of alcoho l = 12 oz or 360 mL o f beer; 5 oz or 150 mL of wine; 
1.5oz or 45 mL of distilled spirits).
[32] have donated blood of more than 500 mL within the previous 30 day sof study  
screening .
[33] show evidence of active or laten t tubercul osis(TB) , as documented through
medical history  and examinat ion, chest x -rays (posteri or,anterior ,and lateral)
for pati ents with psori asis only (Part C ), and TB testing: either a positive 
tuberculin skin test (TST; defined as a skin induratio n >5 mm  at 48 to 
72hours, regardless of Bacillus Calmette –
Guérin or other vaccinat ion history ) 
or a posit ive(not indeterminate) Quant iFERON ®-TB Gold test.  The cho ice to 
perform  a TST or a QuantiFERON -TB Gol d test will  be made by  the 
investigator according to local licensing and standard of care.  The 
Quant iFERON -TB Gol d test can only be used in countries where it is 
licensed, and the use of this test is dependent on previous treatment(s).  This 
test m ay not be sui table if previous treatment(s) pro duce significant 
immunosuppressio n.
[34]
have known hypogammaglobulinemia or a screening serum IgG <565 mg/dL, 
IgM <40 mg/dL, or IgA <70 mg/dL.
[35] are immunocompro mised .
[36]have presence of significant uncontrolled cerebro -cardi ovascular (for 
example, myocardial infarct ion, unstable angina, hypertensio n, moderate to 
severe [New York Heart Associat ion Class III/IV] heart failure, or 
cerebrovascular accident), respiratory , hepa tic, renal , gastrointestinal, 
endocrine, hematologic, neuro logic or neuropsy chiatri c disorders or abnormal 
laboratory  values at screening that, in the opinion of the invest igator, pose an 
unacceptable risk to the subject if part icipating in the study or of interfering 
with the interpretation of data.
[37]in the opinio n of the invest igator or sponsor, are unsuitable for inclusio n in the 
study .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 41
LY33165316.2.2. For Healthy Subjects Only
[38]intend to use herbal, over-the-counter ,or prescript ion medicat ion within 
14days prior to dosing and during the study , other than estrogen/progesterone 
as a form of hormone replacement therapy .  Subjects taking these medicat ions 
shoul d be on stable doses for at least 28 day s prior to screening .  Certain 
medicat ions, for example vitamin s upplements and local anesthet ics, may  be 
permitted at the discretion of the invest igato r.
[
39]have received Ig-based bio logic therapies (such as mAbs, incl uding marketed 
or investigational bio logic therapy )within the past 6 months, or at any  time
received the compounds specified in criteri on#19.
[40]
have an abnorm al blood pressure ,pulse rate,and/ortemperature as determined 
to be clinically significant by the investigator .
[41]have evidence of chronic viral infection:
[41a]show evidence of hepati tis C and/or positive hepat itis C ant ibody with 
confirmed presence of hepat itis C virus (HCV )ribonucl eic acid (RNA )at 
screening .
[41b]show evidence of hepatit is B and/or positive hepat itis B surface antigen or 
are posi tive for hepatit is B core antibody  (HBcAb)
and negative for 
hepat itis B surface antibody ( HBsA b)at screening .
[41c] show evidence of human immunodeficiency  virus (HIV) infecti on and/or 
positive for HIV antibodi es at screening .
[41d] h ave had symptom atic herpes zoster within 3 mo nt
hs(for patients in 
Part C) or 6 months (for healthy subjects in Parts A and B) prior to 
screening that constitutes (per invest igator’s judgment) a risk to the 
subject when taking the study  medicat ion or that may  interfere wi th the 
interpretati on of  study  data.
[42]are not willing to receive mult iple subcutaneous inject ions.
6.2.3. For Patient swith Psoriasis Only
[43] have any other skin condit ions (excluding chronic psori asis vulgaris ) that 
woul d affect interpretation of the results (including, but not limited to, 
scleroderma, eczema, drug- induced psoriasis, guttate psoriasis, pustular 
psori asis, parapsori asis, or cutaneous manifestations of other autoimmune 
diseases such as systemic lupus ery thematosus).
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  42
LY3316531CC I[4 4 ]h a v e  r e c e i v e d  s y s t em i c  n o n b i ol o g i c  p so r i a s i s  th e r apy( i n c lud ing ,  bu t  no t  
l im i t e d  t o ,  o r a l  p s o r a l e n  p l u s  u l t r a v i o l e t  A  l igh t  th e r apy  [PUVA ] ;  
cy c l o s po r in e ;  co r t i co s t e ro i d s ;  m e t h o t r e x a t e ;  o r a l  r e t i n o i d s ;  a p r em i l a s t ;  
to f a c i t i n i b ;  m y c o p h e n ol a t e  m o f e t i l ;  t h i o g u a n i n e ;  h y d r o x y u r e a ;  s i r ol im u s ;  
t a c r o l im u s ;  a z a th i op r in e ;  fum a r i c  a c i d  d e r i v a t i v e s ;  o r  1 , 2 5  d i h y d r o x y  v i t am i n  
D3  and  an a log s )  o r  pho to th e r apy ( i n c l u d i n g  e i t h e r  o r a l  a n d  t o p i c a l  PUVA ,  
u l t r av i o l e t  B ,e x c im e r  l a s e r ,o r  s e l f - t r e a tm en t  w i th  t a n n i n g  b e d s  o r  t h e r a p e u t i c  
s u n b a t h i n g )w ith in  28  d ay s  p r i o r  t o  b a s e l i n e .
[4 5 ]h a v e  r e c e i v e d  t o p i c a l  p s o r i a s i s  t r e a tm e n t  ( i n c l u d i n g ,  b u t  n o t  l im i t e d  t o ,  
co r t i co s t e ro i d s[upp e r  m id  s t r eng th  o r  low e r  po t en cy  top i c a l  s t e ro i d s  a r e  
p e rm i t t e d  o n  t h e  i n t e r t r i g i n o u s  a r e a s  a n d  f a c e ] ,  a n t h r a l i n ,  c a l c i p o t r i e n e ,  t o p i c a l  
v i tam i n  D  d e r i v a t i v e s ,  r e t i n oi d s ,  t a z a r o t e n e ,  p im e c r o l im u s ,  t a c r o l im u s ,  
em o l l i en t s ,a n d  o t h e r  n o n - p r e s c r i p ti o n  top i c a l  p rodu c t s  con t a in ing  u r e a ,  >3%  
s a l i c y l i c  a c i d ,  a l p h a -o r  b e t a - h y d r o x y l  a c i d s ,  o r  m e d i c a t e d  s h am p o o s  [ f o r  
e x am p l e ,th o s e  t h a t  c o n t a i n  > 3%  s a l i c y l i c  a c i d ,  c o r t i co s t e ro i d s ,  co a l  t a r ,  o r  
v i tam in  D3  an a log s ] )w i th i n  1 4  d a y s  p r i o r  t o  b a s e l i n e .
[4 6 ]h a v e  r e c e i v e d  a n ti - TNF  b i ol o g i c s  a n d  a n ti - IL - 1 7  t a r g e t i n g  b i ol o g i c s  w i th i n  
8w e e k s  p r i o r  t o  b a s e l i n e.
[4 7 ]h av e  p r ev iou s  expo su r e  to  any  b i o l og i c  th e r apy  t a rg e t ing  IL - 2 3  ( i n c l u d i n g  
u s t e k i n um a b )o r  CGRP( ) ,  e i th e r  
l i c e n s e d  o r  i n v e s t i g a t i o n a l  ( p r e v i o u s  b r i a k i n um a b  u s e  i s  p e rm i t t e d )( s e e  
E x c l u s i on  # 1 9 ).
[4 8 ]s u f f e r  c h r o n i c  m e d i c a l  c o n d i t i o n  t h a t  a r e  c o n s i d e r e d  ‘ u n s t a b l e ’  b y  t h e  
inv e s t ig a to r .  S u b j e c t s  w i t h  w e l l- c o n t r o l l e d  c h r o n i c  c o n d i t i o n s  s u c h  a s  
h y p e r t e n s i on  o r  hy p e r l i p i d em i a  m a y  b e  p e rm i t t e d  t o  p a r t i c i p a t e ,  p r o v i d e dth e  
t r e a tm e n t  r e g im e n  h a s  b e e n  s t a b l e  f o r  a t  l e a s t  28  d ay s  p r i o r  t o  s c r e e n i n g  a n d  
b o t h  t h e  i n v e s ti g a t o r  a n d  t h e  L i l l y  c l i n i c a l  p h a rm a c o l o g i s ta g r e e  t h a t  t h e  
s u b j e c t  m a y  p a r t i c i p a t e  i n  t h e  s t u d y .
[49 ]h a v e  e v i d e n c e  o f  c h r o n i c  v i r a l  i n f e c t i o n :
[49 a ]s h ow  e v i d e n c e  o f  h e p a t i t i s  C  a n d / o r  p o s i t i v e  h e p a t i t i s  C  a n tibody w ith  
c o n f i rm e d  p r e s e n c e  o f  HCVRNA  a t  s c r e e n i n g.
P a t ien t s  w i th  a  p r e v i o u s  d i a g n o s i s  o f  h e p a ti t i s  Cwho  h av e  b e en  t r e a t ed  
w ith  an t iv i r a l  th e r apy  a n d  a c h i e v e d  a  s u s t a i n e d  v i r o l o g i c a l  r e s p o n s em a y  
b e  e l i g i b l e  f o r  i n c l u s i on  in  th e  s tudy ,  p rov i d e dt h e y  h a v e  n o  d e t e c t a b l e  
HCV  RNA  o n  t h e  s c r e e n i n g  t e s t  f o r  t h i s  p r o t o c o l .  A  s u s t a i n e d  v i r ol o g i c a l  
r e s p o n s e  i s  d e f i n e d  a s  a n  u n d e t e c t a b l e  HCV  RNA  1 2  w e e k s  a f t e r  
com p l e ti o n  o f  a  f u l l ,  d o c um e n t e d  c o u r s e  o f  a n  a p p r o v e d  a n ti v i r a l  t h e r a p y  
f o r  HCV .
P a t ien t s  who  h a v e  s p o n t a n e o u s l y  c l e a r e d  HCV  i n f e c t i o n ,  d e f i n e d  a s :  
( i )a  po s i t i v e  HCV  a n t i b o d y  t e s t  and  CC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 43
LY3316531(ii)a negat ive HCV RNA test, with no history of anti -HCV treatm ent, 
may be eligible for inclusio n in the study , provi ded they  have no 
detectable HCV RNA on screening for thi s study . 
Based on the judgment of the invest igator, any  patient exhibit ing 
behaviors that would put them at risk for re -infect ion with HCV may be 
discontinued fro m the study .
Any pat ient with a history  of HCV infecti on who devel ops el evated ALT 
>3× ULN during the study  will be tested for HCV RNA in addit ion to a 
full liver evaluat ion as described in Sect ion 9.4.4.1 .
Anyo ne diagnosed with hepati tisC during the study  will be discont inued 
from the study  and shoul d receive appropri ate fo llow-up medical care.
[49b]show evidence of hepatit is B and/or positive hepat itis B surface antigen or 
are posi tive for HBcA band negat ive for HBsAb at screening .
[49c]show evidence of HIV infection and/or posit ive for HIV antibodi es at 
screening .
[49d] h ave had symptom atic herpes zoster within 3 mo nt
hs(for patients in 
Part C) or 6 months (for healthy subjects in Parts A and B) prior to 
screening that constitutes (pe r invest igator’s judgment) a risk to the 
subject when taking the study  medicat ion or that may  interfere wi th the 
interpretati on of  study  data .
[50] are unable or unwilling to avoid excessive sun exposure or use of tanning 
booths for at least 4 weeks prior to baseline and during the study .
6.3. Lifestyle and/or Dietary Requirements
Throughout the study , patients/subjects may undergo medical assessment sand review of 
compliance wi th requirements before continuing in the study .
6.3.1. Meals and Dietary Restrictions
Subjects shoul d not eat after midnight duringthe night before study  drug administration. Water 
is permitted. Subjects may eat breakfast approximately 2 hours postdose. A normal diet may be 
consumed at all other times during the study .
6.3.2. Caffeine, Alcohol, and Tobacco
6.3.2.1. Caffeine
Subjects and pat ientsshoul d not consume caffeine from the start of each dosing day to 12 hours 
postdose.  Co nsumpt ionof non
-caffeinated beverages is permitted at any time during the study .
6.3.2.2. Alcohol
Subjects shoul d not consume alcohol for at least24 hours prior to dosing.  During outpatient 
periods, all subjects should be advised to limit alcoho l consumpt ion to no more than 2 units per 
day.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 44
LY33165316.3.2.3. Smoking
Subjects shoul dbe willing and able to abide by smoking restri ctions atthe study sites during 
both the in-house period and outpatient vi sits.
6.3.3. Activity
Subjects should avo id strenuous exercise and/or activit y for at least 48 hours pri or to dosing and
scheduled visits .
6.3.4. Contraception
Women of childbearing potential (WOCBP) are excluded from  Parts A and B of the study .  For 
Part C, WOC BPwho are abstinent (if this is co mplete abstinence, as their preferred and usual 
lifest yle) or in a same sex relati onship (as part of their preferred and usual lifest yle)must agree to
either rem ain abstinent or stay  in a same sex relat ionship wit hout sexual relationships with 
males. Otherwi se, WOCBP must use 2 effect ive methods of contraception for the entiretyof the 
study . Abst inence or con tracepti on m ust continue fo llowing co mpletion of study  drug
administration for 5 half -lives or until plasma concentrati onsare equal  to or bel ow the 
pharmaco logic effect l evel, whichever is l onger.
The WOCBP must test negat ive for pregnancy  prior to i nitiation of treatment as indicated 
by a negative urine pregnancy test at the screening visit fo llowed by  a negat iveserum 
pregnancy test within 24 hours prior to exposure to LY3316531 or placebo .
Two effect ive methods of contraception (such as male or female condoms with 
spermicide, diaphragms wit h spermic ide or cervical sponges) will be used. The subject 
may choose to use a double -barrier method of contraception. Barrier protection methods 
without conco mitant use of a spermicide are not a reliable or acceptable method. Thus, 
each barrier method must include use of a spermicide ( that is, condom  with spermicide, 
diaphragm  with spermicide, female condom with spermicide). It should be noted that th e 
use of male and female condo ms as a double -barrier method is not considered acceptable 
due to the high failure rate when these methods are combined.
oOf note, 1 of the 2 methods of contraception may  be a hi ghly effect ive (less than 
1% failure rate) method of contracepti on (such as combinat ion oral  
contraceptives, implanted contraceptives, or intrauterine devices).
Women not of childbearing potential may participate and include those who are
infertile due to surgical sterilizat ion (hysterectomy, bilateral o ophorectomy, or tubal 
ligation), congenital ano maly such as m ullerian agenesis; or
postm enopausal –defined as eit her
oa wom an at l east 50 y ears of age with an intact uterus, not on hormone therapy , 
who has had either
cessat ion of menses for at least 1 year, or
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 45
LY3316531at least 6 m onths of spontaneous amenorrhea with a fo llicle -stimulat ing 
horm one >40 m IU/mL; or
oA wo man 55 years of age or older not on horm one therapy , who has had at l east 
6months of spontaneous amenorrhea; or
oA wo man at l east 55 years of age wi th a diagnosi s of menopause pri or to starting 
horm one repl acement therapy .
Men, regardless oftheir fertilit ystatus, with non -pregnant WOCBP partners m ust agree to either 
remainabstinent (ifthis i s thei rpreferred and usual lifestyle) or usecondoms as well as 1 
additional highly effect ive(lessthan1%failure rate) methodof contracepti on (such as
combinat ionoralcontracepti ves,implanted contraceptives ,or intrauterine devic es) or effect ive
method ofcontraception (such as diaphragms withspermicide or cervical sponges) forthe
durati on of thestudy and unt il their plasma concentrations are below thelevel that coul d resul t
in arelevant potenti al exposure to a possible fetus, predicted to be5 months following the last 
dose ofstudy  drug.
Men and their partners m ay choose to use a double –barrier methodof contracepti on.
(Barrier protection methods without concomitant use ofa spermicide are not an effect ive 
oracceptabl emethod ofcontracepti on. Thus, each barrier methodmustinclude use of a
spermicide. Itshould benoted ,however ,thatthe use ofmale and female condo ms as a 
doubl e-barrier method i s not considered acceptable due to the high failure ratewhen these
barrier methods arecombined).
Men with pregnant partners shoul d use condoms during intercourse fortheduration of the 
study and until theendofestimated relevant potential exposure inWOCBP (
5months 
following the last dose of study  drug ).
Men should refrain from sperm donat ion for the duration of thestudy  and untiltheir 
plasma concentrations are below thelevel that could result in arelevant potential 
exposure to a possible fetus, predicted tobe5 months fo llowing the l ast dose of study
drug.
Men who are in exclusively same sex relat ionships (astheir pref erred and usual lifestyle) 
are not required to usecontraception.
6.4. Screen Failures
Healthy subjects who do not m eet the cri teria for parti cipat ion in this study  (screen failure ) may  
not be re -screened ; however, re-assessment of laboratory parameters will be allowed once if 
handling issues, damaged samples, or hemo lyzed sam ples m ay have confounded the 
measurement results .
Any pat ient with psoriasis who has a screening laboratory  assessment that falls outsi de of the 
protocol -specified inclusion/exclusio n parameters may (based on investigator judgment) undergo 
repeat l aboratory  testing 1 time without being considered a screen failure (this does not include 
TB testing).
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 46
LY3316531In addit ion, participan ts who were eligible for inclusion in previous cohorts, butwere not 
rando mized for nonmedical  reasons, m ay be reassessed ,following a discussio n with the sponsor .
If rescreening is performed, the individual must sign a new informed consent form (ICF) each
time and will be assigned a new ident ificat ionnumber.
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  47
LY33165317 .T rea tmen t
7 .1 .T rea tmen t  Adm in is te red
T h e  d r u g  p r o d u c t  LY 3 3 1 6 5 3 1  i s  s u p p l i e d  f o r  c l i n i c a l  t r i a l  u s e  a s  s ol u t i o n  f o rm u l a t i o n  i n  g l a s s  
v i a l s .   F u r t h e r  d i l u ti o n  m a y  b e  n e e d e d  f o r  SCa n d  IV  a dm i n i s t r a t i o n .   S e e  P h a rm a c y  I n st ru c t i o n s  
f o r  m o r e  in fo rm a t i o n .
P la c ebo  w i l l  b e  s t e r i l e  s a l i n e  ( 0 . 9%  N aC l ) .   P la c ebo  do s e s  shou l d  b e  h e ld  i n  t h e  p h a rm a c y  f o r  a n  
e q u i v a l e n t  am o u n t  o f  t im e  a s  i s  r e q u i r e d  t o  p r e p a r e  d o s e s  o f  LY 3 3 1 6 5 3 1 .
T h e  IPo r  p l a c ebo  w i l l  b e  a dm i n i s t e r e d  a s  SC  in j e c t ion ( s )o r  a  s l o w  IV  i n f u s i on  o v e r  a t  l e a s t  
3 0m i n u t e s.  S it e s  m u s t  h a v e  r e s u s c i t a t i o n  e q u i pm e n t ,  em e r g e n c y  d r u g s ,  a n d  a p p r o p r i a t e l y  
t r a i n e d  s t a f f  a v a i l a b l e  d u r i n g  t h e  i n f u s i o n  a n d  f o r  a t  l e a s t  6h o u r s  a f t e r  s u b j e c t s  h a v e  c om pl e t e d  
r e c e i v i n g  th e i r  in fu s i o n .
I n j e c t i o n  s i t e  s e l e c t e d  f o r  SC  a dm i n i s t r a t i o n  s h o u l d  b e  t h e  a b d om i n a l  r e g i on  a p p r o x im a t e l y5cm  
f r o m  th e  um b i l i c u s  a n d  t h e  t r e a tm e n t  i s  a dm i n i s t e r e d  th roughth e  n e e d l ea p p l i e d  a t  
a p p r o x im a t e l y4 5 °w ith  p i n c h i n g  o f  t h e  s k i n .B e c a u s e  s u b j e c t s  m ay  r e c e iv e  mu l t i p l e  i n j e c ti o n s
p e r  do s e ,  e a c h  i n j e c t i o n  shou l d  b e  a dm i n i s t e r e d  i n  a  d i f f e r e n t  a b d om i n a l  q u a d r a n t  ( r i g h t  u p p e r  
q u a d r a n t ,  l e f t  u p p e r  q u a d r a n t ,  r i g h t  l ow e r  q u a d r a n t ,  o r  l e f t  l ow e r  q u a d r a n t )  a n d  t h e  q u a d r a n t  u s e d  
shou l d  b e  r e c o r d e d  a t  t h e  t im e  o f  t h e  i n j e c ti o n .   S u b c u t a n e o u s  a dm i n i s t r a t i o n  o f  LY 3 3 1 6 5 3 1  
shou l d  b ed o n e  b y  a  l im i t e d  n um b e r  o f  i n d i v i d u a l s  f o r  c o n s i s t e n c y .  T h e  s am e  ty p e  o f  s y r i n g e  
a n d  n e e d l e( )  s h o u l d  b e  u s e d  f o r  a l l  s u b j e c t s  t o  e n s u r e  a l l  i n j e c t i o n s  a r e  
d e l i v e r e dt o  a  c o n s i s t e n t  d e p t h  t a r g e t  i n t o  t h e  SC  s p a c e .
A l l  c l i n i c a l  t r i a l  m a t e r i a l sp rov i d e d  t o  t h e  i n v e s ti g a t o r  w i l l  b e  s t o r e d  i n  a  s e c u r e  p l a c e ,  a s s ign ed  
u s i n g  th e  i n t e r a c t iv e  w eb  r e spon s e  sy s t em ,a n dd i sp en s e d  b y  a p p r o p r i a t e l y  t r a i n e d  p e r s o n s .T h e
d i sp en s ing  o f  th eIP s  w i l l  b e  f u l l y  d o c um e n t e d .  D e t a i l e d  r e c o r d s  o f  t h e  am o u n t s  o f  t h eIP
r e c e i v e d ,  d i s p e n s e d ,  a n d  r em a i n i n g  a t  t h e  e n d  o f  t h e  s t u d y  w i l l  b em a i n t a i n e d .
T h e  i n v e s ti g a t o r  o r  d e s i g n e e  i s  r e s p o n s i b l ef o r
 e x p l a i n i n g  t h e  c o r r e c t  u s e  o f  t h e  IP ( s )  t o  th e  s i t e  p e r sonn e l
 v e r i f y i n g  t h a t  i n s t r u c t i o n s  a r e  f ol l o w ed  p rop e r ly
 m a i n t a i n i n g  a c c u r a t e  r e c o r d s  o f  IPd i s p e n s i n g  a n d  c o l l e c ti o n ,  a n d
 r e t u r n i n g  a l l  u n u s e d  m e d i c a t i o n sto  L i l ly  o r  i t s  d e s ign e e  a t  th e  end  o f  th e  s tudy .
No t e:I n  s om e  c a s e s ,  s i t e s  m a y  d e s t r o y  th e  m a t e r i a l  i f ,  d u r i n g  t h e  i n v e s t i g a t i v es i t e  s e l e c t i o n ,  t h e  
e v a l u a t o r  h a s  v e r i f i e d  a n d  d o c um e n t e d  t h a t  t h e  s i t e  h a s  a p p r o p r i a t e  f a c i l i ti e s  and  w r i t t e n  
p r o c e d u r e s  to  d i s p o s e  o f  c l i n i c a l  m a t e r i a l s .
7 .1 .1 .Packag ing  and  Labe l ingCC I
LY 3 3 1 6 5 3 1  w i l l  b e  s u p p l i e d  t o  t h e  i n v e s t i g a t i v e  s i t e s  b y  L i l l y .   C l i n i c a l  t r i a l  m a t e r i a l s  w i l l  b e  
l ab e l ed  a c co rd ing  to  th e  coun t ry ’ s  r egu l a to ry  r equ i r em e n t s .   A l l  IP s  w i l l  b e  s t o r e d ,  i n v e n t o r i e d ,  
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 48
LY3316531reconciled, and destroy ed according to applicable regulat ions.  Clinical trial materials are 
manufactured in accordance wit h current good m anufacturing pract ices.
LY3316531 is supplied for clinical trial use as so lution in vial  with study -specific l abels.  Th e 
2-mLvial is manufactured to contain 150 mg of LY3316531 (75 m g/mL ).  Vials will be supplied 
in cartons, wi th the appropri ate quant ity specific to the planned dispensing schedule of the IP. 
Placebo for all cohorts is 0.9% s odium chloride(sterile saline) .
When prepared for dosing according to instructions, it will not be possible to distinguish between 
LY3316531 and placebo .
Detailed instructions for the prepa ration and handling of LY3316531 will be provi ded by  the 
sponsor.
The IPmust be prepared by  an unblinded pharm acist who is not i nvolved in any other 
study -related procedures.
7.2. Method of Treatment Assignment
Rando mization tables for allocat ion of LY33 16531 or placebo will be prepared by the statisti cian or 
designee for the study  and provided to the si te pharmacists involved in dose preparati on.  
Theallocati on and dispens ation of the IPwill be fully documented and verified by  a second person.  
Detailed records of the am ounts of  the IPreceived, dispensed, and re main edat the end of the
study 
will be maintained by the si te pharmac y.
7.2.1. Selection and Timing of Doses
The doses will be administered at approximately the same t imes on each day.  The actual t ime of 
all dose administrations will be recorded in the patient ’s/subject’s electroni c case report form 
(eCRF).
7.3. Blinding
Parts A and B of Study  FFAA aresubject -and investi gator -blind except for the non -sentinel  
subjects and the open -label SC administrati on cohort in Part A (Cohort 5 ).  Part C of Study  FFAA is 
open-label.  As a resul t, all patients wi th psoriasis who enter the study  will receive LY3316531.
Pharmacy staff who prepare and dispense study  medi cation are requi red to be unblinded to 
treatm ent allocation .
Subject treatment assignments and drug accountabilit y records will be held in a secure l ocati on 
accessible only by individuals invo lved with study  drug preparation or dispensation.
Blinding will be maintained throughout the c onduct of the study  as described in the separate 
Blinding Plan.
If a subject’s study  treatm ent assignment is unblinded, the subject must be discont inued from the 
study , unless the invest igator obtains specific approval fro m a Lilly clinical pharmaco logist or 
clinical research physician (CRP) for the study  parti cipant t o continue in the study .
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  49
LY3316531I n  c a s e  o f  a n  em e r g e n c y ,  th e  inv e s t i g a t o r  h a s  t h e  s o l e  r e s p o n s i b i l i t y  f o r  d e t e rm i n i n g  i f  u n b l i n d i n g  
o f  a  s u b j e c t ’ st r e a tm en t  a s s i gnm en t  i s  w a r r an t ed  fo r  m e d i c a l  m a n a g em e n t  o f  t h e  e v e n t .  T h e  
s u b j e c t ’ ss a f e t y  m u s t  a lw a y s  b e  t h e  f i r st  con s i d e r a t i on  i n  m a k i n g  s u c h  a  d e t e rm i n a ti o n .   A t t h e  
d i s c r e t i on  o f  th e  inv e s t i g a t o r ,  i f  a  s u b j e c t ’ s  t r e a tm e n t  a s s i g nm e n t  i s  unb l ind ed ,  a s  j u d g e d  b y  th e  
inv e s t ig a to r , L i l l y  m u s t  b e  no t i f i e dimm e d i a t e l y .I t  i s  th e  r e s p o n s i b i l i t y  o f  th e  inv e s t i g a to r  to  
do cum e n t  t h e  d e c i s i o n  a n d  r a ti o n a l e ,p rom p tl y .
7 .4 .Dose  Mod i f ica t ion
7 .4 .1 .Dose  Dec is ion  (Pa r t  C )
T h e  d e c i s i on  t o  i n i ti a t e  t h e  f i r s t  p a t i e n t  c o h o r t  i n  P a r t  C  w i l l  b e  b a s e d  o n  t h e  t r i a l - l e v e l  s a f e t y  
r e v i ew  f o r  Coho r t  3;  h ow e v e r ,a n y  a v a i l a b l e  p r e l im i n a r y  PK d a t a  f r om  Coho r t s  1 ,  2 ,  and  3  
( th rough  D ay  2 9 )  i n  P a r t  Aw i l l  b e  c o n s i d e r e d  a s  w e l l.   P rog r e s s ion  to  th e  op t i on a l  coho r t s  in  
P a r t  C  w i l l  o c c u r  w h e n  a t  l e a s t  4  w e e k s  o f  c l i n i c a l  a c t i v i ty  d a t a  (PAS I  s c o r e s )  a r e  a v a i l a b l e  f r om  
a t  l e a s t  7  p a t i e n t s  i n  t h e  p r e c e d i n g  c o h o r t .   I n  a d d i t i on  t o  t h e  PAS I  s c o r e s ,  a n y  a v a i l a b l e  PK  a n d  
a p p l i c a b l e  s a f e t y  d a t a  f r om  P a r t  A  w i l l  b e  c o n s i d e r e d  f o r  d e t e rm i n i n g  t h e  d o s e  f o r  t h e  o p t i o n a l  
p a t i en t  coho r t s .   Do s ing  a t  th e  cu r r en t  l ev e l  and  fu r th e r  do s e  e s c a l a t i o n  w i l l  b e  d i s c o n ti n u e di f  
a n y  o f  t h e  s c e n a r i o sd e s c r i b e d  i n  S e c t i o n  7 .4 .2o c cu r.
 
 
 
 
7 .4 .2 .Dose  Esca la t ion(Pa r ts  A  and  B )
By n a t u r e  o f  b e i n g  a  d o s e - e s c a l a t i o n  s tudy ,  d a t a  w i l l  b e  e v a l u a t e d  o n  a n  o n g o i n g  b a s i s .T h e  
h i g h e s t  d o s e  l e v e l  t h a t  i s  t o l e r a t e d  w i l l  b e  d e s i g n a t e d  a s  t h e  MTD .
S a fe t y  d a t aw i l l  b e  th e  p r im a ry  c r i t e r i a  f o r  t h e  d o s e  e s c a l a t i o n .   I n  a d d i ti o n ,  i f  a v a i l a b l e  a t  t h e  
t im e  o f  d o s e - e s c a l a t i o n  d e c i s i on ,  PKr e su l t s  (C m axCC I
a n d  AUC)w i l l  b e  u s e d  a s  s u p p o r t i n g  d a t a  f o r  
d o s e  e s c a l a ti o n ,  b u t  s u c h  d a t a  a r e  r e q u i r e don ly  f o r  Coho r t  1  in  P a r t  B.   N o  d o s e  d e c i s i o n  c a n  
o c cu r  w i th ou t  p r i o r  d i s cu s s i on  a n d  a g r e em e n t  b e tw e e n  t h e  i n v e s t i g a t o r  a n d  t h eL i l l y  c l i n i c a l  
p h a rm a c ol o g i s t  o r  CRP.
P r io r  tod o s ee s c a l a t i o n ,  a  s a f e ty  r e v i ew  m e e t i n g  w i l l  b e  u n d e r t a k e n  b y  t h e  s p o n s o r  ( u n b l i n d e d )  
a n dth ei n v e s t i g a t o r  ( b l i n d e d )  t o  e v a l u a t e  t h es a f e t yd a t a  and  ag r e e  on  th e  app rop r i a t e  do s e  fo r  
th e  n e x t  c o h o r t .   Eme rg in g  PK  d a t a  ( i f  a v a i l a b l e )  m a y  i n f o rm  d o s e  s e l e c ti o n  f o r  t h e  h i g h e r  d o s e  
l e v e l s ,  b a s e d  o n  p l a n n e d  PK  p r e l im i n a r y  a n a l y s e s  a f t e r  SAD  C o h o r t  3  (P a r t  A ) .   I f  c o n s i d e r e d  
a p p r o p r i a t e ,  p r e v i o u s  d o s e  l e v e l s  m a y  b e  r ep e a t ed ,  o r  l ow e r / in t e rm ed i a t e  do s e  l ev e l s  m ay  b e  
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 50
LY3316531tested.  The magnitude of the dose escalat ion may be reduced afterdata review, but subsequent 
escalat ions cannot be increased by more than approximately  3-fold (a half -log increment).
For Cohorts 1 and 2 in Part A, the decisio n to escalate to the next coh ort will occur when at least 
15days have elapsed after all subjects in the preceding cohorts have been dosed.  In Cohorts 3, 
4, 6, and 7, the decisio n to dose the next cohort will occur when all subjects in the preceding 
cohorts have been dosed and data for a minimum of 1 5days are available from at least 7subjects 
in the preceding cohort.  If at the time of the trial level safet y review for Cohort 4, data are also 
available fro m Cohort 5, all available data from Cohorts 4 and 5 will be considered in the review 
to dose the next cohort.
The decisio n to init iate the first m ultiple-dose cohort in Part B will occur when at least 1 5days 
have elapsed after all subjects in the lastcohortin Part A have been dosed (Cohort 7 unless 
safet y concerns prevent escala tion to thi s cohort) .  The tri al-level  safety  review for all previous 
cohorts and the preliminary analyses of PK data (planned to occur after the complet ion of Day 29 
for Cohort 3) will be considered in the decisio n to init iate Part B of the study .  Progre ssion to the 
optional cohort i n Part B will occur when all subjects have received the second dose of study  
drug and data for a minimum o f 15 day s (after the second dose) are available fro m at least 7 
subjects in Cohort 1 of Part B.
Throughout Part A and Pa rt B, safet y data up to and including Day 15 are required for 
dose-escalat ion decisio ns.  If any subjects withdraw before the Day 15 assessment , all available 
safet y data for those subjects will be evaluated.
Safety data, in particular AEs, SAEs, and adver se laboratory  abnorm alities, will be 
independent ly assessed by the invest igator, and will be considered related to the IP unless there 
is clear evidence that the event is not related.
After review of these data, an agreement on the appropriate dose will be made by the invest igator 
and sponsor for the next cohort /dose level .  The magnitude of dose escalat ion
smay be reduced 
following data review ,but subsequent escalat ions cannot be increased by  more than 
approximately  3-fold (a half -log increment).
If any of the f ollowing scenarios occur , dosing at the current level and further dose escalat ion 
will be discont inued :
A single patient/subject experiences a nSAE or clinically significant event that is 
related to LY3316531 administration
OR
Two or more patients/subjects develop A Es within 14 days of dosing that are considered 
to be rel ated to study  treatm ent and graded as at least moderate, clinically significant ,and 
not responsive to supportive care
OR
One or m ore pati ents/subjects develop A Es within 1 4 day s of dosing that are considered 
to be rel ated to study  treatm ent and graded as severe
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 51
LY3316531OR
Two or more subjects develop A Es that are graded as severe, unless there is an obvious 
explanat ion other than IPor study procedures for the event(s)
OR
After the introducti on of  prem edicat ion in accordance wit h the protocol, 2 or more 
patients/subjects develop (according to Common Termino logy Criteria f or Adverse 
Events) Grade 2 acute A Es related to the infusio n, during or within 2 hours of 
completing the infusio nthat do not resolve with a reduced infusion rate and/or supportive 
care.
7.4.3. Special Treatment Considerations
Prem edicat ion for the infusions is not planned.  However, if an infusio n reaction occurs, 
appropriate medicat ion may be used as determined by  the study  invest igator (s).  If infusio n 
reacti ons are observed, but review of the data suggests that dose escalat ion may cont inue, 
acetaminophen 500 to 1000 mg and/or an ant ihistamine may be administered orally 30 to 
60minutes prior to the start of infusion f or subsequent patients /subjects .
The decisio n to implement premedicat ion for infusio ns in subsequent cohorts will be made by 
the invest igator and sponsor and recorded in the study doc umentati on, al ong wi th the 
dose-escalat ion decisio n.
Any prem edicat ions given will be documented as a concomitant therapy  (see Secti on 7.7).
7.4.3.1. Management of Infusion Reactions
There i s arisk of infusio n react ion with any biological agent ; therefore , all patients/subjects
shoul d be m onitored cl osely.  Symptoms and signs that may occur as part of an infusio n react ion 
include, but are not limited to fever, chills, nausea, headache, bronchos pasm, hypotensio n, 
angioedema, throat irritation, rash, pruritus, myalgia, and dizziness.  In the event that a 
significant infusi on react ion occurs, the fo llowing gui dance shoul d be f ollowed:
The IPinfusio n shoul d be sl owed (for example, reduce infusio n rate by  50% [for 
example, an infusio n rate of 12 mL/h becomes 6 mL/h or slower] )or stopped, depending 
on the symptoms/signs present :
oif slowed, the infusi on shoul d be com pleted at the sl ower rate, as tol erated
oif determined by the invest igator that the inf usion shoul d no l onger continue, no 
further attempts to dose the patient/ subject shoul d be made
Supportive care should be emplo yed in accordance with the symptoms/signs
If a patient /subject ’s infusion react ion is sufficient ly severe to di scontinue the infu sion, 
subsequent infusio ns may be ad ministered with premedication at the di scret ion of the 
investigator following agreement with the Lilly CRP or clinical pharmaco logist
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  52
LY3316531 I f  a  p a t i e n t / s u b j e c t ’ s  i n f u s i o n  r a t e  i s  r e d u c e d  d u e  t o  a n  i n f u s i o n  r e a c ti o n ,  s u b s e q u e n t  
i n f u s i o n s  m a y  b e  a dm i n i s t e r e d  a t  t h e  d i s c r e ti o n  o f  th e  i n v e s t i g a t o rf o l l o w i n g  a g r e em e n t  
w ith  t h e  L i l l y  CRP  o r  c l i n i c a l  p h a rm a c o l o g i s t .   I f  f u r t h e r  i n f u s i on sa r e  a dm i n i s t e r e d ,  t h e  
i n f u s i o n  r a t e  m u s t  n o t  e x c e e d  t h e  s l ow e s t  r a t e  u s e d  t o  c om p l e t e  t h e  i n f u s i on  wh enth e  
i n fu s i on  r e a c t i on  o c cu r r ed .   P r em e d i c a t i o n  m a y  b e  a dm i n i s t e r e d  a t  t h e  d i s c r e t i o n  o f  t h e  
inv e s t ig a to r
 I f  i t  i s  d e t e rm i n e d  th a t  th e  p a t i e n t / s u b j e c tshou l d  n o t  r e c e i v e  f u r t h e r  d o s e s  o f  IP ,  t h e  
p a t i e n t / s u b j e c ts h o u l d  c o m pl e t e  AEa n d  o t h e r  f o l l o w -u p  p r o c e d u r e s  p e r  S e c t i o n  2o f  th i s  
p ro to co l .
7 .5 .P repa ra t ion /Hand l ing /S to rage /Accoun tab i l i ty
A l l  c l i n i c a l  t r i a l  m a t e r i a l sp rov i d ed  to  t h e  i n v e s ti g a t o r  w i l l  b e  s t o r e d  i n  a  s e c u r e  p l a c e  a n d  
a l l o c a t e d  a n d  d i s p e n s e d  b y  a p p r o p r i a t e l y  t r a i n e d  p e r s o n n e l .   Th e  a l l o c a t i o n  a n d  d i s p e n sa t i ono f  
th e  IPw i l l  b e  f u l ly  do cum en t ed  and  v e r i f i ed  by  a  s e c o n d  p e r s o n .   D e t a i l e d  r e c o r d s  o f  t h e  
am oun t s  o f  th eIPr e c e i v e d ,  d i s p e n s e d ,  a n d  r em a i n i n ga t  th e  end  o f  th e  s tudy  w i l l  b e  m a i n t a i n e d .
T h e  i n v e s t i g a t o r  o r  d e s i g n e em us t  c o n f i rm  a p p r o p r i a t e  t em p e r a t u r e  c o n d i t i o n s  h a v e  b e e n  
m a i n t a i n e d,  a s  c omm u n i c a t e d  b y  th e  s pon so r ,d u r i n g  t r a n s i t  f o r  a l l  IP sr e c e i v e d  a n d  a n y  
d i s c r e p a n c i e s  a r e  r e p o r t e d  a n d  r e s o l v e d  b e f o r eu s e  o f  th e  s tudy  t r e a tm e n t .
O n l y  p a r t i c i p a n t s  e n r ol l e d  i n  t h e  s t u d y  m ay  r e c e iv e  IP so r  s tudy  m a t e r i a l s ,  and  on ly  au tho r i z e d  
s i t e  s t a f f  m ay  supp ly  o r  adm in i s t e r  IP .A l l  IP s  shou l db e  s to r ed  i n  a ne n v i r o nm e n t a l l y  c o n t r o l l e d  
a n d  m o n i to r ed  (m anu a l  o r  au tom a t e d )  a r e a  i n  a c c o r d a n c e  w i t h  t h e  l a b e l e ds t o r a g e  c o n d i t i o n s  
w ith  a c c e s s  l im i t e d  t o  t h e  i n v e s t i g a t o r  a n d  a u t h o r i z e d  s i t e  s t a f f .
T h e  i n v e s ti g a t o r ,  i n s t i t u t i o n ,  o r  t h e  h e a d  o f  t h e  m e d i c a l  i n s t i t u ti o n  (w h e r e  a p p l i c a b l e )  i s  
r e spon s ib l e  fo r  s tudy  t r e a tm e n t  a c c o u n t a b i l i t y ,  r e c o n c i l i a ti o n ,  a n d  r e c o r d  m a i n t e n a n c e  (s u c h  a s
r e c e i p t ,  r e c o n c i l i a ti o n ,a n d  f i n a l  d i s p o s i t i o n  r e c o r d s ).
I n v e s t i g a t i o n a l  p r o d u c t s  w i l l  b e  s u p p l i e d  b y  L i l l y  o r  i t s  r e p r e s e n t a t i v e ,  i n  a c c o r d a n c e  w i t h  c u r r e n t  
g o o d  m a n u f a c t u r i n g  p r a c t i c e s  a n d  w i l l  b e  s u p p l i e d  w i t h  l o t  n um b e r s ,  e x p i r y  d a t e s ,  and  
c e r t i f i c a t e s  o f  a n a l y s i s ,  a s  a p p l i c a b l e .
7 .6 .T rea tmen t  Comp l ianceCC I
T h e  IPw i l l  b e  a dm i n i s t e r e d  a t  t h e  c l i n i c a l  s i t e ,  a n d  d o c um e n t a t i o n  o f  t r e a tm e n t  a dm i n i s t r a t i o n  
w i l l  o c c u r  a t  t h e  s i t e .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 53
LY33165317.7. Concomitant Therapy
In general, concomitant medicat ion shoul d be avo ided. Use of chronic, stable doses of 
Thyroxine or horm one repl acement th erapy  (estrogens/progesterones) is allowed in both healt hy 
subjects and patients with psoriasis .
Acetaminophen (1 g, maximum 2g/24 hours) may be administered at the discretion of the 
investigator for treatment of headache ,etc.  If the need for concomitan t medicati on (other than
acetaminophen) arises, inclusio n or conti nuati on of the pat ient/subject may be at the discretion of 
the invest igator after consultat ion with a Lilly clinical  pharmacol ogist or CRP .  Any medication 
used during the course of the study  must be documented.
Uses of nonlive (inact ivated) vaccinat ions are allo wed for all subjects.  Use of live, attenuated 
vaccines is prohibited.
Patients in Part C who are on stabl e conco mitant medi cation at the time of study  entry  shoul d 
continue their regular, unchanged dose throughout the study  and the extended fo llow-up peri od 
(up to Week 52).  Concomitant therapies for treatment of psori asisduring the study
 are permi tted 
only as outlined in Table FFAA. 7.1.
Table FFAA .7
.1. Permitted Medications for Treatment of Psoriasis
Drug Class As Needed Chronic Use Conditions for Use
Topical steroids Yes Yes Topical steroids Class 6 [mild] or 7 [least potent] will be permitted 
for use limited to the face, axilla, and/or genitalia, as needed. These 
topical medications should not be used within approximately
24hours prior to study visits.
Topical medications 
for psoriasisNoaNo
aExceptions:  topical steroids will be permitted for use limited to the face, axilla, and/or genitalia.
Topi cal moisturizers/emo llients m ay be used on nontarget lesio ns (that is, plaque psori asis 
lesionsthat have not been or will not be biopsied ) following the Day  1 visi t. 
7.8. Treatment after the End of the Study
Not Applicable.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 54
LY33165318.Discontinuation Criteria
Patients/s ubjects discont inuing from the study  prematurely  for any reason must com plete AEand 
follow-up procedures per Section 2of this protocol.
8.1. Discontinuation from Study Treatment
Discontinuati on of  the IPfor abnormal liver tests should be considered by the invest igator when 
a patient/subject meets 1 of the f ollowing condit ions after consultation wit h the Lilly -designated 
medical mo nitor:
ALT orAST >5×ULN for healthy subjects, 8 ×ULN for pati ents
ALT or AST > 3×ULN for healthy subjects , 5×ULN for pati ents sustained for more than 
2 weeks or
ALT or AST >3 ×ULN and TBL >2×ULN orinternat ional norm alized ratio>1.5 or
ALT or AST >3 ×ULN wit
h the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
ALP >3× ULN
ALP >2.5×ULN and TBL >2 ×ULN
ALP >2.5×ULN wi th the appearance of fat igue, nausea, vo miting, right-quadrant pain or 
tenderness, fever, rash, and/or eosino philia (>5 %).
8.1.1. Discontinuation of Inadvertently Enrolled Patients/Subjects
If the sponsor or invest igator ident ifies a pati ent who di d not m eet enrollment cri teria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  clinical pharmacol ogist or CRP
and the invest igator to determine if the patient may continue in the study.  If both agree it is 
medica lly appropriate to continue, the invest igator must obtain documented approval fro m the 
Lilly clinical pharmaco logistor CRP to allow the inadvertent ly enrolled pat ient to continue in the 
study  with or wi thout continued treatment with IP.
8.2. Discontinuation from the Study
Patients/s ubjects will be discont inued under the following ci rcumstances :
Enrollment in any other clinical study  involving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically  or medically com patible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the patient/subject shoul d be discontinued from the 
study
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 55
LY3316531oif the pat ient/subject, for any reason, requi res treatment with another therapeutic 
agent that has been demonstrated to be effect ive for treatm ent of the study  
indicat ion, di scont inuat ion from the study  occurs pri or to introducti on of  the new 
agent
Subject Decisio n
othe patient/subject ,or legal representative ,requests to be withdrawn fro m the 
study .
Sponsor Decisio n
oLilly stops the study  or stops the subject’s participa tion in the study  for medical, 
safet y, regul atory , or other reasons consistent with applicable laws, regulat ions, 
and GCP
Suicidal  Ideat ion and/or Behavior
oWhen a subject discont inues from a study due to sui cidal i deati on and/or 
behavior, the same fo llow-up procedures can be used as would be done for 
discontinuat ion due to any  other A Es leading to discontinuation.  It is not 
necessary  to collect addi tional information (except what is already requested on 
the C-SSRS, the Self-Harm  Supplement Form , and the Se lf-Harm  Follow-
up 
Form ).  
oInvest igators are responsible for monitoring the safety of patients/subjects who 
have entered this study  and for al erting Lilly  or its designee to any  event that 
seems unusual, even if this event may  be considered a n unant icipated benefit to 
the patient/subject.
oThe invest igator is responsible for the appropriate med ical care of 
patients/subjects during the study .
oThe invest igator remains responsible for fo llowing, through an appropriate healt h 
care opti on, A Es that are serious or that caused the patient/subject to discont inue 
before com pleting the study.  The patient/subject shoul d be f ollowed up until the 
event i s reso lved or explained.  Frequency o f follow-up evaluation is left to the 
discreti on of  the invest igator
Adverse event 
oif a clinically  significant event (CSE) occurs, the IPhas to be discont inued and 
appropriate measures taken.  Lilly  or its desi gnee shoul d be al erted immediately.  
A CSE will be defined as a moderate to severe AE, abnormal clinical sign, or 
clinical laboratory  finding that may  pose a ri sk to the wellbeing of the subject.  
Refer to Safet y Secti on(Secti on 9.4).
oA clinically  significant systemic hyper sensi tivity reacti on occurs fo llowing 
administration of the IP(for example , drug -related symptomat ic bronchospasm, 
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 56
LY3316531allergy -related edem a/angi oedema, or hy potensi on) that requi res parenteral  
medicat ion, does not respond to symptomat ic medication, or results in clinical 
sequelae or an anaphylact ic react ion.
Following the invest igator’s determinat ion that CSE criteria have been met and the invest igator’s 
judgment of relatedness to the IPis documented, a decisio n will be made between the 
investigator an d Lilly or its designee regarding subject discont inuat ion.
The nature of any condit ions, clinical signs or symptoms, or abnormal laboratory  values present 
at the time of discont inuat ion and any applicable follow -up procedures will be documented.   
Refer to the Schedule of Activit ies (Secti on 2)for data to be collected at the time of 
discontinuat ion and fo llow-
up.
8.3. Patients/Subjects Lost to Follow -up
A pat ient/subject will be considered lost to follow -up if he or she repeatedly  fails to return for 
scheduled visits and is unable to be contacted by  the study  site.  Si te personnel are expected to 
make diligent attempts to contact patients/subjects who fail to return for a scheduled visit or were 
otherwi se unable to be fo llowed up by the site .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 57
LY33165319.Study Assessments and Procedures
Secti on 2lists the Schedule of Act ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix 2 lists the laboratory tests that wi ll be perform ed for this study .
Appendix 5 provi des a summary of the maximum  number and vo lume of invasive samples, for
all sampling, during the study .
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin 60 days of receipt of confirmed test resu lts.  Certain samples may be 
retained for a longer period, if necessary , to com ply with applicable laws, regulat ions, or 
laboratory  certificati on standards .
9.1. Efficacy Assessments
This sect ion is not applicable for this study .
9.2. Adverse Events
Invest igators are responsible for monitoring the safety of pat ients/subjects who have entered this 
study  and f or alerting Lilly  or its designee to any  event that seem s unusual, even if this event 
may be considered an unant icipated ben efit to the pati ent/subject .
The invest igator is responsible for the appropriate medical care of pat ients/subjects during the 
study .
Invest igators must document their review of eac h laboratory  safety  report .
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are seri ous or otherwi se medically  important, considered rel ated to the IPor the stud y, 
or that caused the patient/subject to discontinue the IPbefore complet ing the study.  The 
patient/subject should be fo llowed unt il the event reso lves, stabilizes with appropri ate di agnostic 
evaluat ion, or is reasonably  explained.  The frequency of foll ow-up evaluat ions of the AE is left 
to the di scret ion of the invest igator .
After the ICF is signed, s tudy site personnel will record ,via electronic data entry/designated data 
transmissio n methods
,the occurrence and nature of each patient/subject ’s preexist ing condit ions, 
including clinically significant signs and symptoms of the disease under treatment in the study.   
Addit ionally , site personnel  will record any  change in the condit ion(s) and the o ccurrence and 
nature of any  AEs.
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment , or a study procedure, taking into account the disease , 
concomitant treatment ,or pathol ogies .
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the IP, study device ,and/or study  procedure and the AE .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 58
LY3316531Planned surgeries and nonsurgical intervent ionsshoul d not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s/subject’s IP i s discont inued as a result of an AE, study site personnel must report 
this to Lilly or i ts desi gnee via electroni c data entry/designated data transmissio n methods.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1of the f ollowing :
death
initial or prolonged inpatient hospitalizat ion
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospitalization but m ay jeopardi zethe pati ent or may  requi re intervent ion to prevent 1
of the other outcomes listed in the definit ion above
when acondition related totheinject ion syringe or IV drug delivery system necessitates 
medical or surgical intervent ion topreclude eit her perm anent impairment of a body
funct ion or permanent damage to a body structure, theserious outcom e of “requi red 
intervent ion” will be assigned.
Study  site personnel  must al ert the Lilly  CRP/ clinical pharmaco logist, or its desi gnee, of  any 
SAE as soon as pract ically possible .
Addit ionally , study sitepersonnel must alert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin 24 hours of invest igator awareness of the event via a sponsor -approved method.  If 
alerts are issued via telephone, they  are to be immedi ately fo llowed wi th official noti fication on 
study -specific SAE forms.  This 24 -hour notificat ion requirement refers to the init ial SAE 
inform ation and all fo llow-up SAE information .
Although all AEs are recorded in the electroni c data entry/designate d data transmissio n methods
after si gning informed consent, SAE reporting to the sponsor begins after the patient/subject has 
signed inform ed consent and has received IP.  However, if an SAE occurs after signing informed 
consent, but prior to receiving IP, AND is considered Reasonably Possibly Related to a study 
procedure then it MUST be reported .
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued from and/or com pleted the study (the patient/subject summary eCRF has been 
completed).  However, if the investigator learns of any SAE, including a death, at any  time after 
a subject has been discharged fro m the study , and he/she considers the event reasonably possibly  
related t o the study  treatm ent or study  parti cipat ion, the invest igator must prompt ly notify Lilly .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 59
LY3316531Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an AE.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported following the SAE 
process to collect data on the outcome for both mother and fetus .
9.2.1.1. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse rea ctions (SUSARs) are serious events that are not listed 
in the IB and that the investigator reports as related to IPor procedure .  Lilly  has procedures that 
will be fo llowed f or the recording and expedited reporting of SUSARs that are consistent with 
global regulat ions and the associated detailed guidances .
9.2.2. Complaint Handling
Lilly co llects product complaints on IPs and drug delivery  systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements.
Patients/s ubjects shoul d be instructed to contact the invest igator as soon as poss ible if he or she 
has a com plaint or probl em with the IPso that the situation can be assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of LY3316531 is considered any dose higher than the 
dose assigned through rando mizat ion.  There is no specific ant idote to LY3316531 and in the 
case of overdose, subjects should be observed and treated with the appropriate supportive care.
Refer to the I Bfor LY3316531.
9.4. Safety
9.4.1. Laboratory Tests
For each patient/subject, laboratory testsdetailed in Appendix 2 shoul d be conducted according 
to the Schedule of Activities (Secti on2).
With the exception o f safet y laboratory  test resul ts that may  unblind the study , Lilly or i ts 
designee will provide the invest igator wit h the results of laboratory  tests analyzed by a central 
vendor, if a central vendor is used for the study .
9.4.2. Vital Signs
For each patient/subject, vital sign measurements shoul d be conducted according to the Schedule 
of Activities (Secti on 2) and as clinically indicated.   Vital sign measurem ents m ay be repeated at 
the discret ion of the invest igator.
Blood pressure and pulse rate should be measured after at least 5minutes supine (or semi -
recumbent if subject is unable to lie supine) .
If orthostatic measurements are required , pati ents/subjects should be supine for at least 5 minutes 
and stand for at least 3minutes.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 60
LY3316531If the patient/subject feels unable to stand, supine vital signs o nly will be recorded. 
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  Addit ional vital signs may be m easured during each study  period if 
warranted.
Body  temperature will be measured as specified in the Schedule of Activities(Secti on 2)and as 
clinically indicated.
Body  weight will be recorded as specified in the Schedule of Activities(Section 2)and as 
clinically indicated.
9.4.3. Electrocardiograms
For each subject in Part A , a centralized 12-lead digital ECG will be co llected as triplicates 
according to the Schedule of Activities(Secti on 2), except at screening where a single ECG will 
be co llected .
For each patient/subject in Parts B and C, a single ECG will be co llected locally and stored at the 
investigator’s site unless the ECG values for subjects in Part A show clinically significant 
changes ( for example, increase in PR or QT interval) .  In this situation, the ECGs for 
patients/subjects in Parts B and/or C will be collected as in Part A of the study .
Electrocardiograms should be recorded up to 5 minutes before collecting any blood for safet y or 
PK tests.   
Consecut ivetriplicate ECGs will be obtained at approximately 1-minute intervals .  
Patients/s ubjects shoul dbe supine for approximately 5 minutes before ECG collection and 
remain supine ,but awake ,during ECG collection.  Electrocardi ograms may be obtained at 
additional times,when deemed clinically necessary.   
Collection of additional ECGs at a 
particular time point i s allo wed to ensure high -quali ty records.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the si te as soon after the time of ECG collect ion as possible, and ideally while the 
subject is st ill present, to determine whether the patient/ subject meets entry  criteria at the 
relevant visit(s) and for immediate patient/ subject management shoul d any  clinically re levant 
findings be ident ified.
If a clinically significant quantitative or qualitat ive change fro m baseline is ident ified after 
enrollment, the investigator will assess the patient/subject for symptoms (for example, 
palpitations, near syncope, syncope) to determine whether the patient/subject can continue in the 
study .  The investi gator or qualified designee is responsible for determining if any  change in 
patient/ subject management i s needed and m ust docum enthis/her review of the ECG printed a t 
the time o f evaluation fro m at least 1of the triplicate ECGs from  each time point.
Digital ECGs will be electroni cally transmitted to a central ECG laboratory  designated by  Lilly .  
The central ECG laboratory  will perf orm a basic quali ty control  check ( for exam ple, 
demographics and study  details) then store the ECGs in a database.  At a future time, the stored 
ECG data may be overread at the central ECG laboratory  for further eval uation of  machine -read 
measurements or to meet regulatory  requi rements.
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  61
LY3316531T h e  m a c h i n e- r e a d  ECG  i n t e r v a l s  a n d  h e a r t  r a t e  m a y  b e  u s e d  f o r  d a t a  a n a l y s i s  a n d  r e p o r t  w r i t i n g  
p u r p o s e s  u n l e s s  a  c a rd i o l og i s t  o v e r r e a d  o f  t h e  ECG s  i s  c o n d u c t e d  p r i o r  t o  c om p l e ti o n  o f  t h e  f i n a l  
s tudy  r e p o r t  ( i n  w h i c h  c a s e  t h e  o v e r r e a d  d a t a  w o u l d  b e  u s e d ) .
9 .4 .4 .Sa fe ty  Mon i to r ing
T h e  L i l l y  c l i n i c a l  p h a rm a c ol o g i s t  o r  CRP/ s c i e n t i s t  w i l l  m o n i to r  s a f e ty  d a t a  th roughou t  th e  cou r s e  
o f  th e  s tudy .
L i l l y  w i l l  r e v i ew  SAE s  w i th i n  tim e  f r am e s  m a n d a t e d  b y  c om p a n y  p r o c e d u r e s .   T h e  L i l l y  c l i n i c a l  
p h a rm a c ol o g i s t  o r  CRPw i l l  p e r i od i c a l ly  r ev i ew  th e  f o l l o w i n g  d a t a :
 t r end s  in  s a f e ty  d a t a
 l abo r a to ry  an a ly t e s
 adv e r s e  ev en t si n c l u d i n g  m o n i to r i n g  o f  i n c i d e n c e  a n d  n a t u r e  o f  a n y  i n f e c t i o n s ,  i n f u s i on  
r e a c t i o n s ,a n d  i n j e c t i o n -s i t e  r e a c t i o n s .
W h e n  a p p r o p r i a t e ,  t h e  L i l l y  c l i n i c a l  p h a rm a c ol o g i s t  o r  CRPw i l l  c o n s u l t  w i t h  t h e  f u n c ti o n a l l y  
i n d e p e n d e n t  G l o b a l  P a t i e n t S a f e ty  th e r ap eu t i c  a r e a  p h y s i c i a n  o r  c l i n i c a l  r e s e a r ch  s c i e n t i s t .
9 .4 .4 .1 .Hepa t ic  Sa fe ty
I f  a  s tudy  p a t i en t / sub j e c t  exp e r i en c e s  e l ev a t ed  ALT  ≥ 3×ULN ,  ALP  ≥ 2×ULN,  o r  e l ev a t ed  TBL
≥ 2×ULN ,  l iv e r  t e s t s  (A p p e n d i x  4)  shou l d  b e  r ep e a t ed  w i t h i n  3  to5  d a y s  i n c l u d i n g  ALT ,  AST ,  
ALP ,  TBL ,  d i r e c t  b i l i r u b i n ,  g amm a - g lu t amy l  t r an s f e r a s e ,a n d  c r e a t i n i n e  k i n a s eto  con f i rm  th e  
abno rm a l i ty  and  to  d e t e rm in e  i f  i t  i s  i n c r e a s i n g  o r  d e c r e a s i n g .   I f  t h e  a b n o rm a l i ty  p e r s i s t s  o r  
wo r s en s ,  c l in i c a l  and  l abo r a to ry m on i to r ing  shou l d  b e  in i t i a t ed  by  th e  inv e s t i g a t o r  b a s e d  o n  
c o n s u l t a t i o n  w i t h  t h e  L i l l y  c l i n i c a l  p h a rm a c ol o g i s t  o r  CRP.   M o n i t o r i n g  s h o u l d  c o n t i n u e  u n ti l  
l ev e l s  no rm a l i z e  a n d / o r  a r e  r e tu rn i n gt o  a p p r o x im a t e  b a s e l i n e  l e v e l s .  
A d d i ti o n a l  s a f e t y  d a t a  s h o u l d  b e  c ol l e c t e d  i f  1o r  m o r e  o f  th e  f o l l ow i n g  c o n d i ti o n s  o c c u r :  
 e l e v a ti o n  o f  s e rum  A LT  to  ≥ 5×ULN  o n  2o r  m o r e  c o n s e c u ti v e  b l o o d  t e s t s
 e l e v a ti o n  o fs e rum  TBL  to  ≥ 2×ULN  ( e x c e p t  f o r  c a s e s  o f  k n ow n  G i l b e r t ’ s  
s y n d r o m e )
 e l e v a ti o n  o f  s e rum  A LP  to  ≥ 2×ULN  o n  2o r  m o r e  con s e cu ti v e  b l o o d  t e s t s  
 p a t i en t / sub j e c t  d i s c o n t i n u e d  f r om  t r e a tm e n t  d u e  t o  a  h e p a t i c  e v e n t  o r  a b n o rm a l i t y  
o f  l iv e r  t e s t s

CC Ih e p a t i c  e v e n t  c o n s i d e r e d  t o  b e  a nSAE .
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  62
LY33165319 .4 .4 .3 .C -SSRS
T h e  Co lumb i a - Su i c id eS ev e r ity  R a t i n g  S c a l e(C - SSRS )c a p t u r e s  t h e  o c c u r r e n c e ,  s e v e r i t y ,a n d  
f r e q u e n c y  o f  s u i c i d a l  i d e a t i o n  a n d / o r  b e h a v i o rd u r i n g  t h e  a s s e s sm e n t  p e r i o d(P o s n e r  e t  a l .  2 0 1 1 ;  
Co lum b i a  U n i v e r s i ty  M e d i c a l  C e n t e r[WWW ] ) .   T h e  s c a l e  i n c l u d e s  s u g g e s t e dqu e s t ion s  to  
so l i c i t  th e  ty p e  o f  in fo rm a t i o n  n e e d e d  t o  d e t e rm i n e  i f  s u i c i d a l  i d e a t i o n  a n d / o r  b e h a v i o ro c c u r r e d .   
T h e  C- SSRS  i s  a dm i n i s t e r e d  b y  a n  a p p r o p r i a t e l y t r a in ed  h e a l thc a r e  p r o f e s s i o n a l  w i t h  a t  l e a s t  1  
y e a r  o f  p a ti e n t c a r e / c l i n i c a l  e x p e r i e n c e .   T h etoo l  w a s  d ev e l op ed  by  th e  N a t ion a l  In s ti t u t e  o f  
M en t a l  H e a ltht r i a l  g r o u p  f o r  t h e  p u r p o s e  o f  b e i n g  a  c o u n t e r p a r t  t o  t h e  Co lum b i a  C l a s s i f i c a t i o n  
A lgo r ithm  o f  S u i c i d e  A s s e s sm e n tc a t ego r i z a t i o n  o f  su i c id a l  ev en t s .   
T h e  n o n l e a d i n g  AE  c o l l e c ti o n  shou l d  o c cu rp r i o r  t o  t h e  c o l l e c ti o n  o f  t h e  C - SSRS .I f  a  
su i c i d e - r e l a t e d  e v e n t  i s  d i s c o v e r e d  du r ing  th e  C - SSRSb u t  w a s  n o t  c a p t u r e d  d u r i n g  t h e  
n o n l e a d i n g  AE  c o l l e c ti o n ,  s i t e s  shou l d  n o t  c h a n g e  t h e  AE  f o rm .I f  a n  e v e n t  i s  s e r i o u s  o r  l e a d s  t o  
d i s c o n t i n u a t i o n ,  th i s  i s  a n  e x c e p t i o n  w h e r e  t h e  SAE  a n d / o r  AE  l e a d i n g  t o  d i s c o n ti n u a t i o n  s h o u l d  
b e  i n c l u d e d  o n  t h e  AE  f o rm  a n d  t h e  p ro c e s s  fo r  r epo r t i n g  SAE s  shou l d  b e  f ol l o w ed.
9 .5 .Pha rmacok ine t ics
A t t h e  v i s i t s  a n d  t im e s  s p e c i f i e d  i n  t h e  S c h e d u l eo f  A c ti v i t i e s(S e c t i o n  2CC I
) ,  v e n o u s  b l o o d  s am p l e s  
o f  a p p r o x im a t e l y  5mL  e a c h  w i l l  b e  c ol l e c t e d  t o  d e t e rm i n e  t h e  s e r um  c o n c e n t r a t i o n s  o f  
LY3 3 1 6 5 3 1 .   A  m ax im um  of  2s am p l e s  m a y  b e  c o l l e c t e d  a t  a d d i t i o n a l  tim e  p o i n t s  d u r i n g  t h e  
s tudy  i f  w a r r a n t e d  a n d  a g r e e d  u p o n  b e tw e e n  b o t h  t h e  i n v e s t i g a t o r  a n d  s p o n s o r .   I n s t r u c t i o n s  f o r  
th e  c o l l e c t i o n  a n d  h a n d l i n g  o f  b l o o d  s am p l e s  w i l l  b e  p rov id ed  by  th e  spon so r .   T h e  a c t u a l  d a t e  
a n d  t im e  ( 2 4 -hou r  c l o c k  t im e )  o f  e a c h  s am p l i n g  w i l l  b e  r e c o r d e d .
D r u g  c o n c e n t r a t i o n  i n f o rm a ti o n  th a tm ayunb l ind  th e  s tudy  w i l l  n o t  b e  r e p o r t e d  t o  i n v e s t i g a t i v e  
s i t e s  o r  b l i n d e d  p e r s o n n e l  u n t i l  t h e  s t u d y  h a s  b e e n  u n b l i n d e d .
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  63
LY33165319 .5 .1 .B ioana lys is
S amp l e s  w i l l  b e  a n a l y z ed  a t  a  l abo r a to ry  app rov ed  by  t h e  s p o n s o r  a n d  s t o r e d  a t  a  f a c i l i t y  
d e s ign a t ed  by  th e  spon so r .
S e rum con c en t r a t i on s  o f  LY 3 3 1 6 5 3 1  w i l l  b e  a s s a y e d  u s i n g  v a l i d a t e d  e n z ym e - l i n k e d
imm u n o s o r b e n t  a s s a y  m e thod s .  A n a l y s e s  o f  s am p l e s  c o l l e c t e d  f r om  s u b j e c t s  who  r e ce i v e d  
p l a c ebo  a r eno t  p l a n n e d .
B io an a ly t i c a l  s amp l e s  co l l e c t ed  to  m e a su r e  s tudy  d rugc o n c e n t r a t i o n s  w i l l  b e  r e t a i n e d  f o r  a  
m a x im um  of1  y e a r  f o l l o w ing  la s t  sub j e c t  v i s i t  fo r  th e  s tudy .  D u r i n g  t h i s  t im e ,  s am p l e s  
r em a in ing  a f t e r  th eb i o a n a l y s e s  m a y  b e  u s ed  fo r  exp l o r a to ry  m e t a b ol i sm  s t u d i e s  o r  e x p l o r a t o r y  
a n a l y s e s  s u c h  a s  b i o a n a l y t i c a l  a s s a y  v a l i d a t i o n  o r  c r o s s - v a l i d a ti o n  e x e r c i s e s .
9 .6 .Pha rmacodynam ics
M e a s u r em e n t s  o f  t o t a l  CGRP  c o n c e n t r a t i o n s  w i l l  b e  u s e d  t o  e v a l u a t e  t a r g e t  e n g a g em e n ti n  P a r t  
A  o f  th e  s tudy.  S am p l e s  c o l l e c t e d  i n  P a r t s  B  a n d  Co f  th e  s tudy  w i l l  b e  a n a l y z e d  b a s e d  o n  t h e  
c o n c e n t r a t i o n s  o f  to t a l  CGRPob s e rv ed  in  P a r t  A .   S amp l e s  f o r  CGRP  m e a su r em en t s  w i l l  b e  
a n a l y z e d  i n  a  v a l i d a t e d  a s s a y  a t  a  l abo r a to ry  app rov ed  by  th e  spon s o r  a n d  s t o r e d  a t  a  f a c i l i t y  
d e s ign a t ed  by  th e  spon so r .
T h e  s am p l e ( s )  w i l l  b e  s t o r e d  f o r  u pto  a  m ax imum  o f  1 5y e a r sa f t e r  th e  l a s tp a t i e n t / s u b j e c tv i s i t  
f o r  th e  s tudy  a t  a  f a c i l i t y  s e l e c t e d  b y  t h e  s p o n s o r .
9 .6 .1 .Pha rmacodynam ic  Assessmen ts
9 .6 .1 .2 .D isease  Ac t iv i ty  Measu res  fo r  Pa t ients  w i th  Pso r ias is
T h e  d i s e a s e  a c t i v i ty  m e a s u r e s  d e s c r i b e d  b e l ow  w i l l  b e  co l l e c t e d  a t  t h e  t im e s  s h ow n  i n  t h e  
Sc h e d u l eo f  A c t i v i t i e s(S e c t i o n  2 .3 ) .
 T h e  PAS I  s c o r e s  t h e  s e v e r i ty  o f  d i s e a s e  o n  a  s c a l e  f r o m  0  t o  7 2  (w h e r e  a  s c o r e  o f  7 2  
i n d i c a t e s  e x t r em e  d i s e a s e  s e v e r i t y ) by  comb in ing  a s s e s sm en t s  o f  th e  ex t en t  o f  body
s u r f a c e  i n v o lv em en t  i n  t h e  h e a d ,  t r u n k ,  a rm s ,  a n d  l e g s  t o g e t h e r  w i t h  t h e  s e v e r i ty  o f  
d e s q u am a ti o n ,  e ry th em a ,  and  p l aqu e  indu r a t i o n .
 P e r c e n t  BSA  w i l l  b e  e v a l u a t e d  a s  t h e  p e r c e n t  i n v ol v em e n t  o f  p s o r i a s i s  o n  e a c h  p a t i e n t’ s  
BSA  o n  a  c o n t i n u o u s  s c a l e  f r om  0%  ( n o  i n v olv em en t )  to  100 %  ( f u l l  i n v ol v em e n t ) ,  w h e r e  
1%  c o r r e s p o n d s  t o  t h e  s i z e  o f  t h e  p a t i e n t ’ s  h a n d  ( i n c l u d i n g  t h e  p a lm ,  f i n g e r s ,  a n d  t h um b )  
(N a t i on a l  P so r i a s i s  Found a t i on  2009 ) .
CC I
T h e  sPGA  p r o v i d e s  t h e  p h y s i c i a n ’ s  d e t e rm i n a ti o n  o f  th e  p a t i e n t ’ s  p s o r i a s i s  l e s i o n s  
o v e r a l l  a t  a  g i v en  t im e  p o i n t .   O v e r a l l  l e s i on s  a r e  g r a d e d  f o r  i n d u r a ti o n ,  e ry th em a ,  a n d  
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 64
LY3316531scaling, and the sum of the 3 scores is divided by  3 to obtain a final sPGA score (range 0 
to 5).  For the analysis of responder rates, the sPGA scores are rounded to the nearest 
wholenumber, and the patient’s psoriasis is assessed as clear (0), minimal (1), mild (2), 
moderate (3), severe (4), or very  severe (5).
In the Pati ent’s Gl obal Assessment of Disease Severit y, patients are asked to rank on a 
0to 5numeric rating scale the seve rity of their psori asis “today ” from 0 (cl ear; no 
psori asis) to 5 (severe; worst their psoriasis has ever been).
The Psoriasis Symptom  Scale (PSS)is a pat ient-report ed assessment of 8symptom s:  itch, 
pain, di scomfort, stinging, burning, redness, scaling, and cracking.  Respondents are 
asked to answer the questions based on their psoriasis symptoms.  Numeric rating scales 
are used to assess the self -reported overall severit y of each of the 8symptom s 
individually  on an 11 -point hori zontal  scale anchored at 0 (no) and 10 (worst imaginable).  
The overall severit y for each individual symptom from psoriasis is indicated by select ing 
the number fro m 0 to 10 that best describes the worst level o f each symptom  in the 
preceding 24 hours.   The instructions for completion are embedded wit hin the PSS 
questionnaire for subjects to read before responding to the items.   The symptom  severi ty 
scores, ranging from 0 to 10, are the values o f the selected numbers indicated by  the 
subjec t on the instru ment’s horizontal  scale.  Each of the 8 individual items will receive a 
score of 0 to 10 and will be reported as itemscores for i tch, pain, discomfort, stinging, 
burning, redness, scaling, and cracking.  In addition, a total s core ranging from 0 (no 
psori asis symptom s) to 80 (worst imaginable psoriasis symptoms) will be reported.
9.6.2. Immunogenicity Assessments 
At the visit s and t imes specified in the Schedu le of Act ivities(Secti on 2
), venous blood samples 
will be co llected to determine ant ibody  producti on against the LY3316531 .  To interpret the 
resul ts of immunogenicit y, aPK sample will  be collected at the same time points. All samples 
for immunogenicit y shoul d be taken predose when applicable. In the event of drug 
hypersensit ivity react ions (immediate or non -immediate) , 
addit ional samples will be co llected as 
close to the onset of the event as possible, at the resolut ion of the event, and 30 day s following 
the event .  Instructions for the collection and handling of blood samples will be provided by the 
sponsor.  The actual date and time (24 -hour clock time) of each sampling will be recorded.
Immunogenicit y will be assessed by  a validated assay  designed to detect ADA s in the presence 
of LY3316531 at a l aboratory  approved by the sponsor .  Antibodies may  be further characteri zed 
and/or evaluated for their abilit y to neutralize the activit y of LY3316531.   Patients/subject swho 
are treatm ent-emergent ( TE)ADA positiveat the end of the study  or early discont inuat ion will 
be followed up with samples taken approximately  every 3 m onths, until they return to 2 -fold titer 
of baseline or for a m aximum  of1 year.Treatment -emergent ADAs are defined in 
Secti on10.3.4 .
Samples will  be retained for a m aximum  of 15 y ears after the last patient /subject visit, or for a 
shorter period if local regulat ions and ERBs allow, at a facilit y selected by  the sponsor.  The 
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  65
LY3316531du r a t i on  a l low s  th e  spon so r  to  r e spond  to  fu tu r e  r egu l a to ry  r equ e s t s  r e l a t ed  to  LY 3 3 1 6 5 3 1.   A n y  
s am p l e s  r em a i n i n g  a f t e r  1 5  y e a r s  w i l l  b e  d e s t ro y e d.
9 .7 .Gene t ics
A  b lood  s am p l e  w i l l  b e  c o l l e c t e d  f o r  p h a rm a c o g e n e t i c  a n a l y s i s  a s  s p e c i f i e d  i n  t h e  S c h e d u l e  o f  
A c ti v i t i e s(S e c t i o n  2 ) ,  w h e r e  l o c a l  r e g u l a ti o n s  a l l ow.
Sam p l e s  w i l ln o tb eu s e d  t oc o n d u c t  u n s p e c i f i e d  d i s e a s e  o r  p o p u l a ti o n  g e n e ti c  r e s e a r c h  e i t h e r  
n ow  o r  i n  t h e  f u t u r e .   S am p l e s  w i l l  b e  u s e d  t o  i n v e s t i g a t e  v a r i a b l e  expo su r e  o r  r e s p o n s e  t o  
LY 3 3 1 6 5 3 1a n d  t o  i n v e s t i g a t e  g e n e t i c  v a r i a n t s  t h o u g h t  t o  p l a y  a  ro l e  i n  p so r i a s i s .   A s s e s sm en t  o f  
v a r i a b l e  r e s p o n s e  m a y  i n c l u d e  e v a l u a t i o n  o f  AE so r  d i f f e r en c e s  in  e f f i c a cy .
CC IA l l  s am p l e s  w i l l  b e  c o d e d  w i t h  t h e  p a t i e n t/ s u b j e c t  n um b e r .   T h e s e  s am p l e s  a n d  a n y  d a t a  
g e n e r a t e d  c a n  b e  l i n k e d  b a c k  t o  t h e  p a t i e n t/ s u b j e c t  on ly  by  th e  inv e s t i g a t i v es i t e  p e r sonn e l .
S amp l e s  w i l l  b e  r e t a in ed  fo r  a  m ax imum  o f  15  y e a r s  a f t e r  th e  l a s t  p a t i en t  v i s i t ,  o r  f o r  a  sho r t e r  
p e r i od  i fl o c a l  r egu l a t i o n sand /o r  ERB sim p o s e  s h o r t e r  t im e  l im i t s ,  f o r  th e  s tudy  a t  a  f a c i l i t y  
s e l e c t ed  byL i l ly  o r  it s  d e s i g n e e .T h i s  r e t e n t i o n  p e r i o d  e n a b l e s  u s e  o f  n ew  t e c h n ol o g i e s ,  r e s p o n s e  
to  r egu l a to ry  q u e s t i o n s ,  a n d  i n v e s ti g a t i o n  o f  v a r i ab l e  r e spon s e  th a t  m ay  n o t  b e  o b s e r v e d  u n ti l  
l a t e r  i n  th e  d ev e l opm en t  o f  LY 3 3 1 6 5 3 1o r  a f t e r  LY 3 3 1 6 5 3 1i s  c omm e r c i a l l y  a v a i l a b l e .
M o l e c u l a r  t e c h n ol o g i e s  a r e  exp e c t ed  to  imp rov e  du r ing  th e  15 - y ea r  s t o r a g e  p e r i o d  a n d  t h e r e f o r e  
c a n n o t  b e  s p e c i f i c a l l y  n am ed .   H ow e v e r ,  ex i s ti n g  a p p r o a c h e s  i n c l u d e  w h o l e  g e n o m e  o r  e x om e  
s e q u e n c i n g ,  g e n o m e- w id e  a s so c ia t i o n  s t u d i e s ,  m ul t i p l e x  a s s a y s ,  a n d  c a n d i d a t e  g e n e  s t u d i e s .   
R e g a r d l e s s  o f  t e c h n ol o gy  u t i l i z e d ,  d a t a  g e n e r a t e d  w i l l  b e  u s e d  o n l y  f o r  th e  sp e c i f i c  r e s e a r ch  
s c o p e  d e s c r i b e d  i n  t h i s  s e c t i o n .
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  66
LY33165319 .9 .Hea l th  Econom icsCC I
Thi ss e c t i o n  i s  n o t  a p p l i c a b l e  f o r  t h i s  s t u d y .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 67
LY331653110. Statistical Considerations and Data Analysis
10.1. Sample Size Determination
The sample size for each cohort is customary  for the first -in-human study  in which form al power 
analyses is not necessary  to address the obj ectives associated with safet y, tolerabilit y, PK, and/or 
PD assessments. Approximately 86patients/subjects are planned for enrollment; however, up to 
102 s ubjects may be enro lled to allow for replacement of subjects and any addit ional dose 
cohorts (Parts A, B, and C) .
Subjects /patients who wi thdraw from  the study  before com pleting the Day 57 (Part A) or Day  85 
(Part s Band C )assessment may be repl aced if necessary  to have the planned number of 
subjects /patients complete a dose cohort.  A replacement subject /patientwill be assigned the 
same treatment as the subject /patienthe or she replaces (Parts A, B, and C) .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description of patient/subjec t disposi tion will be provi dedat the end of the study .
All subjects who discont inue from the study  will be i dentified, and the extent of their 
participat ion in the study will be reported.  If known, a reason for their discont inuat ion will be 
given.  A dis position tabl e for all  enrolled subjects will be provided.
10.2.2. Study Participant Characteristics
The subject’s /patient’sage, sex, weight, height, racial designat ion, or other demographic and 
study  disease characteri stics will be recorded and summarized.
10.3. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee .
Pharmacokinet ic/PDanalyses (CGRP target engagement) will be conducted on data fro m all 
patients/subjects who receiv eat least 1dose of the IPand have evaluable PK .
Clinical act ivity and PDanalyses will be conducted for all patients with psori asiswho receive 
the study  drug (Part C only).
Safety analyses will be conducted for all enro lled patients/subjects, whether or not they  
completed all  protocol  requi rements.
All protocol deviat ions that occur during the study will be considered for their severit y/impact 
and will be taken into considerat ion when subjects are assigned to analysis populat ions prior to 
database lock and unblinding .  Details of subject assignment to the analysis populat ions will be 
listed.
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  68
LY3316531Th e  p la c ebo  d a t a  f rom  a l l  coho r t s  w i l l  b e  poo l e d  a c r o s s  a l l  d o s e - e s c a l a t i o n  c o h o r t s  f o r  t h e  
p u r p o s e  o f  a n a l y s i s .
A d d i ti o n a l  exp l o r a to ry  a n a l y s e s  o f  t h e  d a t a  w i l l  b e  c o n d u c t e d  a s  d e em ed  app rop r i a t e .   S tudy 
r e su l t s  m ay  b e  poo l ed  w i th  th e  r e su l t s  o f  o t h e r  s t u d i e s  f o r  p o p u l a t i o n  PKan a ly s i s  pu rpo s e s  to  
a v o i d  i s s u e s  w i t h  p o s th o c  a n a l y s e s  a n d  i n c om pl e t e  d i s c l o s u r e s  o f  a n a l y s e s .  
10 .3 .1 .Sa fe ty  Ana lyses
10 .3 .1 .1 .C l in ica l  Eva lua t ion  o f  Sa fe ty
A l l  IP sand  p ro to co l  p r o c e d u r e  AE s  w i l l  b e  l i s t e d ,  a n d  i f  t h e  f r e q u e n c y  o f  e v e n t s  a l l ow s ,  s a f e t y  
d a t a  w i l l  b e  s umm a r i z e d  u s i n g  d e s c r i p ti v e  m e thodo l ogy .
T h e  i n c i d e n c e  o f  s ym p t om s  f o r  e a c h  t r e a tm e n t  w i l l  b e  p r e s e n t e d  b y s ev e r i ty  and  by  a s so c i a t i o n  
w ith  IPa s  p e r c e i v e d  b y  t h e  i n v e s ti g a t o r .   S ym p t om s  r e p o r t e d  t o  o c c u r  p r i o r  t o  t r e a tm en t  w i th  
s tudy  d rugw i l l  b e  d i s ti n g u i s h e d  f r om  t h o s e  r e p o r t e d  a s  n ew  o r  i n c r e a s e d  i n  s e v e r i t y  d u r i n g  t h e  
s tudy .   E a ch  symp tom  w i l l  b e  c l a s s i f i e d  b y  t h e  m o s t  s u i t a b l e  t e rm  f r o m  th e  Me d i c a l  Di c t ion a ry
f o r  R egu l a to ryA c t i v i ti e s .
S a fe t y  a n a l y s e s  w i l l  i n c l u d e  s umm a r i e s  o f  t h e  f o l l o w i n g :
 AE s  a n d  SAE s ,  i n c l u d i n g  s e v e r i ty  and  po s s ib l e  r e l a t i on sh ip  to  s tudy  d rug
 l abo r a to ry  m e a su r e s
T h e  n um b e r  o f  IP - r e l a t e d  SAE s  w i l l  b e  r e p o r t e d  a n d  s umm a r i z e d  b y  p r e f e r r e d  t e rm .
Su ic id a l  i d e a t i o n  a n d / o r  b e h a v i o r  a n d  s e l f - in ju r i o u s  b e h a v i o r  w i t h  n o  s u i c i d a l  i n t e n t ,  b a s e d  o n  t h e  
C -SSRS ,  w i l l  b e  l i s t e d  b y  p a ti e n t/ s u b j e c t(P a r t s  B  a n d  C ) .
10 .3 .1 .2 .S ta t is t ica l  Eva lua t ion  o f  Sa fe ty
S a fe t y  p a r am e t e r s  th a t  w i l l  b e  a s s e s s ed  in c lud e  s a f e ty  l ab o r a to ryp a r am e t e r s ,  v i t a l  s i gn s ,  and  
ECG  p a r am e t e r s .   T h e  p a r am e t e r s  w i l l  b e  l i s t e d ,  a n d  s umm a r i z e d  u s i n g  s t a n d a r d  d e s c r i p ti v e  
s t a t i s t i c s .   A d d i t i o n a l  an a ly s i s  w i l l  b e  p e r fo rm e d  i f  w a r r a n t e d  u p o n  r e v i ew  o f  t h e  d a t a .
B a s e l i n e  f o r  s a f e ty  p a r am e t e r s  w i l l  b e  d e f i n e d  a s  t h e  l a s t  e v a l u a b l e  v a l u e  b e f o r e  t h e  f i r s t  d o s e .
10 .3 .2 .Pha rmacok ine t ic  Ana lyses
10 .3 .2 .1 .Pha rmacok ine t ic  Ana lyses
P h a rm a c o k i n e ti c  p a r am e t e r  e s t im a t e s  f o r  LY3 3 1 6 5 3 1w i l l  b e  c a l c u l a t e d  u s i n gs t a n d a r d  
n o n c om p a r tm en ta l  m e t h o d s  o f  a n a l y s i s .
Th e  p r im a ry p a r am e t e r s  fo r  an a ly s i s  w i l l  b e  C m axCC I
a n d  AUC  o f  LY3316531.   O th e r  
n o n c om p a r tm en ta l  p a r am e t e r s ,  su ch  a s  h a l f - l i f e ,  a p p a r e n t  c l e a r a n c e ,  a b s o l u t e  b i o a v a i l a b i l i t y ,a n d  
a p p a r e n t  v o l um e  o f  d i s t r i b u t i on  m a y  b e  r epo r t ed .   M e a n  a n d  i n d i v i d u a l  p l a sm a  c o n c e n t r a t i o n  
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 69
LY3316531versus time profiles and individual and summary  stati stics of PK parameter estimates by  
treatm ent group will be generated .
Popul ation-based methods of analyses may  also be perform ed, to unders tand factors that 
influence the PK, characterize the inter -and intra -subject variabilit y in PK and support 
simulat ions of m ultiple dose administration.
10.3.2.2. Pharmacokinetic Statistical Inference
The dose proportionalit y of selected LY3316531 PK parameters fo llowing IV administration in 
Part A of the study , including logarithm o f Cmaxand relevant AUC values, will be examined 
across the ent ire dose range using a power -model approach (Smit h et al . 2000).  Other analyses 
of PK parameters may be performed as deemed appropriate.
10.3.3. Pharmacodynamic Analyses and Clinical Activity
Clinical act ivity and PDdata obtained will be documented in the study  report by  dose, pl asma 
drug concentrations, and time fro m dose.  However, the data collected at the visit s leading up to 
and including the Week 4 visit will be the data used for evaluat ion of changes in clinical act ivity 
and PD m easures.  Fi gures showing values of potent ial PD markers versus time will be created 
for each dose, with a line for each pat ient.  Absolute percentage change fro m baseline for all will 
be summarized by providing the mean, standard deviat ion, median, minimum, and maximum for 
each cohort and overall for each sample day /time combinat ion and maximum over the ent ire 
study .  Data m ay be log-transform ed pri or to summarizing if necessary .  The interpati ent and 
intrapat ient variability in human PD responses may also be assessed if appropriate. 
10.3.3.1. Pharmacokinetic/Pharmacodynamic Analyses
Analyses of the relat ionship between LY3316531 exposure and efficacy endpo intscollected in 
Part C (such as PASI score, sPGA ,andBSA ) will be invest igated init ially using graphical 
methods.  Modeling approaches that use a simple direct response relationship (using AUC) or
longitudinal models that link the time cour se of LY3316531 concentrations to the time course of 
response may be explored.  
Analyses of the relat ionship between LY3316531 exposure and total CGRP serum 
concentrations will also be conducted using graphical- and m odel-based approaches. Addit ional 
PD endpoints and safet y endpo ints may be explored for exposure -response relat ionship sif 
warranted upon review of the data.
10.3.3.2. Health Outcome Measures for Subjects with Psoriasis
The Pati ent’s Gl obal Assessment of Di sease Severit ywill be reported and summarized at each 
applicable visit using standard descriptive statist icsincluding number of subjects, mean, standard 
deviat ion, median, minimum, and maximum for cont inuous variables and number of subjects, 
frequency , and percentages for categorical vari ables.  Com parisons between each act ive 
treatm ent and pool ed placebo group will be made.  Results from statistical analyses will be 
provi ded for descript ive purposes only; therefore, no statist ical inferences will be made, and no 
control  for multiplicity is planned.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 70
LY331653110.3.4. Evaluation of Immunogenicity
The frequency and percentage of patients /subjects with baseline ADA , with ADA anytime
postbaseline, and/orwith TEADA to LY3316531 will be tabulated . For pati ents/subjects who 
are ADA negative at baseline, TE ADAs are defined as those with a titer 2 -fold (1 dil ution) 
greater than the minimum required dilut ionof the assay .  For pati ents/subjects who are ADA 
positive at baseline, TEADAs are defined as those with a 4-fold (2 dilut ions) increase in t iter 
compared to baseline. For the patients wi th TE ADA ,the distributi on of  maximum  titers will be 
described.   The frequency and percentage of patients wi th neutralizing antibodies may also be
tabul ated for patients wi thTE ADA .
The relat ionship between the presence of ant ibodies and the PKparameters and PDresponse
including safet y to LY3316531 may be assessed.
10.3.5. Data Review During the Study
Access to safet ydata i s scheduled to occur after every  dosing sessio n.  The purpose of these 
reviews is to guide dose select ion forthe next dosing sessio n, and/or to i nform  the design of 
subsequent studies .  The invest igator and the Lilly sponsor team will make the determinat ion 
regarding dose escalat ion, based upon their r eview of the data.  The investigator will remain 
blinded, and the Lilly sponsor team will be unblinded during these reviews.
In addit ion, data snapshots for preliminary  analyses of PK data are planned to occur after Day  29 
ofCohort 3(Part A) prior to the initiation of the mult iple-dose cohorts (Part B) .  The evaluat ion 
of these data will aid in determining the dose, margin of safet y, and adjust ment of PK sampling 
schedule.   Data snapshots are also planned to occur after Day  29 of  Cohort 6 in Part A and Da y 
57 of Cohort 1 in Part B.  Addit ional data snapshots may be conducted as required.   These 
snapshots and analyses will be conducted while the trial is ongoing, but no changes to the study  
design are planned .
10.3.6. Interim Analyses
An interim analysis will occur when all patients/subjects in Part sA, B, and C have co mpleted all 
requi rements stated i n the Schedule of Activit ies(Secti on 2;up to Day  85 for Part A, up to Day  
141 for Part B, and up to Day 113 for Part C ) or discontinued early fro m the study .Lilly 
employees andempl oyees of any  third-partyorganizat ioninvolved in the interpretati on of  data 
collected during the study  areauthori zed to eval uate unblinded data for the interim analyses.  
This interim analysis will include all  planned analyses of available data .  The data will be used 
for the development of a clinical study  report ( CSR). Results that are not available at the time a
CSR is developed can be provided in a separate report or CSR addendum.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 71
LY331653111. References
Adedoku n OJ, Xu Z, Gasink C, Friedman J, Szapary  P, Lang Y, Johanns J, Gao L -L, Miao Y, 
Davis H, Hanauer S, Feagan B, Sandborn W . OP028 Pharm acokinet ics and exposure- response 
relationships o f intravenously administered ustekinumab during induction treatment in pat ients 
with Crohn’s disease: results fro m the UNITI -1 and UNITI -2 studies [oral presentation]. At: 
11th Congress of European Crohn’s and Co litis Organisation (ECCO): Inflammatory  Bowel  
Diseases; Mar 16 -19,2016; Amsterdam :The Netherl ands. Oral  presentati on (OP) 028.
Bonifac e K, Gui gnouard E, Pedretti  N, Garci a M, Del wail A, Bernard FX, Nau F, Guillet G, 
Dagregori o G, Yssel  H, Lecron JC, Morel  F. A role for T cell -derive d interl eukin 22 in 
psori atic skin in flammat ion. Clin Exp Immunol . 2007;150(3):407 -415.
BrainSD, Williams TJ, Tippins JR, Morris HR, MacInt yre I. Cal citonin gene -related pepti de is a 
potent vasodilator. Nature . 1985;313 (5997) :54-
56.
CadyRJ, Gl enn JR, Smi th KM, Durham PL. Calcitonin gene -related pepti de prom otes cellular 
changes in trigeminal neurons and glia implicated in peripheral and central sensit ization. Mol 
Pain .2011;7:94.
Caruso R, Botti E, Sarra M, Esposito M, Stolf i C, Diluvio L, Gi ustizieri ML, Pacciani V, 
Mazzotta A, Campio ne E, Macdonald TT, Chimenti S, Pallo ne F, Costanzo A, Monteleone G. 
Involvement of interleukin- 21 in the epidermal hyperplasia o f psori asis. Nat Med . 
2009;15(9):1013 -1015.
Chaitman BR, Ho AP, Behm MO, Rowe JF, Palcza JS, Lae them T, Hei rman I, Panebianco DL, 
Kobalava Z, Martsevich SY, Free AL, Bittar N, Chrysant SG, Ho TW, Chodakewitz JA, 
Murphy MG, Blanchard RL. A rando mized, placebo -controlled study of the effects of 
telcagepant on exercise t ime in pat ients with stable angina. Clin Pharmacol Ther . 
2012; 91(3):459 -466.
Columbia Universit y Medical Center. Columbia –Suicide Severi ty Rating Scale (C -SSRS) web 
site. Available at: http://www.cssrs.columbia.edu. Accessed July 19, 2017 .
Crow JM. Therapeutics: silencing psoriasis. Nature. 2012;492(7429):S58
-S59.
Di Cesare A, Di Megli o P, Nestl e FO. The IL -23/Th17 axis in the immunopathogenesis of 
psori asis. J Invest Dermatol. 2009;129(6):1339 -1350.
Ding W, Stohl  LL, Xu L, Zhou XK, Manni M, Wagner JA, Granstein RD. Calcitonin gene -
related p
eptide-exposed endothelial cells bias antigen presentati on to CD4+ T cells toward a 
Th17 response. J Immunol . 2016;196(5):2181-
2194.
Feaga n BG, Sandborn W, Panés J, Ferrante M, Louis E, D’ Haens GR, Franchimo nt D, Kaser A, 
Dewi t O, Sei dlerU, Kim K-J, Neurath M, Scholl P, Vi svanathan S, Padul aS, Herichova I, 
SoaitaA, Hall D, Böcher WO. 812a Efficacy and safety of inducti on therapy  with the select ive 
IL-23 inhibitor BI 655066, in pat ients withmoderate -to-severe Crohn’s disease: results of a 
rando mized, double -blind, placebo -controlled Phase II study . Gastroenterology . 2016;150(4) 
suppl  1:S1266. Abstract 812a.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 72
LY3316531Gordon KB, Callis Duffin K, Bissonnette R, Prinz JC, Wasfi Y, LiS, Shen Y-K , Szapary P, 
Randazzo B, Reich K. A phase 2 trial of guselkumab versus adalimumab for plaque psori asis.
N Engl J Med .2015;373 (2):136-144.
Hirsch S, Corradini L, Just S, Arndt K, Doods H. The CGRP receptor antagonist BIBN4096BS 
peripherally  alleviates inflammatory  pain in rats. Pain . 2013;154(5):700 -707.
Kagam i S, Ri zzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulat ing Th17, Th22, and Th1 cells are 
increased in psoriasis. J Invest Dermatol . 2010;130(5):1373 -1383.
Kashe m SW, Riedl  MS, Yao C, Honda CN, Vulchanova L, Kaplan DH. Nocicept ivesensory  
fibers d
rive interleukin- 23 producti on from CD301b+ dermal dendrit ic cells and drive 
protective cutane ous immunit y. Immunity . 2015 ;43(3):515- 526.
KoppT, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, Kittler H, Blumenschein 
WM, McClanahan TK, Marbury T, Zachariae C, Xu D, Hou XS, Mehta A, Zandvliet AS, 
Montgomery D, van Aarle F, Khalilieh S. Clinical improvement in psoriasis wit h specific 
targeting of interleukin -23. Nature . 2015 ;521(7551):222 -226.
Krue ger JG, Ferri s LK, Menter A, Wagner F, Whit e A, Vi svanathan S, Lal ovic B, Aslanyan S, 
Wang EE L, Hall  D, Solinger A, Padul a S, Scholl P. Ant i–IL-23A mAb BI 655066 for 
treatm ent of m oderate -to-severe psoriasis: safety , efficacy , pharmacokinet ics, and bio marker 
resul ts of a single -rising-dose, randomized, double -blind, placebo -controlled trial. J Allergy 
Clin Immunol . 2015;136 (1):116-124. 
Lee E , Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger 
JG. Increased expressio n of interleukin 23 p19 and p40 in lesio nal skin o f patients wi th 
psori asis vulgaris. J Exp Med . 2004;199(1):125 -130.
Lew W, Bowcock AM, Krueger JG. Psoriasis vulgaris: cutaneous lympho id tissue suppor ts 
T
-cell act ivation and “Type 1” inflammatory gene expressio n. Trends Immunol . 
2004;25(6):295 -305.
Lotti T, D’ Erme AM, Hercogová J. The role o f neuropep tides in the control of regional 
immunit y. Clin Dermatol . 2014 ;32(5):633-645.
Lowes MA, Kikuchi T, Fuentes -Duculan J, Cardinale I, Zaba LC, Haider AS, Bowman EP, 
Krueger JG. Psoriasis vulgaris lesio ns contain discrete populat ions of Th1 and Th17 T cells. 
JInvest Dermatol . 2008;128(5):1207- 1211.
National Psoriasis Foundat ion. The Psori asis and Psori atic Arthri tis Pocket Gui de. Portl and, OR.
2009.
Mulderry PK, Ghatei MA, Spokks RA, Jonhs PM, Pierson AM, Hamid QA, Kanse S, Amara SG, 
Burri nJM, Legon S, Polak JM, Bloom SR. Different ia
l expressio n of α -CGRP and β -CGRP 
by primary  sensory  neuro ns and enteric autonomic neurons of the rat. Neuroscience . 
1988;25(1):195 -205.
Papp K, Thaci D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, 
Bowman EP, Mehta A, Li Q, Zhou Y, Shames R. Tildrakizumab (MK -3222) an anti -
interleukin -23 p19 m onocl onal ant ibody , improves psori asis in a phase IIb rando mized 
placebo -controlled trial. Br J Dermatol. 2015;173 (4):930-939.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 73
LY3316531Piskin G, Tursen U, Sylva -Steenland RM, Bos JD, Teunissen MB. Clinical improvement in 
chronic plaque -type psori asis l esions after narrow -band UVB therapy  is accom panied by a 
decrease in the expressio n of IFN -gamma inducers -- IL-12, IL -18 and IL -23. Exp Dermatol.
2004;13(12):764 -772.
Posner K, Brown G, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin 
GA, Greenhill L, Shen S, Mann JJ . The Col umbia -Suicide Severi ty Rating Scale: init ial 
valid ity and internal  consistency findings from three mult isite studies wit h adolescents and 
adults. Am J Psychiatry. 2011;168(12):1266 -1277.
Riol-Blanco L, 
Ordovas -Montanes J , Perro M , Naval E , Thi riot A, Alvarez D , Paust S , Wood 
JN, von Andrian UH .Noci ceptive sensory neurons drive interleukin -23-mediated psoriasiform 
skin inflammat ion.Nature . 2014;510(7503):157-
161.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB,
Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S,
Lichtiger S, Feagan BG; CERTIFI Study  Group. Ustekinumab induct ion and m aintenance
therapy  in refractory  Crohn’s disease. N Engl J Med . 2012;367(16):1519 -1528.
Sand s BE, Chen J, Penney M, Newhold P, Faggioni R, van der Merwe R, Patra K, Klekotka P, 
Pulkstenis E, Drappa J, Gasser RA. A rando mized, double -blind placebo -controlled phase 2a 
induct ion study  of MEDI2070 (anti -p19 ant ibody ) in patients with act ive Crohn’s disease who 
have failed ant i-TNF ant ibody  therapy . J Crohns Colitis . 2015;9(suppl 1):S15- S16. Abstract 
OP025.
Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callagha n JT, Forgue ST.
Confidenc einterval criteria f or assessment of dose proportion ality.Pharm Res . 
2000;17(10):1278 -83.
Sofen H, Smit h S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, 
Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary  P, Krueg er JG. Gusel kumab (an IL -
23-specific 
mAb) demonstrates clinical and mo lecular response in patients with moderate -to-severe 
psori asis. J Allergy Clin Immunol . 2014;133(4):1032-
1040.
Steenberg hPH, Höppener JW, Zandberg J, Lips CJ, Jansz HS. A second human 
calcitonin/CGRP gene. FEBS Lett . 1985;183(2): 403-407.
Steinman L. A brief history  of T(H)17, the first major revisio n in the T(H)1/T(H)2 hy pothesis of 
T cell -mediated tissue damage. Nat Med. 2007;13(2):139 -145.
Verheg genR, Bumann K, Kaumann AJ. BIBN4096BS is a potent compet itive antagonist of the 
relaxant effects of alpha -CGRP on human temporal artery : comparison wi th CGRP(8
-37). Br J 
Pharmacol . 2002;136(1):120-126.
Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL -17 family  cytokines and the expanding 
diversit y of effector T cell lineages. Annu Rev Immunol . 2007;25:821-852.
Williamson A and Hoggart B. Pain: areview of three commo nly used pain rat ing scales. J Clin
Nurs . 2005;14(7):798 -804.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 74
LY3316531Appendix 1. Abbreviations and Definitions
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 75
LY3316531Term Definition
ADA antidrugantibod y
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treat ment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investig ational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
assent Agreement from a child or other individual who is not legally capable of providing consent, 
but who can understand the circumstances and potential risks involved in participating in a 
study (required by some institutional review boards [IRBs]/ethical revie w boards [ERBs]). 
AST aspartat e aminotransferase
blinding A procedure in which 1or more parties to the study are kept unaware of the treatment 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock.
A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient/subject is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient/subject are no t.  A double -blind 
study is one in which neither the patient/subject nor any of the investigator or sponsor staff 
who are involved in the treatment or clinical evaluation of the subjects are aware of the 
treatment received
CGRP calcitonin gene -related peptide
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
complianc e Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the labo ratory  generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be re -tested at some defined time point, depending on the steps requ ired to obtain 
confirmed results.
CRP clinical research physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician ,or other medical officer.
CRU clinical research unit
CSE clinically significant event
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 76
LY3316531CSR clinical study report
C–SSRS Columbia -Suicide Severity Rating Scale
ECG electrocardiogram
eCRF electronic case report form
enroll The act of ass igning a patient/subject to a treatment.  Patients/ subjects who are enrolled in 
the study are those who have been assigned to a treatment.
enter Patients/ subjects entered into a study are those who sign the informed consent form directly 
or through their legally a cceptable representatives.
ERB ethical review board
GCP good clinical practice
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmoni sation
Ig immunoglobulin
IL interleukin
informed consent A process by which a patient/subject voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study  that 
are relevant to the patient ’s/subject’s decision to participate. Informed consent is 
documented by means of a written, signed ,and dated informed consent form .  
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
product (IP)Apharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study, includ ing products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the author ized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal i nvestigator.
IV intravenous
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 77
LY3316531legal 
representativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective patient/subject, to the patient ’s/subject’s participation in the clinical 
study.
mAb monoclonal antibody
MTD maximum tolerated dose
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PASI Psoriasis Area and Severity Index
PD pharmacodynamic(s)
PK pharmacokinetic (s)
PSS Psoriasis Symptom Scale
PUVA psoralen plus ultraviolet A light therapy
QTc QT interval
randomize The process of assigning subjects/ patients to an experimental group on a random basis .
RNA ribonucleic acid
SAD single -ascending dose;
SAE serious adverse event
SC subcutaneous
screen The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .  
SUSAR suspected unexpected serious adverse reaction
TB tuberculosis
TBL total bilirubin level
TE treatment emergent
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment 
Th Thelper
TNF tumor necrosis factor
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  78
LY3316531TST t u b e r c u l i n  s k i n  t e s t
ULN u p p e r  l im i t  o f  n o rm a l
WOCBP wom e n  o f  c h i l d b e a r i n g  p o t e n t i alCC I
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  79
LY3316531Append ix  2 . C l in ica l  Labo ra to ry Tes ts
Sa fe ty  Labo ra to ry  Tes ts
H em a t o l o g y C l in i c a l  Ch em i s t r y
H em a t o c r i t S o d i um
H em o g l o b i n P o t a s s i um
E ryth ro cy t e  c o u n t  (RBC ) G l u c o s e ,  r a n d om
M e a n  c e l l  v o l um e B l o o d  u r e a  n i t r o g e n  (BUN )
M e a n  c e l l  h em o g l o b i n U ri c  a c id
M e a n  c e l l  h em o g l o b i n  c o n c e n t r a t i o n T o t a l  c h o l e s t e r o l
L e u k o c y t e s  (WBC ) T o t a l  p ro t e i n
P l a t e l e t s A l b um i n
T o t a l  b i l i r u b i n
A b s o l u t e  C o u n t s  o f : A l k a l i n e  p h o s p h a t a s e  (ALP )
N e u t r o p h i l s A s p a r t a t e  am i n o t r a n s f e r a s e  (AST /SGOT )
Lympho cyt e s A l a n i n e  am i n o t r a n s f e r a s e  (ALT /SGPT )
M o n o c y t e s C r e a t i n i n e
E o s i n o p h i l s G amm a- g l u t am y l  t r a n s f e r a s e  ( GGT)
B a s o p h i l s Imm u n o g l o b u l i n s  ( I gA ,  I gM  a n d  I gG )a
S e r o l o g y
H e p a t i t i s  B  s u r f a c e  a n t i g e na
U r in a l y s i s H e p a t i t i s  B  c o r e  a n t i b o d ya
S p e c i f i c  g r a v i t y H e p a t i t i s  B  s u r f a c e  a n t i b o d ya
pH H e p a t i t i s  C  a n t i b o d ya , c
P r o t e i n He p a t i t i s  C  v i r u s  (HCV )  r i b o n u c l e i c  a c i d  (RNA )c
G l u c o s e H IVa
K e t o n e s
B i l i r u b i n O th e r
U ro b i l i n o g e n U rin e  e t h a n o lt e s td
B l o o d U ri n e  d r u g  s c r e e nd
L e u k o c y t e  e s t e r a s e  o r  n i t r i t e Q u a n t iFERON®- TB  G o l d  t e s t  o r  TSTa
M i c r o s c o p i c  e x am i n a t i o n  o f  s e d im e n tfP r e g n a n c y  t e s te( s e r umaa n d  u r i n e )
FSHa , e
HS- C- r e a c t i v e  p r o t e i nb
S e r um  c o n c e n t r a t i o n  o f  LY 3 3 1 6 5 3 1  (PK )
T a r g e t  e n g a g em e n t  a s s a y  (CGRP )
P h a rm a c o g e n e t i c s  ( e x p l o r a t o r y  s t o r a g e  s am p l e s  f o r  DNA )
Exp lor a to ry  s t o r a g e  s am p l e s  ( s e r um ,  p l a sm a ,  RNA )b
Imm u n o g e n i c i t y  ( a n t i - LY 3 3 1 6 5 3 1  a n t i b o d i e s )CC I
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 80
LY3316531Abbreviations:  CGRP = calcitonin gene -related peptide; DNA = deoxyribonucleic acid; FSH = follicle -stimulating 
hormone; HIV = human immunodeficiency virus ;HS = high sensitivity; IL = interleukin; PK = pharmacokinetic; 
RBC = red blood cell; RNA = ribonucleic acid; SGOT = serum glutamic oxaloacetic transaminase ; SGPT = 
serum glutamic pyruvic transaminase ; TB = tuberculosis; TST = tuberculin skin test ; WBC = white blood cell .
aPerformed at screening only .
bPerformed in patients with psoriasis only.
cA positive hepatitis C antibody laboratory assessment will be confirmed with a test for hepatitis C virus (HCV) 
ribonucleic acid (RNA) .
dUrine drug screen and ethanol testwill be performed at screening and repeated prior to admission to the clinical 
research unit (Day  -1), and when clinically indicated .
eFor female patients/subjects only .
fWill o nly be performed if urine dipstick evaluation showsabnormal ity.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 81
LY3316531Appendix 3. Study  Governance, Regulatory ,and Ethical 
Considerations
Informed Consent
The invest igator is responsible for
ensuring that the patient/ patient’s legal representative/ subject understands the nature of 
the study ,the potential risks and benefit s of parti cipating in the study , and that thei r 
participat ion is voluntary.
ensuring that informed consent is given by each patient/subject or legal representative.  
This includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any proto col procedures and prior to the administration of IP.
answering any quest ions the patient/ subject or patient ’s/subject’s legal representative
may have throughout the study  and sharing in a timely  manner any new information that 
may be relevant to the patient’s/subject ’s or pati ent’s/subject’s legal representative ’s
willingness to continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant or the participant’s legal representative and 
retaining a copy  on file .
Recruitment
Lilly or i ts desi gnee is responsible for the central recruit ment strategy  for pati ents.  Individual 
investigators may have addit ional local requirements or processes.   Study -specific recruit ment 
materi al should be approved by Lilly .
Ethical Review
The inve stigator or appropriate local representative must give assurance that the ERB was 
properly const ituted and convened as required by  Internat ional Council for Harmonisat ion (ICH)
guidelines and other applicable laws and regulations.
Docum entati on of  ERB appr oval of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 82
LY3316531Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences Internat ional Ethical Guidelines 
2)applicable ICH GCP guidelines 
3)applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party  organi zation.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or h er knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
Final R eport Signature
The invest igator or designee will sign the clinical study report for this study, indicat ing 
agreem ent wi th the analyses, resul ts, and concl usions of the report.
The invest igator with the most enrolled pat ients/subjects will serve as the fin al report 
coordinat ing investigator.  If this invest igator is unable to fulfill this funct ion, another 
investigator will be chosen by  Lilly to serve as the final report coordinat ing investigator.
The sponsor’s responsible medical o fficer and statistician w ill sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable d ata, Lilly  or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate.
provi de training to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the completion of the CRFs, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax.
review and evaluate CRF data and/or use standard computer edits to detect errors in data 
collect ion.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 83
LY3316531conduct a qualit y review of the database .
In addit ion, Lilly or its representatives will periodically check a sample of the patient/subject 
data recorded against source documents at the study site.  The study  may be audited by Lilly 
and/or regulatory  agencies at any  time.  Investigators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical note s.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this s tudy.  The si te must define and retain all 
source records and must maintain a record of any  data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti on law.  
The p urpose and use of subject/patient personal information co llected will be provided in a 
written docum ent to the subject/patient by  the sponsor .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 84
LY3316531Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a TE hepat ic abnormalit y and m ay be requi red in 
follow-up wi th patients in consultat ion with Lilly  or its desi gnee CRP .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear Antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CPK Anti -smooth Muscle Antibody (or Anti -actin 
Antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized
ratio; RBC = red blood cell; WBC = white blood cell.
aAssay ed by Lilly -designated or local laboratory.
bReflex/con firmation dependent on regulatory requirements and/or testing availability .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 85
LY3316531Appendix 5. Blood Sampling Summary
APP. 5.1. Part A (SAD in Healthy Subjects)
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during Part A .  
Protocol I9H-MC-FFAA Sampling Summary (Part A)
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (mL)
Screening tests a 45 1 45
Clinical laboratory tests a 12 13 156
Pharmacokinetics b 5 18 90
Blood discard for cannula patency 1 4 4
Pharmacodynamics (total CGRP) 2 8 16
Immunogenicity b 7.5 7 52.5
Pharmacogenetics 6 1 6
Total 369.5
Total for clinical purposes 370
Abbreviation :CGRP = calcitonin gene-related p eptide.
aAdditional samples may be drawn if needed for safety purposes.
bIncludes 3 additional samples tobe drawn if needed to aid in the assessment of anti -drug hypersensitivity 
reactions .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 86
LY3316531APP.5.2. Part B (M ultiple -Dose in Healthy Subj ects)
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es, and bioanaly tical assays) during Part B .  
Protocol I9H -MC-FFAA Sampling Summary (Part B)
PurposeBlood Volume per Sample 
(mL)Number of Blood 
SamplesTotal Volume (mL)
Screening tests a 45 1 45
Clinical laboratory tests a 12 9 108
Pharmacokinetics b 5 30 150
Blood discard for cannula patency 1 4 4
Pharmacodynamics (total CGRP) 2 9 18
Immunogenicity b 7.5 11 82.5
Pharmacogenetics 6 1 6
Total 413.5
Total for clinical purposes 420
Abbreviation :CGRP = calcitonin gene -related p eptide.
aAdditional samples may be drawn if needed for safety purposes.
bIncludes 3 a dditional samples tobe drawn if needed to aid in the assessment of anti -drug hypersensitivity 
reactions .
I9H - MC- FFAA(b )C l in ica l  Pha rmaco logy  P ro toco l Page  87
LY3316531APP .5 .3 . Pa r t  C  (S ing le  Dose  in  Pa t ien ts  w i th  Pso r ias is )
T h i s  t a b l e  s umm a r i z e s  t h e  app rox im a t en um b e r  o f  v e n i p u n c t u r e s  a n d  b l o o d  v o l um e s  f o ra l l  
b lood  s am p l ing  ( s c r e e n i n g ,  s a f e t y  l a bo r a to r i e s ,a n d  b i o a n a l y t i c a l  a s s ay s )  du r ing  P a r t  C.   
P r o t o co l  I 9H- MC- FFAA  S amp l in g  Summ a r y
Pu rp o s eB l o od  V o lum e  p e r  S amp l e  
(mL )Numb e r  o f  B l o od  
S amp l e sT o t a l  V o lum e  (mL )
S c r e e n i n g  t e s t s a , b 4 5 1 4 5
C l i n i c a l  l a b o r a t o r y  t e s t s a , b 1 2 1 5 1 8 0
P h a rm a c o k i n e t i c s c 5 2 1 1 0 5
B l o o d  d i s c a r d  f o r  c a n n u l a  p a t e n c y 1 4 4
P h a rm a c o d y n am i c s  ( t o t a l  CGRP ) 2 1 1 2 2
P h a rm a c o d y n am i c s  ( 2 .5 6 1 5
Imm u n o g e n i c i t y c 7 .5 1 0 7 5
P h a rm a c o g e n e t i c s 6 1 6
Exp lor a to ry  s am p l e s  ( s e r um ,  p l a sm a ,
RNA )1 5 5 7 5
T o t a l 5 2 7
To t a l  f o r  c l i n i c a l  p u r p o s e s  5 3 0
A b b r e v i a t i o ns :CGRP  =  c a l c i t o n i n  g e n e- r e l a t e d  p e p t i d e ;  IL  =  i n t e r l e u k i n ;  RNA  =  r i b o n u c l e i c  a c i d .
aA d d i t i o n a l  s am p l e s  m a y  b e  d r aw n  i f  n e e d e d  f o r  s a f e t y  p u r p o s e s .
bT h e  s c r e e n i n g  a n d  c l i n i c a l  l a b o r a t o r y  t e s t s  w i l l  i n c l u d e  a  h sCRP  s am p l e  d r aw  w h e n  i n d i c a t e d  i n  t h e  S c h e d u l e  o f  
A c t i v i t i e s  (S e c t i o n  2 .3 ) .
cCC I
I n c l u d e s  3  a d d i t i o n a l  s am p l e s  tob e  d r aw n  i f  n e e d e d  t o  a i d  i n  t h e  a s s e s sm e n t  o f  a n t i - d ru g  h y p e r s e n s i t i v i t y  
r e a c t i o n s .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 88
LY3316531Appendix 6. Protocol FFAA  PK, Immunogenicity , and ECG 
Sampling Schedule
APP.6.1 .Part A (SAD in Healthy Subjects)
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 89
LY3316531Visit WeekDay 
Relative to 
LY/PL
TreatmentPK Sampling 
Time IV DosingaPK Sampling 
Time 
SC DosingaImmunogenicity 
Samplinga ECGb
2 0 1 Predose Predose Predose Predose
2 0 1 End of infusioncNA NA End of infusionc
2 0 1 2 h afterstart of 
infusionNA NA NA
2 0 1 6 h after start of 
infusion6 h post -injection NA 6 h after SC 
injection or start 
of infusion
2 0 1 NA NA NA 12 h after start of 
infusion
2 0 2 24 h after start of 
infusion24 h post -
injectionNA 24 h after SC 
injection or start 
of  infusion
3 0 4 ± 1 day Any time during 
dayAny time during 
dayNA NA
4 1 8 ± 1 day Any time during 
dayAny time during 
dayNA Any time during 
day
5 1 11 ± 1 day NA Any time during 
dayNA NA
6 2 15 ± 2 days Any time during 
dayAny time during 
dayAny time during 
dayAny time during 
day
7 3 22 ± 2 days Any time during 
dayAny time during 
dayNA NA
8 4 29 ± 2 days Any time during 
dayAny time during 
dayAny time during 
dayNA
9 6 43 ± 3 days Any time during 
dayAny time during 
dayNA Any time during 
day
10 8 57 ± 3 days Any time during 
dayAny time during 
dayNA NA
11 10 71 ± 3 day Any time during 
dayAny time during 
dayNA NA
12 12 85 ± 3 days Any time during 
dayAny time during 
dayAny time during 
daydAny time during 
day
ED ED Any time during 
dayAny time during 
dayAny time during 
daydAny time during 
day
Abbreviations:  ADA = antidrug antibody; ECG = electrocardiogram; ED = early discontinuation; h = hour(s); IV = 
intravenous; LY = LY 3316531 ; PL = Placebo; NA = not applicable (no sampling needed at this time point); 
PK=pharmacokinetic; SC = subcutaneous ; TE = treatment emergent .
aIn the event of drug hypersensitivity reactions (immediate or non -immediate), up to 3 additional samples will be 
collected each for pharmacokinetics and immunogenicity as close to the onset of the reaction event as possible, at 
the resolution of the event, and 30 days following the event .
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 90
LY3316531bECG measurement should occur prior to the blood draw.
cRequired for subjects receiving intravenous dosing only.  ECGs (and vital signs) should be measured within 5 
minutes prior to the end of infusion and PK samples as soon as possible after the infusion is completed
dSubjects who are TE ADA positive at the end of the study or ea rly discontinuation will be followed with samples
for ADA and PK being taken approximately ever y 3 months, until they return to 2 -fold titer of baseline or for a 
maximum of 1 year.
Note:  Samples that are requested to be taken predose through Day 2 should be collected as close to the sampling 
time as possible.  Aberrations to thespecified sampling times will not be considered protocol deviations as long 
as the samples are taken and the actual sampling time is recorded.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 91
LY3316531APP.6.2. Part B ( Multiple -Dose in Healthy Subjects) 
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 92
LY3316531Visit WeekDay 
Relative to 
First Dose 
LY/PL 
TreatmentPK Sampling 
Time IV DosingaPK Sampling 
Time 
SC Dosinga,bImmunogenicity 
Samplinga ECGc
2 0 1 Predose Predose Predose Predose
2 0 1 End of infusion NA NA End of infusiond
2 0 1 2 h afterstart of 
infusionNA NA NA
2 0 1 6 h after start of 
infusion6 h post -injection NA 6 hafter SC 
injection or start 
of  infusion
2 0 2 24 h after start of 
infusion24 h post -
injectionNA 24 h after SC 
injection or start 
of  infusion
3 0 4 ± 1 day Any time during 
dayAny time during 
dayNA NA
4 1 8 ± 1 day Any time during 
dayAny time during 
dayNA Any time during 
day
5 1 11 ± 1 day NA Any time during 
dayNA NA
6 2 15 ± 2 days Any time during 
dayAny time during 
dayAny time during 
dayAny time during 
day
7 3 22 ± 2 days Any time during 
dayAny time during 
dayNA NA
8 4 29 Predose Predose Predose Predose
8 4 29 End of infusion NA NA End of infusionc
8 4 30 24 h after start of 
infusion24 h post -
injectionNA 24 h after SC 
injection or start 
of  infusion
9 4 32 ± 1 days Any time during 
dayAny time during 
dayNA NA
10 5 36 ± 1 days Any time during 
dayAny time during 
dayNA NA
11 5 39 ± 1 day NA Any time during 
dayNA NA
12 6 43 ± 2 days Any time during 
dayAny time during 
dayNA NA
13 7 50 ± 2 days Any time during 
dayAny time during 
dayNA NA
14 8 57 Predose Predose Predose Predose
14 8 57 End of infusion NA NA End of infusiond
14 8 58 24 h after start of 
infusion24 h post -
injectionNA 24 h after SC 
injection or start 
of  infusion
15 8 60 ± 1 day Any time during 
dayAny time during 
dayNA NA
16 9 64 ± 1day Any time during 
dayAny time during 
dayNA Any time during 
day
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 93
LY331653117 9 67 ± 1 day NA Any time during 
dayNA NA
18 10 71 ± 2 days Any time during 
dayAny time during 
dayNA Any time during 
day
19 11 78 ± 2 days Any time during 
dayAny time during 
dayNA NA
20 12 85 ± 3 days Any time during 
dayAny time during 
dayAny time during 
dayAny time during 
day
21 16 113 ± 4 
daysAny time during 
dayAny time during 
dayNA NA
22 20 141 ± 4 
daysAny time during 
dayAny time during 
dayAny time during 
dayeAny time during 
day
ED ED Any time during 
dayAny time during 
dayAny time during 
dayeAny time during 
day
Abbreviations:  ADA = antidrug antibody; ECG = electrocardiogram; ED = early discontinuation; h = hour(s); IV = 
intravenous; LY = LY 3316531; PL = Placebo; NA = not applicable (no sampling needed at this time point); 
PK=pharmacokinetic; SC = subcutaneous ; TE = treatment emergent .
aIn the event of drug hypersensitivity reactions (immediate or non -immediate), up to 3 additional samples will be 
collected each for pharmacokinetics and immunogenicity as close to the onset of the reaction event as possible, at 
the resolution of the event, and 30 days following the event .
bUse this sampling schedule if SC dosing is utilized in the optional cohort.
cECG measurement should occur prior to the blood draw.
dRequired for subjects rece iving intravenous dosing only.
eSubjects who are TE ADA positive at the end of the study or early discontinuation will be followed with samples 
for ADA and PK being taken approximately ever y 3 months, until they return to 2 -fold titer of baseline or for a 
maximum of 1 year.
Note:  Samples that are requested to be taken predose through Day 2 should be collected as close to the sampling 
time as possible.  Aberrations to thespecified sampling times will not be considered protocol deviations as long 
as the samples are taken and the actual sampling time is recorded.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 94
LY3316531APP.6.3. Part C (Single Dose in Patients with Psoriasis)
Visit WeekDay 
Relative to 
LY 
TreatmentPK Sampling 
Time IV DosingaPK Sampling 
Time 
SC Dosinga,bImmunogenicity 
Samplinga ECGc
2 0 1 Predose Predose Predose Predose
2 0 1 End of infusion NA NA End of infusion
2 0 12 h after start of 
infusionNA NA NA
2 0 16 h after start of 
infusion6 h post -injection NA6 h after SC 
injection or start 
of  infusion
2 0 224 h after start of 
infusion24h post -
injectionNA24 h after SC 
injection or start 
of  infusion
3 0 4 ± 1 dayAny time during 
dayAny time during 
dayNA NA
4 1 8 ± 1 dayAny time during 
dayAny time during 
dayNAAny time during 
day
5 2 15 ± 2 daysAny time during 
dayAny time during 
dayAny time during 
dayAny time during 
day
6 3 22 ± 2 daysAny time during 
dayAny time during 
dayNA NA
7 4 29 ± 2 daysAny time during 
dayAny time during 
dayAny time during 
dayNA
8 6 43 ± 3 daysAny time during 
dayAny time during 
dayNAAny time during 
day
9 8 57 ± 3 daysAny time during 
dayAny time during 
dayNA NA
10 10 71 ± 3 daysAny time during 
dayAny time during 
dayNA NA
11 12 85 ± 3 daysAny time during 
dayAny time during 
dayAny time during 
dayAny time during 
day
12 16 113 ± 4 daysAny time during 
dayAny time during 
dayAny time during 
daydAny time during 
day
ED EDAny time during 
dayAny time during 
dayAny time during 
daydAny time during 
day
Up to 
20eUp to 
52e Up to 365e Any time during 
dayfAny time during 
dayfAny time during 
daygAny time during 
day
ED EDAny time during 
dayAny time during 
dayAny time during 
dayAny time during 
day
Abbreviations:  ADA = antidrug antibody; ECG = electrocardiogram; ED = early discontinuation; h = hour(s); IV = 
intravenous; LY = LY 3316531; NA = not applicable (no sampling needed at this time point); 
PK=pharmacokinetic; TE = treatment emergent .
aIn the event of drug hypersensitivity reactions (immediate or non -immediate), up to 3 additional samples will be 
collected each for pharmacokinetics and immunogenicity as close to the onset of the reaction event as possible, at 
the resolution of the event, and 30 days following the event .
bUse this sampling schedule if SC dosing is utilized in an optional cohort.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 95
LY3316531cECG measurement should occur prior to the blood draw.
dPatien ts who are TE ADA positive at the end of the study or early discontinuation will be followed with samples
for ADA and PK being taken approximately ever y 3 months, until they return to 2 -fold titer of baseline or for a 
maximum of 1 year.
eAn extended follow -up period that requires m onthly follow -up visits for patients who respond to treatment with 
LY3316531 after the initial 16 -week follow -up period (see Section 5.1.3 for more details).
fPK sampling will be conducted at each monthly visit during the extended follow -up period for patients who 
responded to LY3316531 treatment.
gPatients should be assessed for ADAs during Weeks 26 (Day 183 ± 7 days) and 52 (Day 365 ± 7 days) of the 
extended follow -up period.
Note:  Samples that are requested to be taken predose through Day  2 shoul d be co llected as close 
to the sampling time as possible.  Aberrations to the specified sampling times will not be 
considered protocol deviat ions as l ong as the samples are taken and the actual sampling time is 
recorded.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 96
LY3316531Appendix 7. Protocol Amendment I9H -MC-FFAA (b) 
Summary  
A Phase 1 Randomized, Placebo -Controlled Study  of 
LY3316531 in Healthy  Subjects and an Open- Label, 
Single -Dose Study  in Patients with Psoriasis
Overview
Protocol  I9H-MC-FFAA, A Phase 1 Rando mized, Placebo -Controlled Study  of LY3316531 in 
Healthy Subjects and an Open -Label , Single -Dose Study  in Patients with Psoriasis has been 
amended.  The new protocol is indicated by  Amendm ent (b ) and will be used to conduct the 
study  in place of any preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are as fo llows:
The number o f patients to be enrolled in the planned and 2optional cohorts of Part C was 
decreased from 8 pati ents to a minimum of 7 pati ents.  A minimum o f7 pati ents are requi red to 
complete a cohort but up to 8 patients would st ill be allowed if 8 eligible patient s can be 
ident ified in a timely manner .    The reduced minimum required sample size was deemed 
sufficient to assess if there is evidence of clinical activit y of LY3316531 based on PASI scores at 
4 weeks, and is adequate for assessment of safet y, tolerabili ty and PK of the com pound in the 
patient popul ation at this stage of development.
Decreasing the cohort size to 7 patients willfacilit ateanalysis of PASI scores for the purpose of 
determining if an optional cohort is needed to proceed once 4 weeks of dat a have been collected 
from 7 pati ents in a preceding cohort , thus prevent ing delay if 8 eligible pati ents cannot be 
ident ified in a timely manner.  This overall decrease in cohort si ze from 8 pati ents to 7 pati ents 
has resulted in the specific changes outl ined below .  The rationale described for the overall 
change applies to these specific changes.
Secti on 1 Protocol  Synopsis
oNumber of Patients/Subjects
Part C:  The number of patients fro m which evaluable data will be 
obtained was changed fro m 24 pati ents to up to 24 patients (total  number 
of patients f or planned an doptional cohorts).
Part C:  The number of patients per cohort was changed fro m 8 pati ents to 
a minimum of 7 pati ents planned but up to 8 patients allowed per cohort.
Secti on 5 Study  Design
o5.1 Overall Study  Design
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 97
LY3316531Table FFAA.5.1.  Tit le was changed from “Summary  of Patient/Subject 
Cohorts” to “Summary o f Maximum Number of Patients/Subject sper 
Cohort” to reflect the planned number of subjects are the maximum 
number per cohort
Table FFAA.5.1.1 Summary  of Maximum Number of Patients/Subject s 
perCohort Part C:  Footnote c was added to Patient Cohorts 1, 2, and 3 to 
explain that a minimum 7 pati ents are pl anned but up to 8 patients are
allowed per cohort.
Figure FFAA.5.1. Study  Design:    Footnote d was added to Patient 
Cohorts 1, 2, and 3 to explain that a minimum 7 patients are planned but 
up to 8 patients are allowed per cohort.
o5.2 Number of Participants
5.2.3. Part C (Single -Dose Design in Patients wit h Psori asis):  The number 
of patients to com plete was changed fro m approximately24 patients to up 
to 24 patients.
Secti on 7 Treatm ent
o7.4. Dose Modificat ion
7.4.1. Dose Decisio n (Part C):  The number of pat ients from which 
4weeks of clinical act ivity data are needed in order to progress to the 
optional cohorts in Part C was changed from all patients (which in prior to 
amendment b is 8 pati ents) to at l east 7 pati ents.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 98
LY3316531Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
1.  Protocol Sy nopsis
Part C:   It is planned that up to 30 patients may be enrolled in Part C of this study to obtain evaluable data 
from up to 24 patients (total number of patients forplanned and optional cohorts) .  The patients with 
psoriasis single -dose part of the study is planned to include up to 3 cohorts (300 mg IV cohort with the 
option for 2 additional cohorts) with a minimum of 7 patients planned but up to 8 patien ts allowed per 
cohort (8 LY3316531).
5.1.  Overall Design
Table FFAA .5.1. Summary of Maximum Number of Patient s/Subject s per Cohort s
Cohort #Planned D ose/
Administration RouteNumber of Planned
SubjectsTotal Number of 
Planned Subjects
LY PBO
Part A
SAD Cohort 1a3 mg/IV 3 1 4
SAD Cohort 2a15 mg/IV 3 1 4
SAD Cohort 3 75 mg/IV 6 2 8
SAD Cohort 4 300 mg/IV 6 2 8
SAD Cohort 5 300 mg/SC 6 0 6
SAD Cohort 6 900 mg/IV 6 2 8
SAD Cohort 7 2000 mg/IV 6 2 8
Part B
Multiple-Dose Cohort 1 2000 mg/IV 6 2 8
Multiple-Dose Cohort 2bRoute and dose TBD 6 2 8
Part C
Patient Cohort 1c300 mg/IV 8 0 8
Patient Cohort 2b,cRoute and dose TBD 8 0 8
Patient Cohort 3b,cRoute and dose TBD 8 0 8
Abbreviations:  IV = intravenous; LY = LY3316531; PBO = placebo; SAD = single -ascending dose; SC = 
subcutaneous; TBD = to be determined.
aSentinel dosing will be used in this cohort.
bOptional subject or patient cohort.  Actual dose and route of administration will be determined based on 
cumulat ive data from previous cohorts, but will not exceed 2000 mg of LY3316531 administered IV.
cA minimum of 7 patients are planned but up to 8 patients are allowed per cohort.
I9H-MC-FFAA (b)Clinical Pharmacology Protocol Page 99
LY3316531Figure FFAA.5. 2. Illustration of study design for Protocol I9H -MC-FFAA .
5.2.3.  Part C (Single -Dose Design in Patients with Psoriasis)
Up to 3 0patients may  be enrolled so that up to approximately 24 pat ients com plete Part C (total 
number of patients planned for Cohort 1 and the 2 optional cohorts) .  For purposes of Part C , a 
patient com pletes the study  when he/she completes all scheduled procedures up to and including 
at least Day  85.
7.4.1 .  Dose Decision (Part C)
The decisio n to init iate the first pati ent cohort in Part C will be based on the tri al-level 
safet y review for Coh ort 3; however, any  available preliminary  PK data from Cohorts 1, 
2, and 3 (through Day  29) in Part A will be considered as well.  Progressi on to the 
optional cohorts in Part C will occur when at least 4 weeks of clinical act ivity data (PASI 
scores) are available fro m allat least 7 patients in the preceding cohort.  In addition to the 
PASI scores, any  available PK and applicable safety  data f rom Part A will be considered 
for determining the dose for the optional pat ient cohorts.  Dosing at the current level and 
further dose escalat ion will  be discont inued if any of the scenarios described in 
Secti on7.4.2 occur .

PPDLeo Document ID = cb0ed918-d8dd-4aa3-83cf-466c1dd988b0
Approver: 
Approval Date & Time: 17-Aug-2018 19:38:54 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 17-Aug-2018 19:38:54 GMT
Signature meaning: ApprovedPPD